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Abstract
Enterovirus type 70 (EV 70) is the causative agent of a highly infectious 
haemorrhagic conjunctivitis that can rarely be complicated by a polio-like flaccid 
paralysis, and is one of only two enteroviruses (out of over 90) that infect the eye. EV70 
has previously been reported to bind to sialic acid and decay accelerating factor (DAE), 
however the mechanism by which EV70 enters the cell is unknown. Using a minimally 
passaged isolate of the J670/71 type strain of EV70 the receptor interactions and cell 
entry processes of this virus have been investigated. As part of this study, an infectious 
cDNA and a subgenomic replicon of EV70 were generated.
In the work presented here multiple different experimental approaches 
demonstrated that sialic acid is the primary determinant of EV70 binding and infection 
and that DAE does not play a significant role. Sialic acid is also responsible for EV70- 
mediated haemagglutination and binding to a range of non-primate mammalian cells as 
diverse as Xenopus in origin. On erythrocytes further characterisation showed the 
receptor to be an a2-3 linked sialated GPI-anchored glycoprotein; although binding of 
EV70 to MRC5 cells was unaffected by the removal of a2-3 linked sialic acid from the 
cell surface, suggesting potential variation in receptor usage. Further studies have 
demonstrated that EV70 uses clathrin-mediated endocytosis as its initial route of entry 
to MRC5 cells, and that tyrosine kinases and the actin cytoskeleton are important. The 
evidence is also suggestive of a role for low pH in exit of the viral genome from late 
endosomes.
The availability of infectious cDNAs for enteroviruses has allowed reverse 
genetic approaches to be used during analysis o f virus structure and function. Prior to 
this study such reagents did not exist for EV70. Long range PCR was used during the 
generation of an infectious cDNA for EV70 that, in turn, was used to derive a 
subgenomic replicon encoding a luciferase reporter gene. The specific infectivity of in 
vitro generated RNA, and growth characteristics of recovered virus, indicated that the 
cDNA was truly representative of the EV70 J670/71 stock. These reagents represent 
invaluable tools for further research into all aspects of the EV70 life cycle.
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Chapter 1 Introduction
CHAPTER 1 
Introduction
Enterovims type 70 (EV70) is a member of the enterovims genus of the 
Picorfiaviridae family. It is the cause of epidemics of acute haemorrhagic conjunctivitis 
and cases of acute flaccid paralysis.
EV70 is an important subject of study, both as a significant human pathogen and 
in relationship to a number of key features which differ from those seen in other human 
enterovimses, of which over 90 are now described (Oberste et al., 2005). In particular 
the vims is unusual in terms of its tissue and host tropism. It is one of only two human 
enterovimses that primarily infect the eye, and is reported to have a much greater host 
range, at least in tissue culture, than other members of the genus. Study of the early 
stages in the viral life cycle, specifically interaction of the vims with its cellular 
receptors, will be cmcial in uncovering the mechanisms behind this unusual tropism.
lA  Classification
Taxonomy within the Picornaviridae is constantly evolving. Among other 
genera it includes; cardiovimses (murine vim ses); aphthovimses (including the 
causative agent of foot and mouth disease in cattle); hepatovims (hepatitis A virus); 
rhinovimses (cause of over half of cases of the common cold) and enterovimses (Fields 
and Knipe, 2004; Minor, 1999). Classically enterovimses and rhinovimses are 
distinguished by their stability to acidic environments, with enterovimses being acid- 
stabile and rhinovimses acid-labile. Molecular phylogenetic analysis, however, suggests 
that enterovimses and rhinovimses cannot be regarded as distinct, and proposals are 
underway to merge them as a single genus (Hyypia et al, 1997; 
F*7cor/7av/77<7aeStudyGroupProposals, 2005). There have also been changes in the 
organisation of vimses within the enterovims genus (Stanway et a l, 2005); originally 
the vimses were grouped into poliovimses, coxsackie A vimses (CVA), coxsackie B 
vimses (CVB) and echoviruses on the basis of differing pathogenesis in newborn mice. 
Classification difficulties resulted in more recently identified vimses being assigned a 
number; hence enterovims type 70. The enterovimses are now arranged on the basis of 
sequence analysis into four phylogenetic groupings (figure 1.1), human enterovims
15
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cluster C 
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CA 19CA 24
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(EV68/EV70 37
Other human 
picornavlruses
80
EV70
EV68
100
100 HAV
S2
nonhuman
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CA12<^A1 6 / ( C A 1 6 - I l k e )BEV2a
Figure 1.1 Consensus phylogenetic tree for human enteroviruses.
Taken from Oberste et al (1999). Shows the phylogenetic relationship o f  
EV70 in cluster D (HEV-D) to other human enteroviruses based on VPl 
sequence. Note also the recent identification o f  EV94, which is the third 
virus to be assigned to HEV-D (Smura et al, 2007). BEY, bovine 
enterovirus; CA, coxsackie A virus; CB, coxsackie B virus; E, 
echovirus; HAV, hepatitis A virus; HRV, human rhinovirus, PEV, 
parechovirus; PV, poliovirus; EV, enterovirus. Figures at branch points 
are bootstrap values, being the percentage o f times random computer 
sampling o f  subsets o f  the viral sequences used to construct the tree 
gives a branch point at that location (Page and Holmes, 1998).
16
Chapter 1 Introduction
(HEV)-A, HEV-B, HEV-C and HEV-D (Oberste et al., 1999). EV70 is a member of the 
smallest group HEV-D, with the only other two members being enterovirus type 68 
(EV68) and the recently identified enterovirus type 94 (EV94). EV68 has subsequently 
been shown to be an isolate of rhinovirus type 87, and indeed shares biological features 
with the rhinovimses, again emphasising the overlap between the two genera 
(Blomqvist et al., 2002; Ishiko et al., 2002; Oberste et al., 2004; Savolainen et al,
2002). EV94 was isolated from environmental samples in Egypt and two cases of acute 
flaccid paralysis in The Democratic Republic of Congo (Smura et al, 2007). Initial 
studies have suggested that it shares the broad tissue range seen for EV70.
1,2 Epidemiolosv and disease
1.2.1 Epidemiology
Some picornavimses seem to have been present in the human population for a 
long time; indeed there is evidence for poliovims in Egypt as far back as 1300bc.
Disease attributable to EV70 is a much more recent phenomenon. The probable first 
reported outbreak of acute haemorrhagic conjunctivitis due to EV70 was in 1969 in 
Ghana, although the vims was not isolated until 1971 (Kono et a l, 1972). Although 
most enterovimses have a worldwide distribution, to date EV70 has been observed 
primarily in Southeast Asia and Africa. A massive epidemic occurred in 1970/1971 
affecting large areas of Southeast Asia, in particular India and Japan. The EV70 
reference strain, J670/71 dates from this epidemic. It is estimated that over one million 
cases occurred in Calcutta alone within a three month period in 1971, and that overall 
15 to 20 million were affected between 1969 and 1971 (Higgins, 1982). Smaller 
outbreaks and epidemics have continued to occur at intervals throughout the following 
decades, mainly in Southeast Asia, but also involving South and Central America, the 
Caribbean and the Southern states of the USA (Hatch et a l, 1981; Maitreyi et al, 1999).
It is not clear why outbreaks of enteroviral conjunctivitis were not known prior 
to 1969. EV70 antibodies, though not the vims, have been reported in a variety of 
animals (Kono et a l, 1981) and the vims has been reported to infect a range of non­
primate mammalian cell lines (Yoshii et al, 1977). This is not the case for other human 
enterovimses, which are restricted to human or primate hosts, with the possible 
exception of the newly identified EV94. These observations raise the possibility that
17
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EV70 may have evolved from an animal enterovirus which adapted to infect humans. It 
has been proposed that human EV70 strains diverged from a single common ancestor 
around 1967 (Takeda et al, 1994). This was based on sequencing of the gene encoding 
the major viral capsid protein (VPl) in eighteen isolates from 1971 to 1981, and 
estimating the time required to accumulate the nucleic acid substitutions observed. This 
estimate is only two years prior to the first recorded acute haemorrhagic conjunctivitis 
cases, and contrasts dramatically with the time believed to have elapsed before human 
immunodeficiency virus (HIV) was first detected in the human population after its 
transmission from the chimpanzee, which is believed to have occurred in the 1930s 
(Hillis, 2000). This difference is readily explained as EV70 is highly infectious with a 
very short incubation period and causes a readily identifiable disease; in contrast, HIV 
exhibits much lower transmissibility, with years required to symptomatic disease, which 
then presents as susceptibility to other illnesses and was therefore much harder to 
differentiate as a distinct disease.
It is of interest to note that the only other cause of infective haemorrhagic 
conjunctivitis is a variant strain of the enterovirus CVA24, and that it too emerged 
around 1970 (Higgins, 1982).
1.2.2 Route of spread
Enteroviruses are characteristically spread by the faecal-oral route (Minor,
1999), however EV70 has only rarely been isolated from faeces, despite its reported 
acid stability (Kono et al, 1972), and thus a faecal-oral or faecal-eye route seems 
unlikely (Higgins, 1982). It is postulated that spread is by direct contact from eye to eye 
or via fomites, analogous to the transmission of adenoviral epidemic 
keratoconjunctivitis. As with faecal-oral spread, this route is particularly relevant in 
areas of socio-economic deprivation, correlating with many of the larger outbreaks.
1.2.3 Disease associations
A distinctive feature of the enteroviruses is the number of different pathologies 
with which they are associated (Minor, 1999), reflecting variation in tissue tropism. 
While poliovirus targets the anterior horn cells of the spinal cord and causes acute 
flaccid paralysis, other viruses target a range of different organs and systems, with 
different viruses causing illnesses such as aseptic meningitis, encephalitis, myocarditis,
18
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vesicular lesions, as in hand, foot and mouth disease and herpangina, and more non­
specific febrile illnesses and severe systemic disease.
The primary manifestation of infection with EV70 (Seal et a l, 1998; Wright et 
a l, 1992) is acute haemorrhagic conjunctivitis (figure 1.2). This arises rapidly with an 
incubation period of 24 hours. Symptoms are usually bilateral and are severe, with 
conjunctival haemorrhage, excessive lacrimation and pain. The pain usually decreases 
within two to three days, with full resolution within ten days. There are no long-term 
ocular consequences.
Acute flaccid paralysis was first noted during the 1971 epidemic in India 
(Bharucha et a l, 1972). Symptoms are indistinguishable from poliomyelitis and occur 
with a frequency of one in ten thousand cases of conjunctivitis. Although relatively rare, 
this is nonetheless highly significant given the size of epidemics. Symptoms develop 
from two to eight weeks after the onset of conjunctivitis with a prodrome of fever and 
malaise. In about fifty percent of cases there is some degree of permanent disability. 
Paralysis has been shown in cynomo logons monkeys after intraspinal injection of the 
virus (Kono et al, 1973). Cranial nerve palsies have also been reported (Katiyar et al, 
1981; W ad iae ta l, 1983).
1 3  Viral structure and life cycle
1.3.1 Viral morphology
Picornavlruses consist of a non-enveloped capsid with icosahedral symmetry, 
which contains a single-stranded RNA genome of messenger sense. The atomic 
structures of rhinovirus type 14 and poliovirus type 1 were first published in 1985 
(Hogle et al, 1985; Rossmann et al, 1985), and picornavlruses conform to a basic 
structural pattern. The capsid consists of 60 protomers each comprising one molecule of 
the four virion proteins: VPl, VP2, VP3, and VP4. Each of the 20 faces of the 
iscosahedron is made up of three protomers, with VP4 being entirely internal Five 
copies of VPl form each of the twelve pentameric apices, which in enteroviruses and 
rhinovimses are encircled by a cleft known as the ‘canyon’. This has been shown to be a 
receptor binding site for many vimses such as poliovims type 1, rhino vims type 16 and 
CVA21 (He et a l, 2000; Olson et a l, 1993; Xiao et al, 2001), although this appears not 
to be the case for receptor binding of other picornavimses, such as echovims types 7
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Figure 1.2 A cute H aem orrhagic Conjunctivitis. From Seal 
et al., 1998.
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and 11, and human rhinovirus type 2 (He et al., 2002; Hewat et a l, 2000; Pettigrew et 
ai., 2005). The canyon is not a universal feature of picornavlruses, however, and is 
absent in foot and mouth disease virus which possesses a relatively smooth capsid 
(Acharya et al., 1989). In addition to the capsid proteins, the N terminus of VP4 is 
covalently attached to a myristic acid residue (Chow et al., 1987). This contributes to 
the surface of the virion apices and may have a role in receptor binding and entry.
1.3.2 Genome structure
The full genome sequence of the EV70 reference strain (1670/71) was published 
in 1990 (Ryan et al., 1990). It consists of a single stranded messenger-sense RNA of 
7390 nucleotides (figure 1.3) and shares the general organisation of enteroviral genomes 
(Minor, 1999). The 5’ untranslated region (UTR) is 726 bases in length and is highly 
structured. The first ninety bases consist of a cloverleaf structure which interacts with 
both host proteins and the viral polymerase during replication of the genome, and this is 
followed by the internal ribosome entry site (1RES), a much larger element of RNA 
secondary structure, which functions to recruit ribosomes to the viral RNA for 
translation of the single open reading frame (ORE) which follows. The EV70 open 
reading frame is 6582 bases in length and thus codes for a polyprotein of 2194 amino 
acids, it is divided into three regions based upon primary proteolytic cleavage events. 
The PI region, located at the 5’ end, encodes the structural proteins in the order VP4, 
VP2, VP3 and VPl (genome segments lA, IB, 1C and ID respectively). The P2 and P3 
regions, which follow PI, encode the non-structural proteins (sections 2A, 2B and 2C, 
and 3 A, 3B, 3C and 3D respectively). Not all the functions of the non-structural 
proteins are known, however they include the virally encoded proteases, 2A and 3C, 
and the viral 3D polymerase. Following the ORF is the 3’UTR, which is 79 bases in 
length and thus much smaller than the 5’UTR. Like the 5’UTR, it contains elements of 
secondary structure and has a role in replication. The genome terminates in a sequence 
of 40-100 adenosine residues that are not virally encoded. In addition to the RNA, the 
5’end of picornavimses genomes is known to be covalently attached to a small protein 
of 22 amino acids, known as VPg (encoded by 3B), which is involved in the initiation 
of replication.
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Figure 1.3 O rganisation o f enteroviral genom es. See text for details.
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1.3.3 Overview of the enterovirus life cycle
Enteroviruses share a comtnon life cycle (Fields and Knipe, 2004; Minor, 1999). 
Individual viruses bind to their target cell via specific cell membrane proteins or 
receptors, they are then internalised by a variety of mechanisms. These early events are 
the subject of the investigations presented in this thesis and are discussed in sections 1.4 
and 1.5 below.
Once in the cytoplasm translation of the viral RNA is initiated after binding of a 
ribosome to the 1RES. A single viral poly protein is produced, which is 
co-translationally cleaved by the viral 2A protease into the three primary products (PI, 
P2 and P3). Subsequent cleavages are carried out by the viral 3C protease. VP4 and 
VP2 remain uncleaved, as the precursor VPO, until late in infection and the mechanism 
by which they are cleaved is unclear. Soon after the start of viral protein synthesis, the 
viral 2A protease catalyses the cleavage of the cellular initiation factor eIF-4G, which is 
required for cap-dependant translation, and thus host cell protein synthesis is shut off.
Viral replication requires a number of factors including the viral proteins 3D 
polymerase and VPg and a number of cis-actmg replication elements, such as the 
cloverleaf within the 5’UTR and a recently identified element within the poliovirus 
3CD region (Goodfellow et al, 2000). A negative sense genome intermediate is made 
from which further positive strands are produced, both for more translation and for 
packaging into virions.
Capsids are initially assembled as pentamers of VPO, VPl and VP2. The exact 
mechanism of RNA insertion is unclear, but appears to occur in association with VPO 
cleavage. Virions are generally released by cell lysis, but other mechanisms may also be 
important.
1.4 Viral receptors
Productive infection of a cell requires that the virus first attach to the cell, 
generally by binding to a specific receptor, and then delivers its genome to the site of 
viral replication. The presence or absence of a specific receptor on the cell surface is 
thus an important determinant of whether a particular vims can infect a cell and hence 
of its tissue tropism (Evans and Almond, 1998).
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A diverse range of cell surface molecules have been reported as receptors for 
different picornaviruses. For example, the first identified and most well characterised is 
the poliovirus receptor (PVR), an immunoglobulin-like transmembrane protein 
(Mendelsohn et al., 1989). Other identified immunoglobulin family receptors are the 
intracellular adhesion molecule one (ICAM-1), receptor for several coxsackie A viruses 
and the major group rhinoviruses (Greve et al., 1989; Shafren et al, 1997a); and the 
coxsackie-adenovirus receptor (CAR), used by the coxsackie B viruses (Bergelson et 
al, 1997). Foot and mouth disease vims requires an integrin for binding (Berinstein et 
a l, 1995), as does echovims type 1 (Bergelson et al, 1992). Decay Accelerating Factor 
(DAF) is a commonly used enterovims receptor. It has been shown to be required for 
the cellular binding of several coxsackievimses and echovimses (Shafren et al, 1995; 
Shafren et al, 1997b; Ward et a l, 1994).
EV70 was reported in the early 1980s (Utagawa et a l, 1982a) to require sialic 
acid for binding to red blood cells (RBC), but prior to the current studies had also been 
reported to bind to DAF on HeLa cells (Karnauchow et al, 1998; Karnauchow et al, 
1996). Both sialic acid and DAF are known to be expressed on the surface of the 
conjunctiva of the human eye (Kawano et a l, 1984; Medof et al, 1987).
1.4.1 The poliovirus model for receptor binding and particle uncoating.
The interaction of poiiovims with its receptor PVR has been studied in detail, 
and binding is known to occur within the depression on the viral surface at the five-fold 
axis o f symmetry known as the canyon (He et al, 2000). The canyon has also been 
shown to be the site of interaction for other picornavimses and their receptors, such as 
rhino vims type 14 with ICAM-1 (Olson et al, 1993) and CVB3 with CAR (Xiao et al, 
2001). Binding of poiiovims to PVR-expressing cells triggers the process of viral 
uncoating. This is required for the release of free RNA into the cytoplasm. Uncoating 
can be tracked by changes in the particle sedimentation coefficient. The 160S native 
infectious vims loses one of the capsid proteins (VP4), forming 135S ‘A’ particles. As 
VP4 is an internal capsid protein and not present on the surface of the 160S particles, 
this marks a major conformational change, during which the N-terminus of VPl is also 
externalised. Subsequently the viral nucleic acid is released with the formation of empty 
(80S) particles. Both 135S and 80S particles are poorly infectious (Curry et a l, 1996) 
and can be detected both intracellularly and extracellularly during productive vims 
infection, indeed binding of poiiovims to its soluble receptor alone is sufficient to
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trigger the full uncoating process (Kaplan et a l, 1990). It should be noted, however, that 
it is not yet clear whether ‘A’ particle formation itself is a necessary step for the 
uncoating of poliovirus or other enteroviruses.
1.4.2 DAF as a viral receptor
DAF is a widely expressed 70kD cell surface protein which acts to prevent cell 
damage from the complement cascade by accelerating the breakdown of the C3 and C5 
convertases (Campbell et al, 1988; Nicholson-Weller and Wang, 1994). It is a member 
of the RCA (regulator of complement activity) group of proteins, other notable 
members being CD46, which is used as a receptor by the Edmonston strain of measles 
virus (Dorig et al, 1993), and CR2, the Epstein Barr virus receptor on B lymphocytes 
(Fingeroth et al, 1984). RCA proteins are characterised by 60 amino acid short 
consensus repeat domains (SCRs). DAF is made up of four such domains connected to 
the cell membrane by a lipid glycosylphosphatidylinositol (GPI) anchor rather than a 
transmembrane domain. SCR4 is separated from the GPI anchor by a serine/threonine 
rich region that is heavily O-glycosylated. In addition there is an N-glycosylation site 
between SCR 1 (the most membrane distal domain) and SCR 2 (figure 1.4).
DAF has been implicated as an important receptor for a considerable number of 
enteroviruses (figure 1.4), in addition it is also bound by the fimbriae of uropathogenic 
Escherichia coli (Nowicki et a l, 1993). DAF’s viral receptor role was first identified for 
echovims 7 (Ward et a l, 1994). A novel technique was used in which non-permissive 
cells were transfected with cDNA clones in high efficiency expression vectors, cells 
rendered permissive for echovims 7 infection were identified using a viral antigen- 
specific mouse monoclonal antibody and an anti-mouse IgG antibody conjugated to 
galactosidase, leading to blue colouration on the addition of substrate. Plasmid DNA 
was extracted directly from individual positive cells, transformed into Escherichia coli 
and the DAF-encoding gene identified by sequencing. Subsequently many other 
enterovimses have been demonstrated to bind DAF, including numerous echovimses, 
some of the coxsackie B vimses and CVA21 (Powell et al, 1998; Powell et al, 1999).
The majority of DAF binding enterovimses require SCR 3 interactions (Powell 
et al, 1999). However CVA21 has been shown to interact with SCR I (Shafren et a l, 
1997b). The observation that different enterovimses bind to different domains of DAF 
has lead to the hypothesis that DAF-binding has evolved convergently, and that there is 
some advantage to the vimses in using this protein as a receptor. Members o f the RCA
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Figure 1.4 DAF structure and sites o f pathogen binding. Diagrammatic 
representation o f  the DAF molecule, showing the GPI anchor and the four 
SCR domains, and illustrating the domains to which the binding sites o f  
various pathogens have been mapped. CHO indicates glycosylation sites. 
Adapted from Powell et al, 1999. ^Echovimses types 3, 6, 7, 11-13, 20, 21, 
29 and 33; Coxsackievims B vim ses types 1, 3 and 5.
26
Chapter 1 Introduction
family act as receptors for not only measles virus and Epstein-Barr virus, but also for a 
wide range of pathogenic bacteria (Lindahl et al., 2000), and it may be that a 
consequence of binding to these molecules is to allow pathogens to evade the 
complement response. A further possible advantage might be the location of DAF on 
the cell surface. GPI-anchored proteins, including DAF, are known to be concentrated 
in areas of the cell membrane known as lipid rafts (Brown and London, 1998). These 
are detergent-resistant, sphingolipid and cholesterol-rich microdomains. They act as 
functional platforms for many cell signalling and endocytotic processes, and may 
facilitate signalling processes required for subsequent viral entry and uncoating (Coyne 
and Bergelson, 2006; Greber, 2002; Simons and Toomre, 2000).
Evidence to date suggests that the interaction of DAF with enteroviruses does 
not involve docking of the receptor into the canyon, but rather binding occurs at the 
two-fold axis of symmetry (He et al., 2002; Pettigrew et al., 2005). Further work has 
looked at the kinetics of the interaction of soluble DAF and echovims type 11 using 
surface plasmon resonance (Lea et al, 1998). It was shown that the interaction is of a 
low affinity with a very fast dissociation rate constant, similar to the kinetics seen with 
cell to cell recognition molecules (Lin et a l, 2001; van der Merwe and Barclay, 1994).
In contrast interaction of ICAM-1 with the rhinovims canyon has a low dissociation rate 
constant, consistent with binding at a more inaccessible site (Casasnovas and Springer, 
1995).
DAF further differs from canyon binding receptors, in that in soluble form it 
does not induce uncoating of DAF binding vimses as is the case for poiiovims and 
PVR, although uncoating does occur when vims binds to DAF on the cell surface 
(Powell et a l, 1997). The fact that soluble DAF does not cause viral uncoating suggests 
that either multiple interactions between the virion and DAF molecules are required for 
uncoating, or that some other cellular factor is required. Indeed coxsackie B vimses 
require both DAF and ICAM-1. In this case it has been shown that binding of vims to 
DAF acts as an initial attachment event, activating pathways required to relocate the 
vims to the relatively inaccessible tight junction where ICAM-1 is located and 
uncoating occurs (Coyne and Bergelson, 2006). Alternatively for some vimses, such as 
the major group rhinovimses, uncoating requires receptor binding in combination with 
exposure to low pH in the cellular late endosome (Nurani et al, 2003).
EV70 has been reported to bind DAF on HeLa cells, following the observation 
that a DAF-specific mouse monoclonal antibody could block vims binding
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(Karnauchow et al., 1996). Using chimeric molecules containing domains from both 
DAF and CD46 it was shown that, as is the case for CVA21, this interaction occurred 
with SCR 1, the most membrane-distal domain of DAF (Karnauchow et al., 1998).
1.4.3 Sialic acid as a viral receptor
Sialic acids are negatively charged monosaccharides, which are commonly 
found as the terminal components of carbohydrate (glycan) chains in glycoproteins and 
glycolipids (Flint et a l, 2000; Schauer, 2004; Varki, 1999). They are found in all higher 
animals and some microorganisms, but there is ongoing debate regarding their presence 
in invertebrates. Sialic acids are structurally diverse, with the potential for a number of 
substitutions at the amino and hydroxyl groups. The most common form on human cells 
is N-acetylneuraminic acid (NeuSAc), shown in figure 1.5, which has an N-acetyl group 
at the 5-carbon position. Further diversity is generated by variation in the linkage from 
the 2-carbon to the underlying sugar, usually galactose. Most commonly this takes the 
form of an a2-3 or a2-6 linkage. This can vary in a species- and tissue-specific fashion, 
such that, for example, a2-3 predominates in the avian intestine and a2-6 predominates 
in the majority of the human respiratory tract, with a2-3 found in human lung alveolar 
cells (Shinya et a l, 2006). Glycosylation sites can be present on lipids or proteins; in the 
latter case, attachment to the underlying protein is via either a serine or threonine 
residue (0-glycosylation) or an asparagine residue (N-glycosylation). The same 
molecule can have a different glycosylation pattern in different tissues, and indeed 
glycosylation is believed to play an important role in cellular differentiation (Schauer, 
2004; Varki, 1999).
Influenza virus was the first virus to be shown to use sialic acid as its cellular 
receptor (Klenk and Stoffel, 1956; Skehel and Wiley, 2000), and since then it has been 
shown to be an important receptor component for multiple other viruses, including 
enveloped vimses such as parainfluenza, mumps, Newcastle Disease vims and some 
coronavimses; and non-enveloped vimses such as the human polyomavimses, 
adenovims type 37, and some rotavimses (Arnberg et al, 2000; Gee et al, 2006; Isa et 
a l, 2006; Schwegmann-Wessels et a l, 2003; Villar and Barroso, 2006). While all these 
vimses bind sialic acid there is variation in the form of sialic acid, the requirement for 
specific downstream sugars and the linkage to them. In addition specificity may be 
determined by components of the underlying lipid or protein. For example human 
influenza vims appears to bind to all a2-6 sialated glycolipids and glycoproteins,
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although a requirement for cell surface N-glycoproteins for endocytosis post attachment 
has been reported (Chu and Whittaker, 2004). In contrast polyomavimses seem to 
require a specific glycolipid (Tsai et al., 2003). For some sialic acid binding vimses, 
such as reovimses and polyomavimses, there is known to be a requirement for an 
additional receptor distinct from sialic acid (Barton et al., 2001; Camso et al, 2003).
The interaction of influenza virus haemagglutinins with sialic acid has been 
studied in great detail (Skehel and Wiley, 2000). Species tropism is largely dependant 
on the linkage of the sialic acid to galactose, with avian vimses, such as the H5N1 
currently circulating in poultry, binding to the a2-3 form present in avian intestine and 
human viruses binding to the a2-6 form in the human respiratory tract. Linkage 
preference therefore not only determines species tropism, but also the primary site of 
viral infection. Studies of H5N1 influenza suggest that several separate adaptive 
changes would be required to change its receptor specificity to a2-6 linked sialic acid, 
and this is postulated to be part of the reason for the lack of human to human spread 
observed in the sporadic human cases associated with the outbreaks (Russell et al, 
2006).
One striking feature of many vimses predominantly infecting the human 
conjunctiva is the proportion which utilise sialic acid for binding (Olofsson et al, 2005). 
These include adenovims 37 (Arnberg et al, 2000), one of the primary causes of viral 
keratoconjunctivitis, and the avian vimses influenza vims H7N7 (Fouchier et a l, 2004; 
Koopmans et al, 2004) and Newcastle Disease Virus (Ferreira et a l, 2004), which both 
cause conjunctivitis in humans. EV70 also fits into this group as another vims that 
infects the eye and has a requirement for sialic acid. EV70 infection was first reported to 
potentially involve sialic acid in 1982 when loss of viral-induced haemagglutination 
(HA) was observed on removal of sialic acid from the RBC membrane using 
neuraminidase (Utagawa et a l, 1982b). Subsequently it has been shown that the DAF 
binding phenotype is distinct from the sialic acid requirement, as removal of the DAF 
N- and 0-glycosylation sites, by site-directed mutagenesis and the use of chimeric 
proteins respectively, did not affect DAF binding by the vims (Alexander and Dimock, 
2002). Interestingly EV68, the other HEV-D group virus, has also been shown to 
require sialic acid for infection (Uncapher et a l, 1991). No other human enterovims has 
been reported to use sialic acid as a receptor
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1.4.4 Species Tropism
EV70 is unusual among human enterovimses in that it has been shown to 
replicate in a range of non-primate mammalian cell lines, including rodent, rabbit, 
porcine and bovine (Yoshii et a l, 1977), and antibodies to EV70 have been reported in 
a number of animals (Kono et al., 1981). These observations support the hypothesis that 
the human vims may have emerged from an animal reservoir, although EV70 has only 
been isolated from humans.
DAF homologues have been identified in several species, including the mouse 
(Fukuoka et al., 1996). The divergence between human and murine DAF is 63% at the 
nucleotide level, which is sufficient to prevent other DAF binding vimses from binding 
and infecting murine cells. Sialic acid is found on all vertebrate cells, although the 
relative amounts of the different side chain substituted forms, and tissue-specific 
patterns of expression, may vary (Varki, 1999). The recently identified enterovims 
HEV-D member, EV94, has also been reported to have wide tropism in tissue culture 
(Smura et al, 2007). Its receptor is unknown, although preliminary studies suggest it 
does not bind DAF. EV68, the other HEV-D member has been reported to require sialic 
acid (Uncapher et a l, 1991), however it has not been observed to have a wide tissue 
tropism.
1.4.5 Tissue culture adaptation and receptor usage
Vimses adapt to growth in tissue culture, and this is especially tme for RNA 
vimses due to the high error rate of RNA polymerases. This is not a new concept as 
serial passage of vims in vitt o has long been used to generate attenuated strains of 
vimses for use in vaccination. One commonly observed culture adaptation is a change 
in viral receptor usage due to changes in the viral capsid. For example, foot and mouth 
disease vims adapts to use heparin sulphate as a receptor on culture in CHO cells (Sa- 
Carvalho et a l, 1997), and cultured measles vims adapts to use CD46 as a receptor 
(Ono et a l, 2001).
The majority of research into viral life cycle and pathogenicity has been carried 
out using reference strains, which are highly passaged. Tissue culture induced changes 
are thus a very important consideration. Particularly misleading results could occur in 
the development of antiviral dmgs where inhibition of a passaged vims in vitro may not 
reflect activity against circulating strains. Antiviral candidates with activity against
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enteroviruses, such as pleconaril, have mainly targeted the viral capsid, which appears 
particularly susceptible to adaptive change (Zhang et al, 2004).
All the studies to date on EV70 have used the reference strain, J670/71, obtained 
during the 1970/71 epidemic in Southeast Asia. As with all reference strains, it has 
undergone extensive passage in tissue culture. Different laboratories have used a variety 
of cell lines to culture this vims (Karnauchow et a l, 1996; Ryan et a l, 1990; Yoshii et 
a l, 1977). It is therefore important to interpret results using reference strains with 
caution and where possible to attempt to verify the observations made, using clinical 
isolates.
1,5 Viral entry
Following attachment, a vims (or its genome) requires a mechanism to enter the 
cytoplasm of the cell A vims may either penetrate the plasma membrane directly, or 
utilise one of the existing endocytotic pathways. The latter have the potential advantage 
of specifically delivering the vims to its site of replication, however a mechanism is still 
required for the vims to exit the endocytic vesicle and release its nucleic acid into the 
cytoplasm. The identity of the viral receptor plays an important role in viral entry, by 
virtue of its location (for example within lipid rafts), and also potentially by triggering 
signalling events required for internalisation.
Cells utilise a large number of different endocytic pathways (Marsh and 
Helenius, 2006; Pelkmans and Helenius, 2003; Sieczkarski and Whittaker, 2002a), most 
of which can be exploited by vimses (figure 1.6). These include the clathrin-mediated 
pathway, best studied as the route of influenza vims entry, and the caveolar pathway, 
best studied as the route of entry of the polyomavirus S V40, and a number of less well- 
defined non-clathrin, non-caveolin-dependant pathways. Some vimses have been 
reported to enter the cell via multiple routes. For example, influenza virus can still enter 
the cell when the clathrin route is blocked (Sieczkarski and Whittaker, 2002b), 
suggesting that it can utilise alternative entry pathways.
Different enterovimses appear to use different mechanisms as their primary 
route of entry into the cell, partially reflecting the variety of receptors used. These 
include direct entry via the plasma membrane, as suggested for poiiovims (Hogle,
2002), and endocytic entry via the clathrin or caveolar pathways. The entry route of 
EV70 is unknown.
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Figure 1.6 Diagram  o f cellular endocytotic pathways. From Marsh and 
Helenius, 2006. * The clathrin and caveolar pathways are discussed in the 
text. The other pathways shown have also been implicated in viral entry, but 
are less well defined (Marsh and Helenius, 2006).
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1,5.1 The poliovirus model for cell entry
Despite poliovirus being arguably one of the best-studied viruses, and certainly 
the most studied picornavirus, the mechanism of its entry into the cell remains the 
subject of considerable uncertainty and debate. A general consensus now seems to be 
emerging (Hogle, 2002; Rossmann et a l, 2000), aided by recent studies on the structure 
of the 135s ‘A’ particle (Bubeck et al, 2005) and the use of liposome-based systems to 
allow the analysis of entry in a controlled, cell free system (Tuthill et a l, 2006).
Growing evidence suggests that poliovirus RNA does not enter the cell by an 
endocytic pathway, but rather does so directly via the formation of a pore within the 
plasma membrane. This process appears to be associated with the formation of the 135S 
‘A’ particle following viral binding to PVR on the cell surface. As mentioned in section 
1.4.1, this structural change results in externalisation of the VP4 capsid protein and the 
N-terminus of VPl. The latter has a sequence compatible with an amphipathic helix and 
has been shown to allow tethering of viral particles to liposomes, independently of 
receptor. Evidence suggests that both the N-terminus of VPl and VP4 may be involved 
in the formation of a membrane pore, through which viral RNA can be extruded directly 
into the cytoplasm.
Little work has been done examining the potential for this model to be applied to 
other enterovimses and rhinoviruses. Although all have a predicted amphipathic helix at 
the N-terminus of V Pl, not all the vimses can attach to liposomes in their 135S form 
(Airaksinen et al, 2001). One vims that appears not to is EV68, another group D 
enterovims. Although not all viral receptors bind in the canyon and can induce 135S 
formation directly, 135S particles are still observed during productive infection. The 
additional cellular or physical factors that might be required for this are unclear.
In contrast to poiiovims, endocytosis does appear to have a critical role in the 
entry of many other enterovimses. It remains possible, however, that similar 
mechanisms to those used by poiiovims may play a role in the exit from endocytotic 
vesicles following internalisation. Additional factors, such as pH, may be required to 
trigger further changes in the virion within the endocytotic vesicle, which could 
potentially be associated with pore formation within the vesicle membrane.
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1.5.2 The clathrin-mediated endocytic pathway as a route of viral entry
The clathrin-mediated route was the first pathway of endocytosis described and 
is the most studied and best understood mechanism (Brodsky et al., 2001). In brief, 
receptor binding triggers the recruitment of clathrin to the cytoplasmic side of the 
membrane (figure 1.6). Subsequent invagination results in the formation of a clathrin 
coated vesicle within the cytoplasm. Clathrin then uncoats from the vesicle, which fuses 
to early endosomes, with progression through late endosome and lysosome stages. The 
pH of these compartments progressively drops to 6.0 in the early endosome and 5.5 in 
the late endosome. These cellular compartments also contain a number of acid- 
dependant proteases.
Increasing research is making apparent the complexities involved in these 
processes. Many additional proteins are required, such as adapter proteins for the 
recruitment of clathrin and for subsequent vesicle formation. Elements of the 
cytoskeleton, such as actin and dynamin, also seem to have a role, which as yet remains 
poorly defined. The pathway is also capable of targeting ligands or viruses to distinct 
locations, as endosomes are not all identical in terms of function and location (Marsh 
and Helenius, 2006). One major requirement for clathrin endocytosis is the activation of 
cell signalling pathways. Recent work suggests that over 90 kinases may be involved in 
the clathrin-mediated entry of vesicular stomatitis virus (Pelkmans et al., 2005). 
Membrane lipid composition is believed to play an important part in vesicle formation 
and lipid rafts can have a role in clathrin-mediated endocytosis. Although these are 
classically the site of internalisation via the caveolar route, clathrin entry can also occur 
at these sites, and raft-based cell signalling is known to have important roles in the 
clathrin-mediated endocytosis of receptors such as the epidermal growth factor receptor, 
the B cell receptor and the HIV receptor CCR5 (Puri et al., 2005; Signoret et al., 2005; 
Stoddart et al., 2002).
Influenza is perhaps the best studied virus to use the clathrin pathway (Skehel 
and Wiley, 2000). After entering late endosomes, the low pH induces a conformational 
change in the viral haemagglutinin, which results in fusion of the viral and endosomal 
membranes with release of viral RNA into the cytoplasm. Some rhinoviruses are also 
reported to require low pH for entry (Nurani et a l, 2003). In addition to direct pH 
effects on viral proteins, viruses such as coronaviruses and rotavirus, require the action 
of proteases present within late endosomes for release of their nucleic acid (Ebert et al, 
2002; Simmons et a l, 2005).
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Picornaviruses believed to enter cells via a clathrin route include human 
rhinoviruses type 2 and 14 (DeTulleo and Kirchhausen, 1998), parechovirus 1 (Joki- 
Korpela et al, 2001) and foot and mouth disease virus (Berryman et al., 2005). Many of 
these are reported to be dependant on late endosomal pH for entry, however there is 
ongoing debate regarding the exact role of pH and the exact method by which the viral 
RNA is released. This could involve pore formation comparable to that suggested for 
poliovirus or disruption of the endosome itself.
1.5.3 The caveolar endocytotic pathway as a route of viral entry
A subset of lipid rafts contain caveolin and can be observed by electron 
microscopy to form pits or caveolae in the plasma membrane, Caveolar endocytosis is 
somewhat slower than that mediated by clathrin. Following internalisation ligands or 
viruses are taken up into pH-neutral vesicles known as caveosomes and hence to the 
endoplasmic reticulum (Anderson, 1998). Low pH endosomes and lysosomes do not 
appear to be involved (figure 1.6). The caveolar pathway has been best studied as the 
route of entiy of the simian polyomavirus, SV40 (Pelkmans et al., 2001). As with 
clathrin pathways, caveolar entry pathways are complex involving several protein 
components, as well as signalling pathways, the cyto skeleton and lipids. The cellular 
uptake of SV40 may be associated with changes in the activity of 80 different kinases, 
largely distinct from those affecting clathrin-mediated endocytosis (Pelkmans et al,
2005). SV40 penetration into the cytosol is believed to occur via the ER and an ER 
protein has been shown to be capable of causing a structural change in the SV40 capsid 
resulting in exposure of a hydrophobic domain (Magnuson et a l, 2005), perhaps in a 
manner similar to poliovirus uncoating and pore formation.
Picornaviruses believed to enter cells via the caveolar route include echovims 
type 1 (Pietiainen et al, 2004) and the coxsackie B vimses (Coyne and Bergelson,
2006). There is currently no information on how these vimses might release their RNA 
from caveosome or ER compartments.
1.6 Use o f full"lensth clones and revlicons
The RNA alone of picornavimses is infectious on introduction into cells (Evans, 
1999; Racaniello and Baltimore, 1981). As the positive sense RNA genome acts as its 
own messenger RNA, and its translation is dependant on host rather than viral proteins,
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the viral polyprotein can be produced from the RNA. Subsequently poly protein 
cleavage and viral replication occur with production of viable viral particles. Using full- 
length DNA clones of the viral genome, with subsequent in vitro transcription and RNA 
transfection, viable virus can be efficiently recovered from transfected cells. 
Complimenting the use of full-length clones are subgenomic replicons. These contain 
reporter genes, usually in place of capsid-encoding sequences, allowing viral replication 
to be quantified and studied (Percy et a l, 1992).
The first demonstration of an infectious enterovims clone was of poiiovims 
(Racaniello and Baltimore, 1981). Viral sequences were cloned directly from multiple 
cDNAs derived from portions of the poiiovims genome. More recently PCR 
(polymerase chain reaction) -based cloning strategies have been used, and direct cloning 
of entire enterovims genomes using long distance reverse transcription and polymerase 
chain reaction (RTPCR) has been reported (Lindberg et al, 1997). The constmction of a 
poiiovims subgenomic repli con was first reported in 1985 and included a 
chloramphenicol acetyltransferase reporter gene (Percy et al, 1992). More recently 
firefly luciferase has been used as a reporter gene, allowing more rapid automated 
quantification (van Kuppeveld et al, 1996).
Enteroviral clones have been used extensively for reverse genetic research 
approaches, where specific mutations are introduced into the viral cDNA, allowing 
vims containing these mutations to be generated (Evans, 1999). Full-length clones also 
allow virus isolates that have not undergone passage in tissue culture to be used in 
research. It is not practical to generate full-length clones for all clinical isolates, as it 
remains a difficult and time consuming procedure. An alternative strategy of subcloning 
portions of the viral genome of interest into a generic backbone, such as that generated 
from a reference strain, is more feasible, and could enable the study of larger numbers 
of clinical isolates. Subgenomic replicons are particularly useful for the investigation of 
viral translation and replication, and have also been used to investigate viral packaging 
by co-transfecting helper vims RNA to supply capsid proteins in trans.
Subgenomic replicons and infectious viral clones have also been used in the 
study of other vimses. Until recently there has been no cell culture model for hepatitis C 
vims (HCV) infection, however research has been greatly facilitated by the availability 
of subgenomic HCV replicons (Lohmann et a l, 1999). These replicate in a hepatoma 
cell line and have been used to investigate HCV translation and replication. More 
recently a full-length HCV clone has been derived from a patient with Eliminant
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hepatitis which enables productive HCV infection of hepatoma cells and is currently 
revolutionising research into HCV infection (Zhong et al., 2005).
Both full-length clones and subgenomic replicons are proving invaluable tools in 
many areas of picornavirus research, however, before now, these have not been 
available for EV70. Such clones would be extremely valuable in future studies of EV70, 
in particular by enabling the use of virus derived directly from circulating strains.
1,7 Aims
As can be seen from the preceding introduction, much work has been done, and 
is ongoing, regarding the interaction of enteroviruses with the cell via specific receptors 
and the subsequent pathways of cellular entry. In addition the importance of cell 
signalling pathways and the cyto skeleton to virus infection is becoming increasingly 
apparent. Although this research has encompassed members of HEV-A, B and C 
relatively little work has been done on the HEV-D viruses, in particular EV70.
EV70 is an important human pathogen in terms of morbidity and the potential 
economic impact of epidemics. From a virological point of view it is of interest as an 
unusual enterovirus in terms of its tropism for the conjunctiva, reported broad species 
range and use of sialic acid as a receptor.
Although it has been reported to bind both sialic acid and DAF, the relative 
importance of these is unknown, as is their importance in determining the tropism of the 
virus. In addition little is known regarding the sialic acid component of the receptor, for 
example whether a specific sialated protein or lipid is required, or if there is specificity 
for a particular linkage to the underlying sugar. Furthermore the route used by EV70 to 
enter the cell is completely unknown.
The overall aim of this study was to determine the molecular basis of the early 
events in the EV70 life cycle.
Specific aims
> To develop tools to facilitate research into the EV70 life cycle, and enable the use of 
viruses derived directly from uncultured clinical isolates. Specifically the 
construction of a full-length infectious EV70 clone and subgenomic replicon.
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> To determine the receptor interactions required by EV70 to enable binding and 
infection of the cell.
> To investigate the route of entry of EV70 into the cell, including the potential 
involvement of cellular signalling pathways and the cytoskeleton.
> To investigate the determinants of EV70 tissue tropism.
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CHAPTER 2 
Materials and Methods 
2.1 Reasents
2.1.1 Antibodies and conjugates
Antibodies were diluted in phosphate buffered saline (PBS) with 0.5% bovine serum 
albumin (BSA) for flow cytometry or immunofluorescence (IF) and in blocking buffer 
for western blots (WB). The supplier and dilution used for each technique is indicated 
below.
Anti-actin rabbit polyclonal (Sigma) -  1:40 (IF)
Anti-alpha tubulin mouse monoclonal (Abeam) -  1:50 (IF)
Anti-Caveolinl rabbit polyclonal (Santa Cruz) -1 :2  000 (WB)
Anti-DAF rabbit polyclonal antiserum (raised against Pichia expressed human DAF in- 
house, Prof DJ Evans laboratory) -  Working concentrations detailed in relevant 
sections
Anti-enterovirus 70 mouse monoclonal 854 (Chemicon) -  1:667 (flow cytometry),
1:250 (IF)
Anti-enterovirus mouse monoclonal 5-D8/1 (Dako) -  1:400 (flow cytometry, IF) 
Anti-mouse IgG Fluorescein isothiocyanate (FITC) conjugate produced in goat 
(ImmunologicalsDirect) -  1 ;400 (flow cytometry, IF)
Anti-rabbit IgG FITC conjugate produced in goat (Sigma) -  1:320 (IF)
Anti-rabbit IgG peroxidase conjugate produced in goat (Sigma) -  1:3 000 (WB)
Anti-5Tc rabbit monoclonal (Cell signaling) -  1:1 000 (WB)
Transferrin from human serum, fluorescein conjugated (Invitrogen) -  5mg/ml in PBS
2.1.2 Growth Media and supplements
Dulbecco’s minimum essential medium (DMEM) (Invitrogen)
F12 Ham (Invitrogen)
Foetal Calf serum (FCS) (Invitrogen)
Glutamine 200mM (Invitrogen)
Leibovitz’s L -15 medium (Invitrogen)
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Minimum essential medium with Earle’s salts (EMEM) (Invitrogen)
Methionine/cysteine free DMEM (Sigma)
Non-essential amino acids lOmM (Invitrogen)
Opti-MEM -  reduced serum medium (Invitrogen)
Penicillin/Streptomycin lOOx, 10 OQOIU/10 OOOpg per ml (Invitrogen)
Sodium Bicarbonate 7,5% (Invitrogen)
Sodium Pyruvate lOOmM (Invitrogen)
Trypsin, porcine, 25g/litre (Invitrogen)
Versene -  0.2g/litre ethylenediaminetetraacetic acid (EDTA) in PBS (Invitrogen)
2.1.3 Buffers and Solutions
Brij-58 (Sigma) -  1% in 2mM EDTA in PBS
Crystal Violet solution -  0,5g crystal violet dissolved in 20ml ethanol, made up to 1 litre 
in a solution of 4% v/v formaldehyde, with 0.9g NaCl.
Paraformaldehyde -  4% v/v in PBS, stored at -20°C 
PBS/BSA - 0.5% v/v BSA in PBS, stored at 4°C 
PBS/Tween (PBjST)- PBS with 0.1% v/v Tween 20
Plaque assay overlay medium- 1 x EMEM (from 10 x EMEM), 2% v/v FCS, 2mM 
glutamine, Ix penicillin/streptomycin, 3ml 7.5% sodium bicarbonate, 20mM MgCl% 
and 0.6% low melting point agarose (made up as 2% stock in deionised water 
(dHzO), melted and added just prior to use)
TAB (5Ox) -  242g Tris base, 57.1ml glacial acetic acid, 0.05M EDTA pH8.0, made up 
to 1 litre
TM buffer -  lOmM TrisHCl pH 7.5, ImM MgCh (1 protease inhibitor tablet/10ml). 
TNE buffer -  lOmM TrisHCl pH7.5, 150mM NaCl, ImM EDTA 
Tris-glycine electrophoresis buffer (lOx) -  250mM Tris base, 2.5M glycine, 1% sodium 
dodecyl sulphate (SDS)
Triton XlOO - 0.1% v/v in PBS
Western Blot Blocking Buffer -  PB ST with 4% v/v skimmed milk powder
Western Blot Transfer Buffer -  25mM Tris, 0.2M glycine, 20% v/v methanol, 10% SDS
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2.1.4 Chemicals, inhibitors and enzymes
Solvent and concentration of initial stock solution are given; working concentrations are 
detailed in the relevant results sections. All other unlisted basic chemicals were obtained 
from Sigma, unless noted elsewhere in this section.
a2-3 specific neuraminidase from Streptococcus pneumoniae (Sigma) -  lU/ml in PBS
Ammonium Chloride (NH4CI) (Sigma) -  3M in dH20
Ampicillin (Sigma) -  lOOmg/ml in dH20
Bafilomycin (Sigma) - 40pM in dimethyl sulphoxide (DMSO)
Bisindoylmaleimide (Sigma) -  2mM in DMSO
Brefeldin A (Sigma) -  36mM in ethanol
Chiorpromazine (Sigma) -  78mM in dH20
Chymotrypsin (Sigma) -  lOOmg/ml in H2O
Cytochalasin B (Sigma) -  20mM in DMSO
Genistein (Sigma) -  18mM in DMSO
Guanidine Hydrochloride (Sigma) -  200mM in dH20
Kanamycin (Sigma) - 50mg/ml in dH20
Methyl-p-cyclodextrin (Sigma) - 38mM in dH20
N-Acetylneuraminic Acid (Sialic Acid, Sigma) -  lOOmg/ml in dH20
Neuraminidase from Clostridiumperfringens (Sigma) -  lU/ml in PBS
Nocodazole (Sigma) -  33mM in DMSO
Nystatin (Sigma) -  52mM in dH20
Phospholipase C (PLC, Sigma) -  5U/ml in PBS
Phosphotidylinositol specific phospholipase C (PfPLC, sigma) -  5U/ml in PBS 
PP2 (Calbiocheiu) -  lOmM in DMSO 
Progesterone (Sigma) -  32mM in ethanol
Protease Inhibitor Tablets (Roche) -  1 Tablet/10ml solution (added just prior to use) 
Proteinase K (Sigma) -  1 mg/ml in dH20 
Trypsin (Sigma) -  lOOmg/ml in dH20
2.1.5 Molecular biology enzymes, reagents and kits
Plasmids are listed in table 2.1
Agarose (Roche) Used as a 1% solution in Ix TAE
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Table 2.1 Description of plasmids
-p^U)
Plasmid Source Description
p5’70Rep3 This project
(section 3.3.1 / figure 3.10)
Chimeric PV3 luciferase-encoding subgenomic replicon, with EV70 5’UTR. 
Contains ribozyme and T7 promoter. Ampicillin resistant.
pBIuescript H SK- Stratagene Cloning vector with polylinker and LacZa blue-white selection. Ampicillin 
resistant.
pFLC70 This project
(section 3.1.5 / figure 3.4)
EV70 hill length infectious clone with ribozyme and T7 promoter. Ampicillin 
resistant.
pFLC70p This project
(section 3.1.4 / figure 3.2)
EV70 full length infectious clone with ribozyme and T7 promoter. Contains 
changes within 5’UTR (table 3.3). Ampicillin resistant.
pLuc70 This project
(section 3.3.1/ figure 3.10)
EV70 luciferase-encoding subgenomic replicon with ribozyme and T7 
promoter. Ampicillin resistant.
pLuc7 Ointermediate This project
(section 3.3.1 / figure 3.10)
Intermediate in the construction of pLuc70. Contains EV70 5’UTR, partial PI, 
P2, P3 and 3’UTR. Also encodes luciferase and a small portion of the PV3 
P1/2 junction. Ampicillin resistant.
pFCR-BIuntn-TOPO Supplied with Zero Blunt 
TOPO PCR Cloning Kit 
(Invitrogen)
TOPO cloning vector with ccdB lethal gene selection, T7 and SP6 promoters 
and M l3 forward and reverse primer binding sites. Supplied linearised, with 
Vaccinia virus DNA topoisomerase I covalently linked to 3’end of each strand. 
Kanamycin resistant.
pT7rep3-L+R Prof. DJ Evans, in house 
(Goodfellow et al., 2000)
PV3 luciferase-encoding subgenomic replicon with ribozyme and T7 
promoter. Ampicillin resistant.
pTOPOFLC70 This project
(section 3.1.2/ figure 3.2)
EV70 full length infectious clone with T7 promoter. Contains changes within 
5’UTR (table 3.3). No ribozyme. Kanamycin resistant.
I
?
I
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BC A Assay Kit (Pierce)
Deep Vent DNA Polymerase (invitrogen). Supplied with lOOmM MgS0 4  and lOx 
thermopol reaction buffer 
Deoxyribonucleotide triphosphates (dNTPs); dATP, dUTP, dCTP, dGTP (Invitrogen) 
supplied separately at lOOmM each and diluted to a single stock solution in dHzO 
containing lOmMeach 
Ethidium Bromide Solution lOmg/ml (BioChemika)
KOD Hot Start DNA polymerase (Novagen). Supplied with 25mM MgS0 4 , dNTP 
solution containing d ATP, dXTP, dCTP and dGTP at 2mM each and 1 Ox PCR 
buffer
Lipofectamine 2000 (Invitrogen)
Low Melting Point Agarose (Roche) Used as a 1% solution in TAE 
Luciferase Assay System (Promega)
Megascript T7 kit (Ambion)
Platinum Pfx DNA Polymerase (Invitrogen). Supplied with 50mM MgS0 4  and lOx PCR 
buffer
Primers (VHbio) - diluted on receipt to a stock of 100 picomolar in dH20 
QIAfilter Plasmid Midi Kit (Qiagen)
QIAquick Gel Extraction Kit (Qiagen)
QIAquick PCR purification Kit (Qiagen)
QIAamp Viral RNA Mini Kit (Qiagen)
RNaseOUT (Invitrogen)
RNeasy Mini Kit (Qiagen)
Ribonucleotide triphosphates (rNTPs): rATP, rUTP, rCTP, rGTP (Promega) supplied 
separately at lOOmM each and diluted to a single stock solution in dH^O containing 
1 OmM each 
RQl RNase-Free DNase (Promega)
Restriction endonucleases (New England Biolabs)
SP6 RNA polymerase (Invitrogen). Supplied with 5x buffer and O.IM DTT 
Superscript II Reverse Transcriptase (Invitrogen)
T4 DNALigase (New England Biolabs). Supplied with lOx buffer 
T7 RNA Polymerase (Invitrogen). Supplied with 5x buffer and O.IM DTT 
Zero Blunt TOPO PCR Cloning Kit (Invitrogen)
44
Chapter 2 Materials and Methods
2,2 Cell lines and tissue culture
All cells were grown at 37°C in 5% carbon dioxide unless otherwise stated. Cells were 
washed with PBS and detached in versene supplemented with 2.5g/litre trypsin.
MRC5 are primary human embryonic lung fibroblast cells and were obtained from the 
European Collection of Cell Cultures and LGC Promochem. The cells were grown in 
EMEM, supplemented with O.lmM non-essential amino acids, 2mM glutamine, Ix 
penicillin/streptomycin and 10% FCS. Cells were recovered on receipt (16 population 
doublings) and frozen at approximately 18 population doublings. Following recovery 
they were split 1 ;6 and used for assays up to 36 total population doublings.
RD are human embryo rhabdomyosarcoma cells. They were grown in DMEM, 
supplemented with 2mM glutamine, Ix penicillin/streptomycin and 10% FCS and were 
split 1:5 to 1:20.
RD-ICAM are RD cells engineered to express human ICAM-1, and were a generous 
gift from Dr Darren Shafren, University of Newcastle, Australia. The cells were grown 
under the same conditions as RD cells.
FleLa are human cervix epitheloid carcinoma cells. They were grown in DMEM 
supplemented with 2mM glutamine, Ix penicillin/streptomycin and 10% FCS and were 
split 1:5 to 1:10.
RK13 are rabbit kidney cells, obtained from LGC Promochem. They were grown in 
EMEM supplemented with O.lmM non-essential amino acids, ImM sodium pyruvate, 
2mM glutamine, Ix penicillin/streptomycin and 10% FCS and were split 1:5 to 1:20.
CHO are Chinese hamster ovary cells. They were grown in F I2 Ham medium, 
supplemented with 2mM glutamine, Ix penicillin/streptomycin and 10% FCS and were 
split 1:5 to 1:20.
CHODAF are CHO cells engineered to express human DAF. Cells were transfected 
with a DAF expression vector based on the plasmid pDR2AEFla and stable 
transfectants selected (in-house. Prof. DJ Evans laboratory). The cells were grown under 
the same conditions as CHO cells.
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XTC-2 are Xenopus laevis, African clawed toad cells and were generously provided by 
Prof. R Elliott, University of Glasgow. They were grown at 28“C in Leibovitz’s L-15 
medium, supplemented with 2mM glutamine, Ix penicillin/streptomycin and 10% FCS 
and were split 1:5 to 1:10.
XTC-2DAF are XTC-2 cells engineered to express human DAF. Cells were transfected 
with a DAF expression vector based on the plasmid pDR2AEFla and stable 
transfectants selected (in-house, Prof. DJ Evans laboratory). The cells were grown under 
the same conditions as XTC-2 cells.
C6/36 ?iXQAedes albopictus larvae cells and were generously provided by Prof. R 
Elliott, University of Glasgow. They were grown in EMEM supplemented with O.lmM 
non-essential amino acids, ImM sodium pyruvate, 2mM glutamine, Ix 
penicillin/streptomycin and 10% FCS and were spilt 1:5 to 1:10.
2,3 Viruses, vassase and quantification
2.3.1 Viruses
The viruses used are listed in table 2.2, together with details of where the viruses were 
obtained and the growth conditions used for cultivation of viral stocks.
2.3.2 Viral Passage
Cells were grown to 80-90% confluency, washed with PBS and inoculated with virus at 
a multiplicity of infection (m.o.i.) of at least three in a volume of under 1ml. After 
45min absorption at room temperature, the inoculum was removed and cells washed 
with PBS before adding lOmls of serum-free growth medium. Inoculated cells were 
incubated in 5% carbon dioxide at the temperatures detailed in table 2.2. After the 
appearance of full cytopathic effect (CPE), vims was harvested at 16-24hr by two 
freeze-thaw cycles followed by centrifugation for 5min at 4 OOOrpm. The clarified vims- 
containing supernatant was then stored in 1ml aliquots at -70®C (EV70) or -20'^C (other 
vimses).
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Table 2.2 List of viruses used with details of source and culture conditions
Virus Source Cell line used for 
cultivation
Growth
temperature
EV70 (also referred to as wild 
type EV70)
A fresh aliquot of EV70 (strain J670/71) from ATCC 
was passaged in MRC5 cells and all work carried out 
using virus obtained from the fifth passage
MRC5 33°C
E V 7 0 ^ Derived from pFLC70 full length EV70 infectious 
clone (chapter 3)
MRC5
(RNA transfection)
33°C
Echovirus type 7 Dr D Williams (University of Glasgow), originally 
derived from an infectious clone generously provided 
by Prof. M. Lindberg (University of Kalmar, Sweden)
RD 37°C
Echovirus type 11 (strain 207) Generously provided by Dr T. D. K. Brown 
(University of Cambridge), Stuart et al., 2002
RD 37X
CVA21 Generously provided by Prof. Glyn Stanway, 
(University of Essex)
RD-ICAM 37°C
Influenza B virus Generously provided by Dr Wendy Barclay, 
(University of Reading)
Egg, allantoic fluid 37°C I
I
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2.3.3 Plaque Assay
A ten-fold dilution series o f virus in serum-free EMEM was made, and 200p] of each 
added to wells of a 6-well tissue culture dish containing 90% confluent MRC5 cells. 
Following 45min adsorption, 4ml plaque assay overlay medium was added per well 
without washing. Once set, plates were inverted and incubated for 72hr at 37°C or 33°C 
as appropriate (table 2.2). Plates were stained with Crystal Violet solution overnight 
prior to the removal of overlay, and plaques counted.
2.3.4 50% Tissue Culture Infectious Dose (TCIDso) Assay
Four replicates of a ten-fold dilution series of virus in serum-free EMEM were made in 
50p.l volumes in a 96-well tissue culture plate. MRC5 cells were detached in trypsin and 
made up to a concentration of 1 x 10  ^ cells/ml in growth medium and lOOpl added to 
each well. A further volume of 50pf semm-free EMEM was added to make a final 
volume of 200gl/well. Cells were incubated for 96hr at 37°C or 33°C as appropriate 
(table 2.2). The proportion of wells at each dilution showing CPE was scored and the 
TCIDso calculated. Where required, the effect of potential inhibitors of viral infection 
was determined, by treating cells prior to their addition to the viral dilution series.
2.3.5 Growth Curves
90% confluent cells in 35mm dishes were infected with virus at an m.o.i. of three and 
dishes incubated at 33°C. Dishes were frozen at -20°C at time points detailed in the 
relevant sections. After two freeze-thaw cycles virus was harvested and titrated by 
plaque assay or TCIDso.
2.4 Molecular Biolosv Protocols
A list of plasmids used is provided in table 2.1.
2.4.1 DNA Purification
Small scale plasmid DNA preparation was carried out by alkaline lysis using published 
protocols (Sambrook and Russel, 2000). Larger scale plasmid DNA preparation was 
carried out using the QIAfilter Plasmid Midi Kit (Qiagen), according to the 
manufacturer’s protocol.
48
Chapter 2 Materials and Metliods
Purification of PCR products was carried out using the QIAquick PCR purification Kit 
(Qiagen) or, following electrophoresis, with the QIAquick Gel Extraction Kit (Qiagen), 
both according to the manufacturer’s protocol with a final elution volume of 30pl dH^O.
Phenol/chloroform extraction was carried out by adding an equal volume of phenol: 
chloroform: isoamyl ethanol (25:24:1) to the solution. The sample was then vortexed 
and centrifuged for 5min at 13 OOOrpm. The upper aqueous, DNA containing layer was 
then transferred to a fresh sample tube.
Ethanol precipitation of DNA was carried out by the addition of 1/10 volume 3M 
sodium acetate pH5.3 and 7>A volumes 100% ethanol. Samples were then centrifuged at 
13 OOOrpm at 4°C for 30min, washed with 70% ethanol, centrifuged for a further lOmin 
at 13 OOOrpm and resuspended in dH20.
2.4.2 DNA, RNA and protein quantification
DNA and RNA were quantified using an Eppendorf BioPhotometer. Protein 
quantification was carried out using a BCA assay kit (Pierce), following the 
manufacturer’s protocol and using an MRX Microplate Reader (Dynex Technologies).
2.4.3 DNA Electrophoresis
Gel electropheresis of DNA was carried out at 5V/cm in 1% agarose supplemented with 
O.lpg/ml Ethidium Bromide Solution. The mnning buffer was Ix TAE. Where 
purification of DNA fragments from the gel was required low melting point agarose was 
used.
2.4.4 Viral RNA extraction and reverse transcription
Viral RNA was extracted from viral tissue culture supernatant using the QIAamp Viral 
RNA Mini Kit (Qiagen) according to the manufacturer’s protocol. 140pl of clarified 
viral tissue culture supernatant was used per spin column.
Reverse transcription was carried out using lOpl of extracted viral RNA, primer E70rt 
(Table 3.1) and superscript II reverse transcriptase (Invitrogen) in a reaction volume of 
20pl. The enzyme supplier’s protocol was used with the modification of a longer 
extension incubation of 130min at 46°C. Following reverse transcription, RNA was
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hydrolysed by the addition of IM  sodium hydroxide to a final concentration of 0. IM, 
and incubation at 37°C for 20min. The cDNA was precipitated with ethanol and 
resuspended in 20pl dH20. Integrity of the full-length RTPCR product was then 
assessed using PCR targeted at the viral 5’UTR (section 2.4.5, table 2.3).
2.4.5 PCR
PCR was carried out using PTC 200 DNA engine Thermal Cycler (MJ Research). 
Conditions were optimised at a range of magnesium concentrations and annealing 
temperatures using a gradient PCR block. The optimised conditions used are detailed in 
table 2.3. Reactions were analysed by electrophoresis, using 2-5p.1 of the reaction 
mixture.
2.4.6 Restriction endonuclease digestion
Reactions were carried out with a minimum of 5 units of enzyme per digest for 2hr 
using the recommended temperature and buffer.
2.4.7 Cloning Protocols
Detailed descriptions of the cloning strategies used to make the EV70 full-length 
infectious clone and subgenomic replicon are contained in chapter 3. Where necessary 
plasmids were digested with the restriction endonucleases detailed in the relevant 
sections, and insert and vector fragments separated by agarose gel electrophoresis prior 
to purification using the QIAquick Gel Extraction Kit (Qiagen), according to the 
manufacturer’s protocol. Ligation, transformation and the selection of insert containing 
clones are described in sections 2.4.8 and 2.4.9. For cloning using the Zero Blunt TOPO 
PCR Cloning Kit (Invitrogen), the manufacturer’s protocol was followed using a vector 
to insert ratio of 1:3.
2.4.8 Ligation
Ligations were carried out in a lOpl reaction volume containing 50~100ng of vector, 
insert (in a vector to insert ratio of 1:3), 400 units T4 DNA ligase and Ix ligase buffer. 
Reactions were incubated overnight at 16°C, DNA was precipitated with ethanol and 
5 pi used per transformation.
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Table 2.3 PCR reaction contents and conditions
PCR* Polymerase
Primersf
fl©
PM '-HCt
H
©
Cycles (30)
9
i |
©Sense Anti-sense
g
'■*3
2
9
C5
sQ
W)
9
1
9<
9O
&
9O
Full length 
EV70
lunit KOD Hot Start 
DNA Polymerase 
(Novagen)
EV70s5p EV70a3p 2min
94°C
15s
94°C
30s
58.5X
390s
72X
20min
72°C
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^Reactions were carried out in a 50{o.l volume containing the polymerase and 0.4pl of the primers detailed, and in the appropriate 
polymerase buffer with 4pl cDNA, 2mM MgSO^ and 0.2mMdNTPs. f  Primer sequences are detailed in table 3.1.
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2.4.9 B acterial transfo rm ation  and  selection of positive clones.
Transformations were carried out using either commercially available chemically 
competent TO?\Q E.coli (Invitrogen) according to the supplier’s protocol, or 
alternatively, using in-house electrocompetent Kcoli DH5a (see below). For TOPO 
cloning One Shot®Electrocompetent E,coli (Invitrogen) were used following the 
manufacturer’s protocol.
Electrocompetent Æco/z DH5a were made as described in Sambrook and Russel, 2000. 
Plasmid or ligated DNA was added to 45pl of electrocompetent cells. Electroporation 
was then carried out using an ECM 630 electroporator (BTX) at settings of 1600V,
400D and 25 pF. After addition of 1ml of L-Broth, cells were incubated at 37°C for 
60min and plated on selective agar.
For all transformations agar were supplemented with either kanamycin at SOpg/ml or 
ampicillin at lOOpg/ml as appropriate. Plates were incubated inverted overnight at 37°C.
2.4.10 Sequencing
Sequencing was carried out by The Sequencing Service, School of Life Sciences, 
University of Dundee, Scotland fwww. dnaseq.co.ukL and analysed using Bioedit (Tom 
Hall, Ibis Therapeutics) and Clustal X software (Thompson et al., 1997). Plasmid 
templates were purified using the QIAfilter plasmid midi kit (Qiagen) and PCR 
templates purified using the QIAquick PCR purification Kit (Qiagen), according to the 
manufacturer’s protocol. Sequencing primers used are listed in table 2.4. In addition 
M l3 forward and reverse primers supplied with the TOPO cloning kit (Invitrogen) were 
used to sequence the ends o f cloned inserts.
2.4.11 RNA transcrip tion
5pg of Plasmid DNA, from the viral ftill-length clone or subgenomic replicon, was 
linearised in a 50pl volume using the restriction endonuclease Sal I, extracted with 
phenol/chloroform, ethanol precipitated and resuspended in 20pi dH^O. The 
transcription reaction was carried out for 2hr at 37°C in a 50pl volume containing lOpl 
linearised DNA, lOOU T7 or SP6 RNA polymerase as appropriate, 120U RNaseOUT,
Ix polymerase buffer and ImM rNTPs. Transcribed RNA was treated with RQl DNase
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Table 2.4 Primers used for sequencing of EV70 genome
Primer* Sequence (5’ to 3’)
497F ATCCTGTGAGTGGTTTGTCG
518R TAG G AC AAAC C AC T CAC T GG
1057F C TAG C T GATAAT GAGGCAG
1442F CTCTTGTATACCCTCACCAG
1620R TGGCACATAGGAGT T T GAG
2620F TCTGCACTTGTGTGTATGCG
2801R C TAAGGG TGGG TACAATAG
3200F TGCCCTATACCAACATCCTC
3552F CCCTGGTATTCAGTGGATC
4107F ATTGAGAGGCCTGGATTGG
4690F ATTGAGAGGCCTGGATTGG
4877F CAGAAAAGT GCAGAC CAACC
4882R TTTCTGGGTTGCACAACTCC
5246F CGCTACAGGCAATAACCAC
6419R GCCCTTCTCTACTTTCTCTC
6432F GAAGGGCAAGTCTAGTGTC
6992F CAGCAGACAAGAG TAG T G G
7092F CCCAGTTATGCCAATGAAGG
* In the primer names, numbers refer to the position of the 5’ base in the 
published EV70 sequence (Ryan et al, 1990) and ‘F’ and ‘R ’ represent 
sense and anti sense orientations with respect to the EV70 genome.
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(Promega) according to the supplier’s protocol and purified using the RNeasy mini kit 
(Qiagen), according to the manufacturer’s protocol, with a final elution volume of 50pl. 
RNA integrity was checked by gel electrophoresis (as for DNA electrophoresis above, 
using ribonuclease free solutions and buffers) and RNA quantified by 
spectrophotometry. Where a large amount of viral RNA transcript was required a 
Megascript T7 kit (Ambion) was used, according to the manufacturer’s protocol.
2.4.12 Eukaryotic Cell transfection
For electroporation cells were detached with trypsin, washed and resuspended at 2 x 10  ^
cells/ml. 2pg of RNA was added to 450pl of cells and electroporation carried out using 
a BioRad GenePulserXCell at exponential wave settings of 250V, 250mF, ooQ. Cells 
were then added to 4ml of growth medium, transferred to a 6-well tissue culture dish, 
and incubated at 33°C.
Lipofection was carried out in 6-well dishes using Lipofectamine 2000 (Invitrogen) and 
following the manufacturer’s protocol. In brief 2 gg of RNA in lOOpl Opti-MEM 
(Invitrogen) was added to 4pl lipofectamine 2000 in lOOpl Opti-MEM, mixed, and 
incubated at room temperature for 20mins. Growth medium was removed from a 
monolayer of cells in one well of a 6-well dish, replaced with SOOpl of Opti-MEM and 
the 200pl solution of RNA/lipofectamine added. Cells were incubated at 33°C and the 
culture medium replaced after 1-2 hours.
2.5 Experimental Protocols
2.5.1 Chemical treatments of cells
All reagents were made up in serum-free EMEM from stock solutions (section 2.1.3) at 
the concentrations detailed in the relevant chapters. Controls were treated with serum- 
free EMEM alone. Cells were used at 90% confluency. To prevent detachment, plates to 
be used for cytochalasin B treated cells, were pre-treated with 0.01% poly-L-lysine 
(Sigma), according to the supplier’s protocol. All cells were washed in PBS and treated 
with reagents in a volume of 200pl per coverslip, 500pl per well of a 6-well plate or 6ml 
per 150cm^ flask. For binding assays and the TCIDso-based infectivity assay, cells were 
first detached, washed with PBS and resuspended in SOOpl reagent per 10^  cells.
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Incubations were for Ihr at 3TC  for non-specific and a2-3 specific neuraminidase, Ihr 
at 4°C for anti-DAF rabbit polyclonal and 30min at 3TC  for NH4CI, bafilomycin, 
bisindoylmaleimide, brefeldin A, chlorpromazine, cytochalasin B, genistein, methyl-p- 
cyclodextrin, nocodazole, nystatin & progesterone and PP2. The agents were also 
maintained in the culture medium during virus adsorption and incubation stages.
2.5.2 Toxicity Assay
MRC5 cells were treated with agents for 6 hr at 37°C. All cell treatment solutions were 
tested on Whatman pH 6 - 8  indicator paper to ensure maintenance of neutral pH. 
Subsequently cells were detached with trypsin and stained with trypan blue (Sigma), to 
indicate viability. Only intact, unstained (viable) cells were counted. Three wells were 
counted per reagent concentration and compared to the numbers of intact cells in three 
control wells. Concentrations resulting in more than a 0.5 logio reduction in viable cells 
were considered toxic.
2.5.3 pH stability assay
A series o f solutions were made up between pH 1 and pH 7 by dilution of IM HCl with 
IM NaOH using a PH211 Microprocessor pH Meter (Hanna Instruments). These were 
used to dilute viral stock from tissue culture supernatant to 1 in 100. In parallel, 
supernatant from a mock-infected flask incubated with the viral cultures was also 
diluted 1:100 in the pH solutions, and the pH measured to obtain an accurate pH at the 
time of the assay. Virus containing solutions were incubated for 20min at 37°C, adjusted 
to pH 7 with 7.5% sodium bicarbonate using Whatman®pH 6 - 8  indicator paper and 
assayed by TCID50, using the neat solution ( 1 :1 0 0 ) as the starting dilution.
2.5.4 Flow cytometry -based Infectivity Assay
MRC5 cells were treated with enzymes, inhibitors or antibody in 6 -well plates as 
detailed in section 2.5.1. Cells were washed with PBS and infected with virus at an 
m.o.i. of three. Assays were carried out in duplicate with three wells being used per 
replicate. After 6 hr incubation, cells were detached with trypsin, washed with PBS and 
transferred to a V-bottom 96-well plate. Subsequent steps were carried out at room 
temperature. Washes were carried out by centrifugation for 3min at 2 OOOrpm, followed 
by resuspension of the cell pellet in PBS/BSA. Cells were fixed in 4% 
paraformaldehyde for 20min, washed once and permeabilised with 0.1% triton X I00 for
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lOmin. After a further wash, cells were treated with the primary antibody for Ihr, 
washed twice and treated with the secondary antibody (goat anti-mouse IgG FITC) for 
Ihr. After a further three washes stained cells were analysed using a FACSCalibur Flow 
Cytometer (Becton Dickinson). A minimum of 10 000 events were counted per sample.
2.5.5 Transferrin Uptake Assay
Cells were pre-treated with enzymes or inhibitors in 6-well plates as detailed in section 
2.5.1, with all assays being conducted in duplicate. Plates were transferred to 4°C and 
washed with PBS. Fluorescein-conjugated transferrin was made up from stock to 
0.2mg/ml in serum-free EMEM and 500pi added per well. Plates were incubated for 
20min at 4°C and then either processed immediately or transferred to 37“C for 15min. 
For analysis, cells were detached with trypsin and washed once with 0. IM glycine-0. IM 
NaCl (pH3) to remove non-internalised conjugate, and washed again with PBS. Cells 
were then analysed using a FACSCalibur Flow Cytometer (Becton Dickinson), with a 
minimum of 5 000 events counted per sample.
2.5.6 Phospho Src specific ELISA
Cells were treated with enzymes or inhibitors as detailed in section 2.5.1. The assay was 
carried out in duplicate using one 150cm^ flask of MRC5 cells per replicate. Cells were 
detached with versene and lysed in a volume of 1 OOpl of cell extraction buffer. Lysates 
were tested neat and at a dilution of 1:2 in cell extraction buffer. Tyr"^ ^^  phosphorylated 
src was assayed using the PhosphoDetect Src (pTyr"^^ )^ ELISA Kit (Calbiochem), 
following the manufacturer’s protocol.
2.5.7 Indirect Fluorescence
Cells were grown on coverslips and either infected with virus at an m.o.i. of three, and 
incubated for 6hr at 37°C (echovirus type 7) or 33°C (EV70), or treated with 
cytochalasin B or nocodazole as described in section 2.5.1. All washes were carried out 
with PBS/BSA and all incubations were at room temperature. Cells were washed, fixed 
with 4% paraformaldehyde for 20min and permeabilised with 0.1% triton XIGO for 
lOmin. Coverslips were treated with primary antibody for Ihr, washed twice, treated 
with secondary antibody (goat anti-mouse or goat anti-rabbit IgG FITC) for Ihr and 
washed a further three times before mounting on microscopy slides. Cells were viewed 
and photographed using a LSM 510 Meta Confocal Microscope (Zeiss).
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2.5.8 Haemagglutination and haemagglutiiiatioii inhibition assays
Human blood of type O positive was obtained from the blood transfusion service at the 
Western Infirmary, Glasgow. The units used were generally within the week after 
becoming out-of-date for transfusion purposes. RBC were washed at 4°C by 5 min 
centrifugation at 2 OOOrpm, with resuspension in PBS until the supernatant was clear (3- 
4 washes) and the packed cells were retained. Assays were done on ice, unless 
otherwise stated. EV70 and CVA21 were first concentrated from infected tissue culture 
supernatant by sucrose cushion ultracentrifugation (section 2.5.9). Echovirus type 7 was 
used directly from tissue culture supernatant at a titre of at least 1 x lOVml and 
influenza virus used in allantoic fluid.
HA assay - Packed RBC were resuspended in PBS to give a 0.5% v/v solution. A two­
fold dilution series of virus was made in duplicate in 50pl PBS in a U-bottom 96-well 
plate. A starting dilution of 1 in 10 was used and PBS only controls included. 50pl o f 
0.5% v/v solution RBC in PBS was added to each well and the plate incubated on ice 
until a clear RBC pellet was seen in control wells (approximately 2-3 hr). HA was 
assessed visually and the HA titre scored as the highest dilution displaying HA in both 
duplicate wells (1 HA unit).
HA Inhibition assay (RBC treatment) -  4HA units of vims in 50pl of PBS were added 
to wells in a U-bottom plate. 10% v/v RBC were incubated for Ihr at 37°C in enzyme 
solutions made up in PBS from stock solutions, at the concentrations detailed in the 
relevant chapters. Treated RBC were washed with PBS, made up to 0.5% RBC v/v with 
PBS and 50pl added to wells containing vims or controls. Plates were incubated on ice 
and HA titre scored as above.
HA Inhibition assay (vims treatment). A two-fold dilution series of soluble Fc DAT 
(Harris et al., 2005) or N-acetylneuraminic acid (sialic acid) was made in 25pi PBS in a 
U-bottom plate at the concentrations detailed in the relevant chapters. 4HA units of 
vims in 50pl o f PBS were added to each well and plates incubated on ice for Ihr. 25 pi 
of a 1% v/v solution of RBC was added to each well. Plates were incubated on ice and 
HA titre scored as above.
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2.5.9 Preparation of labelled virus
90% confluent cells in a 75cm^ flask were washed and incubated in methionine/cysteine 
free DMEM (Sigma) for Ihr and infected with virus at an m.o.i. of between five and 
ten. Following 45min adsorption, cells were washed and 10ml methionine/cysteine free 
DMEM added. Flasks were then incubated at 37“C or 33°C as appropriate. 200pCi Pro­
mix -[^^S] methionine/cysteine (Amersham) was added after 2hr (EV70, echovirus type 
7) or 4hr (CVA21) incubation. After overnight incubation and the development of full 
CPE, labelled virus was harvested by addition of lOOpl NP40 (Sigma) and 
centrifugation for 5min at 4 OOOrpm. Virus-containing supernatant was concentrated and 
partially purified by pelleting through a 2.5ml 30% sucrose cushion at 40 OOOrpm for 
6hr in a Sorvall Ultra Pro 80 centrifuge using a Sorvall TH641 rotor. The pellet was 
resuspended in 300pl of PBS. To obtain 160S infectious particles, the virus was further 
centrifuged through a 12ml 10-25% linear sucrose gradient (prepared using a Biocomp 
Gradient Master) for 90min at 40 OOOrpm in a Sorvall Ultra Pro 80 centrifuge using a 
TH641 rotor. The gradient was harvested in 500pl fractions using a Biocomp Gradient 
Fractionator and 5 pi of each fraction added to 3 ml of scintillation fluid (Ecoscint A, 
National Diagnostics) prior to counting in a Beckman LS5000CE liquid scintillation 
counter. The two fractions containing peak activity (typically the 5* and 6**^ fraction 
from the bottom of the gradient) were further centrifuged at 40 OOOrpm for 6hr in a 
Beckman TL-100 benchtop ultracentrifuge using a Beckman TLS55 rotor. Pelleted, 
labelled virus was resuspended in 200pl PBS and stored in aliquots at -70°C.
2.5.10 Binding Assays
Cells were detached with versene. If required they were then treated with antibody, 
enzymes or inhibitors as detailed in section 2.5.1. Treated or untreated cells were 
washed in PBS/BSA and 10  ^cells incubated on ice with 10 000-20 000 counts per 
minute (cpm) of ^ ^S labelled vims in a volume of 50pl for Ihr. Cells were washed three 
times in 4°C PBS/BSA, transferred to scintillation vials and counted as described in 
section 2.5.9. All assays were conducted in duplicate.
2.5.11 Raft fractionation
Cells were detached with versene and 10  ^used per fractionation. After two washes in 
semm free EMEM cells were incubated for Ihr on ice with 200 OOOcpm of 35^ labelled
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160S viral particles. Cells were washed twice with TM buffer to remove unbound virus, 
made up to 5ml with TM buffer and broken up using 80 strokes in a Dounce 
homogeniser. Unbroken cells were removed by centrifugation at 2 OOOrpm for 5min at 
4°C. Supernatant was then centrifuged at 33 OOOrpm for 15min at 4*^ 0 in a Beckman 
TL-100 benchtop ultracentrifuge using a beckman TLA100.3 rotor. This was repeated a 
total o f three times, the pellet being resuspended in TM buffer each time. The final 
membrane pellet was resuspended in 1ml 1% Brij-58 solution, and incubated on ice for 
2hr. An equal volume of 80% sucrose in TNE buffer was added to give a 40% solution 
and overlaid stepwise in a 5ml ultracentrifuge tube with 2ml o f 30% sucrose and 1ml of 
4% sucrose (both in TNE buffer). Gradients were centrifuged at 40 OOOrpm for 16hr at 
4°C in a Sorvall Ultra Pro 80 ultracentrifuge using a Sorvall AH650 rotor. 500pl 
fractions were collected using a Biocomp Gradient Fractionator. 250pi of each fraction 
was transferred to a scintillation vial and counted as described in section 2.5.9. A 
portion of each fraction was used for western blot analysis.
2.5.12 Western Blot
Cell lysates or membrane fractions were denatured at 100°C for 2min and subjected to 
SDS polyacrylamide gel electrophoresis on a 12.5% polyacrylamide gel using the 
BioRad Miniprotean 3 system at 30mA in Ix tris-glycine electrophoresis buffer.
Samples were subsequently transferred to nitrocellulose membrane using western blot 
transfer buffer and a BioRad TransBlot SD for Ihr at 200V. The membrane was then 
blocked using western blot blocking buffer for a minimum of Ihr at room temperature 
and incubated with primary antibody for either Ihr at room temperature (anti-caveolin 
1) or overnight at 4®C (anti-.s/‘c). Membranes were washed three times in PB ST and 
incubated for Ihr with anti-rabbit IgG peroxidase conjugate. After a further three 
washes with PB ST the protein was detected using ECL Western Blot Detection 
Reagents (Amersham), and the blot exposed for l-5min on Kodak film. Films were 
developed using a Compact X2 Automatic Film Processor (X-ograph Ltd.).
2.5.13 Luciferase assay
RNA was transcribed from subgenomic replicons and 2pg transfected into cells by 
electroporation or lipofection as described in section 2.4.12 (if required cells were first 
treated with inhibitors or enzymes as described in section 2.5.1). Cells were then added 
to 4ml of growth medium and 2ml transferred to two wells of a 6-well tissue culture
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dish. One of the duplicate wells was supplemented with 4mM guanidine hydrochloride. 
Cells were incubated at 33°C. All samples were tested in duplicate (4 wells per sample). 
The Promega Luciferase Assay System was used, Cells were harvested at 6hr 
(electroporation) or lOhr (lipofection) by scraping of cells, which were then washed 
with PBS and lysed with lOOpl of lysis buffer for 5min at room temperature. Following 
centrifugation the protein content of the lysate was quantified using the BCA assay.
100pi of luciferase substrate was added to 20pl of lysate (normalised for protein), and 
assayed using a TD-20/20 luminometer (Turner BioSystems).
2.5.14 Specific Infectivity Assay
RNA was transcribed from full-length clones and quantified. Six serial ten-fold 
dilutions were made in a volume of 250pl and transfected into cells by lipofection as 
described in section 2.4.12. After 3hr lipofectamine containing medium was removed, 
cells washed in PBS and 4 ml plaque assay overlay medium added. Subsequent 
processing was as for standard plaque assays. Results were expressed as plaque forming 
units (pfu) per pg of input RNA.
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CHAPTER 3 
Construction and Characterisation of an Enterovirus type 70 
Full-Length Infectious Clone and Subgenomic Replicon
The study of picornavinjses has been greatly facilitated by the availability of 
both full-length and subgenomic clones o f viral genomes. RNA transcribed in vitro 
from full-length clones can be transfected into cells to generate viable virus particles, 
while RNA from subgenomic replicons can be transfected into cells for the study of 
viral translation and replication processes. To date there have been no reports of an 
EV70 full-length infectious clone or subgenomic replicon.
Infectious viral clones enable reverse genetic approaches in research and where 
available, have become extremely valuable research tools. They are used not only in 
picornavirus research, but are also useful tools in other fields of virology. One very 
important recent development is the report of a full-length HCV clone which is capable 
of generating infectious virus in a hepatoma cell line (Zhong et al., 2005). As there has 
not previously been an in vitro model of HCV infection, this now makes possible 
infectivity studies, which previously could only be done in humans and chimpanzees.
A full-length infectious clone of the EV70 reference strain 1670/71, in which all 
studies have been carried out to date, would be extremely valuable tool in the study of 
all aspects of the viral life cycle. In particular, in the study of the interaction between 
EV70 and its receptor/s, it would facilitate reverse genetic approaches aimed at 
identifying the specific capsid residues involved in binding and potentially in 
determining cellular and species tropism. In addition it would allow one of the major 
concerns with viral receptor studies, including those in EV70, to be addressed -  that is, 
that in highly passaged viral reference strains, receptor usage may have diverged from 
that of wild type virus. It is not practical to generate full-length clones for all clinical 
isolates as it remains a difficult and time-consuming procedure, however, an alternative 
strategy of subcloning portions of the viral genome, specifically the capsid sequences, 
into a generic backbone is more feasible, and could enable the study of larger numbers 
of clinical isolates.
Infectious clones have been made using several strategies. The first polio vims 
clone was made directly from multiple viral cDNAs spanning the whole genome 
(Racaniello and Baltimore, 1981). Subsequently a CYB3 infectious clone was made
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from the cloning of a single full-length viral cDNA (Kandolf and Hofschneider, 1985). 
More recently clones have been constructed using RTPCR of viral genome segments. 
The successful construction of full-length enteroviral clones using a single long distance 
RTPCR has now also been reported (Lindberg et al., 1997). The drawbacks of this 
latter method include difficulties with optimisation of long distance RTPCRs and the 
potential for introduction of reverse transcriptase and PCR generated sequence errors. 
However, this is a potentially timesaving method, requiring fewer cloning steps than 
construction of the clone from smaller segments of the genome. For these reasons, long 
distance RTPCR was chosen here for the construction of a full-length EV70 clone, 
based on the approach previously described by Lindberg et al (1997).
An important consideration in the making of an enteroviral infectious clone is 
the requirement that the in vitro transcribed RNA have both an accurate 5’ and 3’ end. 
These are necessary for efficient poliovirus replication (Herold and Andino, 2000; 
Sarnow, 1989). At the 3’ end a polyadenosine sequence is required, followed by a 
restriction site to allow removal of additional sequences prior to transcription. An 
accurate 5’ end can be achieved with the use of the hammerhead ribozyme, derived 
from a plant viroid, (Birikh et al., 1997). When positioned immediately upstream of the 
viral sequence within an infectious clone and transcribed into RNA, it catalyses 
cleavage of the phosphodiester bond immediately upstream the first base, thereby 
generating the correct genomic 5’ end.
In addition to full-length clones, subgenomic viral replicons have also proven 
valuable tools in picornavirus and HCV research (Lohmann et al., 1999; Percy et al., 
1992). These contain a reporter gene, such as chloramphenicol acetyltransferase or 
firefly luciferase. The reporter gene sequence replaces the capsid-encoding section of 
the genome, which is not required, as viral binding and entry are by-passed by direct 
RNA transfection of the cell. On transfection of RNA into the cell, the viral 
poly protein, including reporter sequences, is translated and cleaved into its constituent 
proteins. Subsequent viral replication results in a proportionate increase in reporter gene 
product, which can then be measured. For HCV, the availability of subgenomic 
replicons (Lohmann et al., 1999) has allowed research into HCV translation and 
replication to progress prior to the availability of an in vitro culture system.
In addition to the requirement for a ribozyme (as for full-length clones), there 
are a number of further considerations in the construction of a subgenomic replicon. The 
reporter gene sequence replaces the capsid-encoding section of the virus and must be
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cloned in-frame with the rest of the viral open reading fi'ame, both 5% to ensure the 
reporter gene is correctly translated, and 3% to allow correct translation of the P2 and P3 
portions of the polyprotein required for proteolytic processing and viral replication. It is 
also important to include an intact P1/P2 junction to ensure correct processing by the 
viral 2A protease (Skern et al, 1991). It was decided to construct the EV70 subgenomic 
replicon with a luciferase reporter gene, This allows highly sensitive and rapid 
quantification of replication.
Chanter Outline
This chapter details the constmction of a full-length infectious EV70 clone and 
functional luciferase-encoding subgenomic replicon. Characterisation of these clones is 
described, including sequence data and the specific infectivity and growth 
characteristics of RNA and virus derived from the full-length clone.
3.1 Construction and Sequence Analysis o f a Full-Lensth EV70 
Clone usins Lons Distance Enterovirus RTPCR
To construct an EV70 infectious clone using long distance RTPCR of the viral 
genome, the strategy previously described by Lindberg et al. was used (Lindberg et al, 
1997).
3.1.1 Reverse Transcription and PCR
The primer used for reverse transcription, E70rt (table 3.1), included a Sal I 
restriction site to facilitate future cloning and 27 thymidine residues for annealing to the 
viral poly A tail. The reaction was carried out using viral RNA extracted from EV70 
J670/71 tissue culture supernatant. In view of the large size of the target (7390 bases) an 
extension step of 130 minutes at 46°C was used (Lindberg et al, 1997).
Following the reverse transcription step, the entire 7390 base EV70 sequence 
was amplified by PCR. The sense primer, EV70s5p, included a Sma I restriction site for 
future cloning and the initial 27 bases of the EV70 genome. The antisense primer, 
E70a3p, was identical to that used for reverse transcription with the addition of a further 
24 bases complimentary to the 3’ end of the EV70 genome. Problems were encountered 
with the efficiency and fidelity of several different proofreading polymerases during the
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Table 3.1 Primers used in construction of EV70 full length clones and subgenomic replicon
O n
4^
Name Sequence (5’ TO 3’)
E70rt ATAAGAATGTCGACTTTTTTTTTTTTTTTTTTTTTTTTTT (poly A  tail)
E70s5p ACGCCTCGAGCCCGGGTTAATTAAAACAGCTCTGGGGTTGTTCCCAC (1-27)
E70a3p ATAAGAATGTCGACTTTTTTTTTTTTTTTTTTTTTTTTTTTGATTCCCAATTAACCAAAATTTAC (poly A  tail-7367)
E70aJUPI
*
CTAGAAACTTGAGCTCCCATTATG (746-723)
EV70s3121
* * * 4=
GTCCAATACACACTAACAGTGCGCGCATATATGAAGCCTAAGC (3121-3163)
E70a3596 CTAGCTGGATAGTAATCAC (3596-3578)
EV70sJUPl
%
CATAATGGGAGCTCAAGTTTCTAG (723-746)
EV70aJP12
* * *
GCTTCATATATAACGCGTACTGTTAGTGTGTATTG (3157-3124)
EV70 derived sequence are underlined (numbers in parentheses refer to position relative to the published EV70 sequence) 
* Mismatches to EV70 sequence due to introduction of restriction sites.
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optimisation of the PCR reaction, including platinum pfx DNA polymerase (Invitrogen) 
and Deep Vent DNA polymerase (New England Biolabs). Despite extensive attempts at 
optimisation of the PCR reactions using these enzymes, the yield of full-length product 
remained poor, with even very minor changes in the reaction conditions resulting in 
failure to obtain detectable product. Attempts to amplify a smaller 3.5kb segment of the 
genome using pfx polymerase resulted in improved yield, but sequencing revealed 
multiple errors in the products. In contrast, KOD polymerase (Takagi et a l, 1997), from 
Novagen, proved to be much more reliable in terms of both yield and fidelity, it gave 
consistently good yield of the full-length product and was much less sensitive to 
changes in magnesium concentration or annealing temperature. KOD polymerase was 
therefore used for this and all subsequent PCR-based cloning. 30 PCR cycles, with 
extension times of 390 seconds, was identified as the minimum required to reliably 
yield sufficient product. The expected product of 7451 base pairs (bp) was produced, 
with a further non-specific product of approximately 2 kilobase pairs (kbp) (figure 3.1).
3.1.2 Cloning of full-length RTPCR product
A diagrammatic representation of the initial cloning steps is provided in figure 
3.2. The full-length RTPCR product was first purified from an agarose gel, to remove 
the non-specific product and any other smaller products that might interfere with 
cloning. It was initially cloned into the pPCR-Blunt II-TOPO cloning vector using the 
Zero Blunt TOPO PCR Cloning Kit (Invitrogen). The vector was supplied linearised, 
with Vaccinia vims topoisomerase I covalently linked to the 3’end of each strand, 
which acts as a ligase, and facilitates efficient cloning of blunt-ended PCR products. 
This vector also includes T7 and SP6 RNA polymerase promoters at either end of the 
insert site.
Sixteen clones were identified as containing inserts of the expected size and 
restriction pattern. Fourteen contained inserts orientated for transcription using the T7 
promoter, and two for transcription using the SP6 promoter. To test whether these 
clones were capable of generating infectious EV70 vims, the DNA was linearised at the 
3 ’ end of the poly A tail using the Sal I restriction site and RNA transcripts obtained 
using T7 or SP6 RNA polymerase as appropriate. 2pg of transcribed RNA was 
transfected by electroporation into MRC5 cells and incubated at 33°C. Cells transfected 
with twelve of the clones demonstrated CPE, seven by 48 hours and a further five by 96 
hours. RNA from the remaining four clones showed no CPE even after seven days
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<-----  c. 7400 bp RTPCR product
<-----  Non-specific 2 kbp product
Figure 3.1 Gel electrophoresis o f full-length EV70 RTPCR product.
Ethidium bromide stained agarose gel showing the full-length EV70 
RTPCR product o f  7451 bp at the expected size. There is also a further non­
specific band o f  just over 2 kbp. Lane 1, DNA size marker; lane 2, No 
template control; lane 3, EV70 full-length RTPCR.
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EV70 J670/71 Full-length RTPCR
5’ changes
rS
5’UTR
5’ changes
rS
PI (capsid} P2 P3
3 ’UTR
Cloned into 
pPCR-Blunt II-TOPO
T7 Promoter ^
PI (capsid) I P2
Pml I
pTOPOFLC70 
(plasmid sequences from pPCR-Bluntll-TOPO)
Ribozyme 
T7 Promoter / a
5’ changes
rS
To produce ribozyme- 
containing clone, EV70 
sequence sub-cloned into 
pT7Rep3-L+R
PU caB sid li P2 I P3
pFLC70P 
(plasmid sequences from T7Rep3-L+R)
Figure 3.2 Construction o f pFLC70p, a full-length EV70 clone with a 
ribozym e, but with 5’UTR sequence changes. The full-length EV70 RTPCR 
product (containing two 5’ changes) was cloned into pPCR-Blunt II-TOPO which 
contains a T7 promoter but no ribozyme using topoisomerase (full description in 
section 3.1.2). To obtain a ribozyme-containing clone, the full EV70 sequence, 
excluding the first 42 bp o f  the EV70 5’UTR, was sub-cloned into pT7Rep3-L+R, 
a luciferase-encoding PV3 replicon (see figure 3.10), using the restriction 
endonucleases Pm! I and Sal I. All PV3 and luciferase-encoding sequences were 
removed from the latter during cloning, except for the first 42 bases o f  the PV3 
5’UTR which are identical to the EV70 sequence (full description in section 
3.1.4). ■ ■  EV70 sequence.
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incubation. Supernatant from the transfections demonstrating CPE was passaged onto 
fresh cells following clarification by centrifligation and filtration. All twelve showed 
CPE at 24 hours, excluding the possibility that the initial observations were due to 
toxicity following electroporation. To confirm that the CPE was due to EV70, RTPCR 
of the viral capsid sequence was carried out on the passaged supernatant using EV70~ 
specific primers. The expected product of 2435 bp was observed for all CPE-exhibiting 
clones, but not for those without CPE (figure 3.3).
3.1.3 Sequence analysis of full-length clones
The two clones showing the most marked CPE 48 hours after transfection were 
fully sequenced and compared with the published J670/71 EV70 sequence (Ryan et al., 
1990). The clone with fewer differences from the published sequence (21 bases) was 
designated pTOPOFLC70 (tables 3.2 and 3.3). To establish whether the sequence 
differences were present in the original virus stock or were introduced during RTPCR, 
the RTPCR product and seven additional clones were sequenced.
Fifteen of the differences were present in the RTPCR product and in all clones 
(table 3.2). These are assumed to be true differences between the J670/71 strain used 
here and that originally sequenced. Of these fifteen differences, one was a G nucleotide 
insertion in the 5’ UTR, eight were synonymous and three resulted in conservative 
changes to related amino acids (alanine to valine, aspartate to glutamate and threonine 
to serine in VPl, 3 A and 3D respectively). The remaining three differences resulted in 
changes of amino acid o f arginine to glutamine and aspartate to asparagine, both in 
VPl, and alanine to threonine in 2C.
The remaining six differences were not found in the RTPCR sequence (table 
3.3). Two resulted in conservative changes (leucine to isoleucine in VP2 and isoleucine 
to valine in 3 A). These were both found in a proportion of the other clones sequenced, 
suggesting they may form part of the viral quasispecies. The remaining four were found 
only in single clones, and although these could be minor components of the 
quasispecies, they may also be due to errors during RTPCR. Two (in VP3 and VPl 
respectively) are synonymous and so of less concern, the remaining two lie within the 
5’UTR, and could therefore impact on either the stmcture or function of this region, 
which is important in viral translation and replication. All six changes were maintained 
after a further three passages in MRC5 cells, suggesting that there was no strong 
selection for reversion to wild type or consensus sequence at these sites. MFOLD
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Figure 3.3 Gel electrophoresis o f EV70 capsid RTPCR on cells transfected  
with RNA from pTO PO FLC 70 clones. PCR primers and conditions are 
detailed in tables 3.1 and 2.3 respectively. The expected product size o f  2435 bp 
is observed only for cells showing CPE. Lane 1, DNA size marker; lanes 2, 3 
and 4, no template - extraction, RT and PCR controls respectively; lane 5,
EV70 wild type culture supernatant; lane 6, mock transfection; lanes 7 and 8, 
two clones showing CPE; lanes 9 and 10 two clones showing no CPE.
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Table 3.2 Differences from published EV70 sequence present in EV70 
RTPCR product and all sequenced clones.
Location BasePosition* Base Change
Amino Acid 
Change
5’UTR 352 G insertion -
ID 3051 C t o T No change
3233 C to T Ala to Val
3239 G to A Arg to Gin
3252 C t o T No change
3277 G to A Asp to Asn
2C 4780 G to A Ala to Thr
4959 G to A No change
3A 5202 C t o T No change
5220 C to G Asp to Glu
3C 5721 C t o T No change
3D 5940 T t o G No change
5963 C to G Thr to Ser
5970 G t o C No chatige
5976 A to C No change
5’UTR and coding changes are marked in bold.
* Numbered relative to published sequence (Ryan et al, 1990).
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Table 3.3 Differences from published EV70 sequence present in one or 
more clones, but not seen in EV70 RTPCR product.
Location BasePosition*
Base
Change
Amino
Acid
Change
Frequency 
of changesf
1 5’UTR 267 T t o C - 1 of 9
2 5’UTR 443 G to A 1 of 9
3 lA  (VP4) 735 A t o T No change
Introduced 
during cloning
4 IB (VP2) 1558 T to A Leu to He 4 of 9
5 1C(VP3) 2241 T t o C No change 1 of 9
6 ID (VPl) 3027 T t o C No change 1 of 9
7 3A 5275 A to G He to Val 3 of 9
All changes are present in pTOPOFLC70 and pFLC70j3 with the exception of 
change 3. pFLC70 contains changes 3, 4 and 7 only. pLuc70 contains change 7. 
* Numbered relative to published sequence (Ryan et al, 1990) 
fRefers to full-length clones sequenced (section 3.1.3)
5’UTR and coding changes are marked in bold.
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prediction (Zuker, 2003), and comparison to the proposed secondary structure of 
poliovirus (Stewart and Semler, 1997), suggests that both 5’ changes occur in stem-loop 
IV of the 1RES structure, with the change at base 267 likely to be present in an unpaired 
loop, and the change at base 443 disrupting the base pair at the base of the stem.
3.1.4 Construction of a ribozyme-containing full-length EV70 clone (pFLC70p).
Transcripts generated from pTOPOFLC70 using T7 RNA polymerase will not 
have an accurate viral 5' end, which is important for efficient replication in poliovirus 
clones (Herold and Andino, 2000). The BV70 viral sequence was therefore subcloned 
into pT7Rep3-L+R (figure 3.2). This vector encodes a poliovirus type 3 (PV3) 
subgenomic luciferase-encoding replicon (Goodfellow et al., 2000), and was used here 
as it contains the hammerhead ribozyme sequence and also suitable restriction sites and 
a T7 polymerase promoter. To generate insert and vector fragments for ligation, both 
pTOPOFLC and pT7Rep3-L+R were digested with the restriction enzymes Pml I, 
which cleaved within the 5’UTR 42 bases from the end of the genome, and Sal I, which 
cleaved at the end of the poly A tail. This resulted in the removal of the PV3 replicon 
sequences, with the exception of the initial 42 bases of the PV3 5’UTR which are 
identical to those of EV70. The resultant clone was designated pFLC70p and contains 
all the sequence differences present in pTOPOFLC70 (table 3.2 and 3.3). Transfection 
of RNA from this clone into MRC5 cells reproducibly resulted in CPE within 24 hours.
3.1.5 Construction of a ribozyme-containing full-length EV70 clone lacking 5’UTR 
changes (pFLC70).
As shown in table 3.3, and discussed in section 3.1.3, the infectious EV70 clones 
constmcted directly from firll-length RTPCR product, pTOPOFLC70 and pFLC70(3, 
contain six sequence changes in comparison to the consensus sequence of the parent 
virus. Two of these result in conservative amino acid changes and are present in other 
clones, suggesting they form part of the viral quasi species, however the other four are 
not seen in other clones, and may represent tme RTPCR errors. The two non-coding 
changes in VP3 and VPl are unlikely to be detrimental, as enteroviral capsid sequences 
are not thought to have significant secondary structure or function at the RNA level.
The 5’UTR changes, however, are of concern as they occur in an area rich in secondary 
structure required for translation and replication. In addition these changes are not 
present in the subgenomic replicon, pLuc70 (see section 3.3), making difficult full
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comparisons of infectivity and replication, based on the use of these clones. The cloning 
strategy described here resulted in a full-length EV70 clone lacking these 5’ changes 
and also the two non-coding capsid changes.
The clone was constructed using pLucVOinteriuediate (figure 3.4). This is a 
plasmid generated from pTOPOFLCVO as an intermediate during the construction of a 
luciferase-containing EV70 replicon (section 3.3.1). pLuc70intermediate contains the 
wild type EV70 5’UTR without errors and the full P2, P3 and 3’UTR regions and 
partial PI region from pFLC70p. It also contains sequence encoding luciferase and a 
small stretch of poliovirus sequence.
RTPCR was carried out of the EV70 capsid coding region using viral RNA 
extracted from EV70 J670/71 tissue culture supernatant. The sense PCR primer, 
EV70sJUPl, contained a single non-coding base change from the published sequence to 
introduce a Sac I restriction site for cloning (table 3.1) within PI, nine bases 
downstream of the translational start site. The antisense primer, EV70aJP12, contained 
three non-coding base changes, and introduced aM///1 restriction site (although this 
was not required for the cloning strategy used here). The 2434 bp product was initially 
cloned into pPCR-Blunt II-TOPO, and this was digested with the restriction enzymes 
Sac I and Dra III to generate a 1358 bp fragment from the 5’ end of the capsid 
sequence. This was subcloned into pLuc70intermediate in place o f the luciferase gene 
and PV3 sequences forming a ribozyme-containing infectious EV70 clone without 
5’changes, designated pFLC70. This clone contains all the sequence changes from the 
published sequence which are also seen in the RTPCR product (table 3.2), however it 
contains only three further changes not seen in the RTPCR (table 3.3). These are the 
presumed viral polymorphism in the 3 A region (derived from pFLC70p), the non­
coding change required to introduce the Sac I restriction site in the 1A region and the 
presumed viral polymorphism in the IB region (also present in the capsid RTPCR 
product cloned here).
Following linearisation of pFLC70 at the 3’ end and T7 RNA transcription, a 
single predominant transcript was obtained (figure 3.5). On transfection into MRC5 
cells, CPE was observed within 24 hours. Virus recovered from cells transfected with 
RNA transcribed from pFLC70 will be referred to as EV70^^^ for the remainder of this 
thesis.
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PI* P2*
Ribozyme Luciferas^§[ g  Pi |
T7 Promoter /
Sac I
P2
Dra III
pLucTOintermediate
Portion replaced 
in next step
1358bp o f  capsid RTPCR product 
inserted (initially cloned into 
pPCR-Blunt II-TOPQ)
Ribozyme
T7 Promoter
pFLC70
Figure 3.4 Construction of pFLC70, a full-length EV70 clone with a 
ribozym e, and wild type 5’UTR sequence. To obtain a full-length EV70 viral 
clone without 5 ’ changes, the EV70 capsid RTPCR product was initially 
cloned into pPCR-Blunt II-TOPO (not shown) and then a fragment containing 
the 5’ 1358 bp was sub-cloned into pLuc70intermediate in place o f  the PV3 
and luciferase sequences using the restriction endonucleases Sac I and Dra III 
(full description in section 3.1.5).
*Partial PI or P2 sequence EV70 sequence PV3 sequence
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Figure 3.5 Gel electrophoresis o f pFLC70 and pLuc70 RNA transcripts.
RNA was transcribed using T7 polymerase and run on a 1% agarose gel.
The RNA transcript from pFLC70, o f  expected size 7417 bases, runs slightly 
higher than the RNA transcript from pLuc70 o f  expected size 6844 bases. 
Lane 1, DNA size marker as point o f  reference only; lane 2, T7 transcript 
from pFLC70; lane 3, T7 transcript from pLuc70.
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3.2 Characterisation o f vFLCTO and other full4en2th EV70 
clones
During the cloning procedures outlined in the preceding sections three related 
but distinct EV70 infectious clones were derived: pTOPOFLCVO lacking a ribozyme 
and containing the potentially deleterious 5’UTR changes; pFLCVOp with a ribozyme, 
but still containing the 5’UTR changes; and pFLCVO with a ribozyme and without the 
5’UTR changes.
Virus recovered from cells transfected with RNA from all three clones was 
passaged successfully in MRC-5 cells and confirmed to be EV70 by indirect 
immunofluorescence of the infected cells using an EV70-specific mouse monoclonal 
antibody (data from EV70^^^ is shown in figure 3.6). The cells exhibited only very pale 
staining with a broadly reactive Dako enteroviral antibody, as is also obseiwed for the 
wild type virus. An echovirus type 7 control failed to stain with the EV70 antibody, but 
did stain with the enterovirus antibody. The three clones were further characterised with 
respect to growth characteristics and kinetics.
Specific infect ivity of transcribed viral RNA was assessed in MRC5 cells (figure 
3.7). Naked poliovirus RNA is reported to have a specific infectivity in HeLa cells of 
around lO^pfu/pg RNA (Crotty et ah, 2001; Koch, 1973). The specific infectivity of 
RNA transcribed from pFLCVO was above 10  ^pfli/pg RNA. This was comparable to 
that of RNA transcribed from pFLCVOp, suggesting that the sequence differences 
between these two clones (consisting of the two 5’UTR changes and two non-coding 
changes in the capsid-encoding sequence) did not significantly affect specific 
infectivity. RNA transcribed from pTOPOFLCVO had a specific infectivity over two 
logio lower than that of the other EV70 clones. Its sequence is identical to pFLCVOp and 
the difference must therefore be ascribed to the lack of a ribozyme and accurate 5’end, 
as is known to be important for the specific infectivity of poliovirus RNA (Herold and 
Andino, 2000).
Virus recovered from all three clones showed very similar plaque phenotype on 
MRC5 cells, in terms of both size and plaque margins. The latter were more irregular 
than those of another enterovirus, echovirus type 7, which exhibited much smoother 
plaque margins in these cells (figure 3.8).
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Anti-enterovirus 70 
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Figure 3.6 Indirect Im m unofluorescence o f clone-derived EV70 in M RC5 
cells. Cells were infected with virus at an m.o.i. o f  three and stained after 6hrs 
incubation with either the broadly reactive Dako anti-enterovirus antibody 5- 
08/1 or with EV70 monoclonal 854. Very pale staining was observed for wild 
type EV70 and EV70''^^  ^ using the enterovirus antibody at the time o f  
microscopy, but is less clear on reproduction. Identical staining patterns to 
wild type EV70 and EV70^^^ were obtained from virus recovered from cells 
transfected with RNA transcribed from the clones pFLC70p and 
pFLCTOPO70 (data not shown).
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Figure 3.7 Specific Infectivity o f RNA transcripts derived from  infectious 
clones. Serial 10-fold dilutions o f  RNA transcribed from the infectious EV70 clones 
were transfected into MRC5 cells using lipofectamine 2000 (Invitrogen) and overlaid 
with plaque assay overlay medium. After 72hrs incubation plaques were counted and 
specific infectivity expressed as pfu/pg transfected RNA.
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Figure 3.8 Plaque Phenotypes o f clone-derived EV70 in M RC5 cells.
MRC5 cells were infected with a 10-fold dilution series o f  virus and overlaid 
with plaque assay overlay medium. After 72hrs incubation plaques were 
viewed and photographed. Where appropriate virus was first recovered from 
MRC5 cells transfected with RNA transcribed from the infectious clones.
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One-Step growth curves in MRC5 cells were derived (figure 3.9). Despite 
irregularities during the initial phases, which may have been due to variation in the 
amount of virus in the initial innocula, virus recovered from all three infectious clones 
exhibited very similar growth kinetics, comparable to wild type EV70. These consisted 
of an exponential growth phase at between four and six hours, and a final plateau at a 
viral titre of 10  ^pfu/ml. Despite the lack of a ribozyme and the lower specific infectivity 
of RNA derived from pTOPOFLCVO, the wild type growth curve is not unexpected for 
virus recovered from this clone. After transfection and an initial low efficiency round of 
replication, a correct 5" end would be generated, resulting in recovered virus identical to 
that obtained from pFLCVOp.
In summary virus recovered from all three infectious EV70 clones had 
phenotypic and growth characteristics comparable to wild type virus. The primary 
difference between the clones is the lower specific infectivity of pTOPOFLCVO derived 
RNA due to the lack of a ribozyme and therefore of an accurate 5’ end. The sequence 
differences between pFLCVO and pFLCVOp do not appear to affect viral growth or 
infectivity.
3.3 Construction and Characterisation of an EV70 Subsenomic 
Viral Revlicon
The EVVO genome does not contain suitable sites to allow the direct cloning of 
the luciferase reporter gene into the full-length infectious clone. It was therefore decided 
to construct the EVVO subgenomic replicon by taking advantage of the restriction sites 
in the plasmid pTVRep3-L+R, the poliovirus subgenomic replicon also used to construct 
pFLCVOp. In addition to the firefly luciferase gene, this vector also contains a TV RNA 
polymerase promoter sequence required for in vitro RNA transcription and a 
hammerhead ribozyme sequence to generate the accurate 5’ end required for efficient 
replication of the replicon RNA.
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Figure 3.9 O ne step growth curves o f clone-derived EVVO in M RC5 cells.
Cells were infected with virus at an m.o.i. o f  3 and titres determined by plaque 
assay on virus harvested by freeze-thawing after 0, 1.5, 3, 4.5, 6, 8, 12 and 
24hrs incubation. Where appropriate virus was first recovered from MRC5 
cells transfected with RNA transcribed from the infectious clones.
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3.3.1 Construction of a ribozyme-containing EV70 subgenomic replicon with 
luciferase reporter gene (pLuc70).
Cloning was carried out in three steps: insertion of the EV70 5’UTR upstream of 
the luciferase gene, insertion of the 3’ end of the EV70 genome downstream of the 
luciferase gene, and a final step to remove unnecessary sequences (figure 3.10).
In the first step the EV70 5’UTR was amplified by RTPCR using viral RNA 
extracted from EV70 J670/71 tissue culture supernatant. The sense Snia I-containing 
primer E70s5p, used in the fiill-length PCR, was used, with the anti sense primer 
E70aJUPl, which contained a single non-coding base change from the published 
sequence to introduce a Sac I restriction site for cloning (table 3.1). This change was 
within PI, nine bases downstream of the translational start site. The 766 bp product was 
initially cloned into pBluescript II SK- using the restriction endonucleases Sma I and 
Sac I and then subcloned into pT7Rep3-L+R in place of the PV3 5’UTR. Both insert 
and vector fragments for this ligation reaction were generated by digestion with the 
restriction enzymes Pml I and Sac I. Pml I cleaved within the 5’UTR 42 bases from the 
end of the genome, ensuring maintenance of the intact ribozyme sequence within the 
vector. The initial 42 bases of the PV3 5 ’UTR are identical to those of EV70. 
Sequencing showed the insert contained no changes from the published EV70 5’UTR 
sequence. The resultant plasmid was designated p5’70Rep3, it contains the luciferase 
gene and preserves the open reading frame. It encodes a chimeric replicon with the 
EV70 5’UTR in a PV3 backbone.
In the second step the 3’ end of the EV70 genome, derived from the 
pTOPOFLC70 full-length clone, was cloned into p5’70Rep3. Fragments for ligation 
were generated from both plasmids using the enzyme Dra III, which cleaves within the 
PI region of EV70 and the P2 region of PV3, and Sal I, which cleaves at the end of the 
poly A tail. The resultant clone included the entire EV70 P2, P3 and 3’UTR and also 
1247 bp of the PI region. This clone was designated pLuc7 Ointermediate and still . 
contained some PV3 sequence immediately downstream of the luciferase gene.
In the final step a 475 bp RTPCR product from the EV70 P1/P2 junction was 
inserted, removing all remaining PV3 sequences and leaving only 198 bp of the EV70 
PI. The sense primer, EV70s3121 contained four mismatches from the EV70 sequence 
to introduce a j^jf^HII restriction site for cloning downstream of the luciferase gene 
(table 3.1), however these occurred in the redundant residual PI section. Fragments for
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Figure 3.10 Construction of pLuc70, an EV70 subgenom ic replicon. (See 
legend on following page)
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Figure 3.10 (previous page) Construction of pLuc70, an EV70 
subgenomic replicon. The EV70 5’UTR RTPCR product was initially 
cloned into pBluescript II SK- vector (not shown) and then sub-cloned 
(excluding the first 42bp which are identical to the PV3 5’UTR) using the 
restriction endonucleases Pw /1 and Sac I, into pT7Rep3-L+R, in place of 
the PV3 5’UTR, forming p5’70Rep3. In the second step the 3’ portion of the 
EV70 genome derived from pTOPOFLC70 and extending 1247bp into PI, 
was sub cloned using the restriction endonucleases Dra III and Sal I, to form 
pLuc70intermediate which retains 81bp and 319bp of the PV3 PI and P2 
respectively. In the final step a 475 bp EV70 RTPCR product comprising 
198 bp of PI and 214 bp of P2 was inserted in-frame, using the restriction 
endonucleases P^^HII and Apa I, and removing the remaining PV3 
sequences. Full description in section 3.3.1.
^Partial PI or P2 sequence (^ 3  EV70 sequence L— i PV3 sequence
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cloning were generated using the restriction endonucleases and Apa I, which
cleaves 214 bases front the 5’ end of the 2 A sequence. This final clone contained the 
luciferase gene in frame with the viral polyprotein and was designated pLuc70. It 
contains the EV70 5’UTR upstream of luciferase with the EV70 P2, P3 and 3’UTR 
downstream. It also retains 214bases of the EV70 PI, so maintaining the P1/P2 junction 
sequences necessary for cleavage of the polyprotein by the viral 2A protease. This 
replicon contains all the sequence changes outwith the PI region, listed in tables 3.2 and 
3.3, with the exception of the two base changes in the 5’UTR.
3.3.2 Testing of pLuc70 subgenomic replicon
Following linearisation of the replicon with the restriction endonuclease SaJ I, an 
RNA transcript was generated from pLuc70 utilising T7 RNA polymerase. A single 
band could clearly be seen on agarose gel (figure 3.5), indicating the presence of a 
single predominant transcript. The expected size of this transcript was 6844 bases, and 
the band seen was marginally smaller than that for the transcript generated from the full- 
length clone, pFLC70 (expected size 7417 bases). Luciferase was assayed in MRC5 
cells transfected with 2pg of RNA transcripts from pT7Rep3-L+R (a well-characterised 
PV3 replicon, Goodfellow et al., 2000), pLuc70 and p5’70Rep3 (the chimeric PV3 
replicon with the 5’UTR of EV70). All three replicons gave strong luciferase readings 
within 0.3 of a logio, suggesting comparable replication efficiencies (figure 3.11). 
Guanidine hydrochloride is a potent inhibitor of the replication of polioviruses 
(Baltimore et al., 1963) and other enteroviruses, and the failure to detect luciferase 
activity in its presence in cells transfected with pLuc70, confirms that the signals seen 
are due to replication of the replicon RNA.
3.4 DISCUSSION
A  full-length infectious clone of the EV70 reference strain (J670/71) has been 
constructed, with subsequent characterisation demonstrating that virus derived from the 
clone is comparable to the wild type virus on which it was based. In addition a 
luciferase-encoding subgenomic replicon of EV70 (J670/71) has been constructed, with 
replication demonstrated by the production of luciferase on transfection of RNA. These 
clones will prove extremely valuable resources for future investigation of all aspects of 
the EV70 life cycle.
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Figure 3.11 Luciferase assay com paring replication of subgenom ic replicons.
Luciferase was assayed 6 hours after MRC5 cells were transfected with 2|ig o f  
RNA transcribed from luciferase-encoding subgenomic replicons, in the presence 
and absence o f  the replication inhibitor guanidine hydrochloride. Error bars show  
the range o f  results over duplicate assays. Replication o f  the EV70 subgenomic 
replicon pLuc70 is comparable to that o f  the PV3 subgenomic replicon (pT7Rep3- 
L+R), and a chimeric PV3 replicon with EV70 5’UTR sequence (p5’70Rep3).
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The virus used in the current studies contains fifteen differences from the 
published EV70 J670/71 sequence (Ryan et al., 1990). These are present in both the 
RTPCR product and all clones sequenced. As both sequences are derived from the same 
reference strain it is likely that the differences have occurred during passage in tissue 
culture, either by progressive sequence drift or active selection by growth in different 
cell types. The virus sequenced by Ryan et al was grown in Hep-2c cells, while here 
MRC5 cells have been used. The earlier passage history of both viruses is unknown.
One difference, the G nucleotide insertion at position 352 of the 5’UTR is also present 
in other EV70 5’UTR sequences in genbank and may represent an error in the original 
sequence. Of the other changes, within the open reading frame of the virus, the majority 
are non-coding or represent conservative amino acid changes. Of note is that four 
changes occur within a 37 base region of the viral polymerase sequence, although as 
three are non-coding and one highly conservative it is not possible to suggest a common 
selective pressure for these at the protein level. Of more potential import to receptor 
studies is a cluster of four changes within a 45 base region of ID, of which three are 
coding changes, two being non-conservative. This region encodes the major viral capsid 
protein VPl and the differences may be the result of selective pressure, potentially at 
the level of receptor binding.
As mentioned in the text, problems were encountered attempting to amplify the 
7451 bp RTPCR product using a variety of proofreading DNA polymerases. These 
related to low and variable yield and multiple RTPCR errors. The polymerase 
eventually used was KOD polymerase (Takagi et al, 1997). This is derived from the 
2LXc\\?LQon Pyrococcus sp. strain KODl. It contains polymerase and 3’-5’ exonuclease 
activity. Fidelity is claimed to be comparable to that of other proofreading polymerases 
in the same assay, however the manufacturers also claim that the enzyme has ten to 
fifteen times greater processivity than similar polymerases. The improved reliability and 
yield observed in the full-length EV70 PCR with KOD polymerase seem likely to be the 
result of this improved processivity. Low fidelity observed in the EV70 RTPCR with 
other enzymes may be a function of poor processivity on a long target with the resultant 
inability to accurately optimise PCR conditions. These findings emphasise the 
importance of the choice of polymerase when carrying out RTPCR on long targets and 
suggests the advisability of assessing a panel of different proofreading enzymes.
CPE was evident by 48 hours in seven of the sixteen full-length EV70 clones 
obtained. Five clones required a further 48 hour incubation before CPE was observed.
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Although this may have been due to variation in transfection efficiency, it seems likely 
that some contained RTPCR errors resulting in defective viral sequence. The remaining 
four clones showed no CPE after prolonged incubation of transfected cells, suggesting 
fatal errors during RTPCR The final clone used from the full-length RTPCR cloning, 
contained six differences from the published sequence of EV70 J670/71, which were 
also not found in the RTPCR sequence. Two result in conservative changes in amino 
acid; leucine to isoleucine in the VP2 sequence and isoleucine to valine in 3 A. Both 
were present in other clones sequenced, suggesting that they form part of the viral 
quasispecies. Of the remaining four differences two are non-coding changes within the 
capsid and two occur in the 5’UTR. Although these changes were not apparent on 
sequencing of the EV70 RTPCR product or found in the additional clones sequenced, it 
is possible that some or all of them may be represented at low frequency within the viral 
quasispecies, alternatively they may represent true PCR errors. KOD polymerase is 
reported to have an error rate equivalent to other proofreading DNA polymerases of 
approximately 1 in 10  ^nucleotides (Cline et af, 1996; Takagi et a l, 1997), in contrast 
the viral RNA dependant RNA polymerase has no proofreading capacity and has a 
much higher error rate, estimated at approximately 1 in 10“^ for the poliovirus 
polymerase (Ward and Flanegan, 1992). Therefore the viral polymerase is not an 
unlikely source of the sequence differences seen. The capsid sequences of enteroviruses 
are not believed to have significant RNA secondary structure, in view of which the two 
non-coding capsid changes seem unlikely to be of significance. The 5’UTR changes 
occur in the EV70 1RES, an area rich in functional secondary stmcture and are therefore 
potentially significant. However, the changes are predicted to be in an unpaired loop 
and at the base of a stem-loop stmcture, therefore neither would be expected to cause 
major stmctural dismption, although binding of factors essential to translation might 
still be compromised.
Three EV70 full-length infectious clones were constmcted: pTOPOFLC70, 
made by direct cloning of a full-length RTPCR product, which lacks a ribozyme; 
pFLC70B which is identical to pTOPOFLC70 but has been sub cloned into a vector 
containing a ribozyme; and pFLC70 which encodes a ribozyme but does not contain the 
two 5’UTR changes and two non-coding changes in PI present in the other two clones. 
All three vimses show similar profiles on a single-step growth curve to wild type EV70 
and indistinguishable plaque phenotypes. This, together with the absence of reversion of 
the changes on passage of recovered vims, suggests that they do not confer a significant
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growth disadvantage on the virus in tissue culture. The potential for an in vivo effect 
still remains. The major difference noted between the clones relates to specific 
infectivity. Both ribozyme-encoding clones generate over lO*" pfu/pg RNA, a result 
comparable to that seen for poliovirus virion RNA in HeLa cells (Crotty et af, 2001; 
Koch, 1973). However, RNA transcribed from pTOPOFLCVO, which lacks a ribozyme, 
has a specific infectivity over two logio lower. The presence of an upstream ribozyme 
results in transcribed RNA being cleaved to generate an accurate 5’end to the viral 
genome. It has been shown that an accurate 5’end is necessary for the efficient 
replication of poliovirus RNA (Herold and Andino, 2000). This result illustrates that an 
accurate 5’end is also required for efficient EV70 infection. Following transfection, 
however, the additional nucleotides are removed (Herold and Andino, 2000) and 
replicated viral RNA and progeny virions will have the correct 5’end, as evidenced by 
the growth curve for virus recovered from pTOPOFLCVO which is comparable to that of 
the ribozyme-encoding clones and wild type virus.
The construction of a luciferase-containing EVVO subgenomic replicon has also 
been described. A luciferase replication assay has shown that this replicon is functional 
and replicates to comparable levels as the equivalent well-characterised PV3 
subgenomic replicon. In addition, an intermediate from the first step of construction of 
the replicon, which consists of a chimera with the 5’UTR of EVVO in the backbone of 
the PV3 replicon, also replicates to comparable levels. Although not directly related to 
the subject of this study this is an interesting observation and will be briefly discussed 
here. It is known that the initial 100 bases o f the 5’UTR forms a cloverleaf structure 
which interacts with the viral 3CD polymerase (Andino et al., 1993; Andino et al.,
1990). Substitution of the cloverleaf of CVB4 or human rhinovirus type 2 into a 
poliovims replicon result in replication competent chimeras, whereas substitution with 
the human rhinovirus type 14 sequence does not (Rohll et al., 1994). It has further been 
shown (Rieder et al., 2003) that 3CD polymerase binding and replication can be 
restored in the rhinovirus type 14/PV3 chimera by both the insertion of a G nucleotide 
within the loop of stem-loop d of the cloverleaf to form a tetra loop and an additional 
mutation to a C nucleotide at the third position of the loop (figure 3.12B). MF OLD 
analysis (Zuker, 2003) reveals that the EVVO cloverleaf d-loop has a similar structure to 
that of PV3 and has a tetra loop with a C nucleotide at the third position (figure 3.12), 
predicting that there is likely to be a functional interaction with the PV3 3 CD
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CVB4 UG— Yes
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Figure 3.12 Sequences im portant for poliovirus 3CD polym erase binding.
A MFOLD prediction o f  EV70 cloverleaf bases 1-90 (Zuker, 2003). B Table 
based on Rohll et al, 1994 and Rieder et al, 2003, showing the d-loop sequence 
for several viruses and their compatibility with poliovirus polymerase, 
including a mutant o f  human rhinovirus type 14 (M2-R14, Rieder et al, 2003) 
which confers replication competence on a human rhinovirus type 14/PV3 
chimera. The EV70 d loop is included, which forms a replication competent 
chimera with PV3 (figure 3.11 and section 3.3.2).
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polymerase. This is consistent with the observed efficient replication of the EV70 
5’UTR/PV3 chimera in the luciferase assay.
The availability of a functional subgenomic replicon and infectious clone for 
EV70 will provide valuable tools for further research into all areas of the EV70 life 
cycle, including investigations into viral receptors and cell entry. In the current study 
the replicon has been utilised to assess the relative importance of replication, as opposed 
to viral binding and entry, in the species tropism of EV70, and to exclude non-specific 
effects on viral replication when using inhibitors to investigate the EV70 entry pathway.
The EV70 infectious clone has also been utilised in the investigation of species 
tropism. It has not yet been possible, however, to construct a clone with the capsid from 
an unpassaged EV70 isolate, due to difficulty obtaining a clinical EV70 isolate. This is 
planned as future work, as is the use of the clone in reverse genetic strategies to identify 
the capsid sequences important for receptor binding and cell entry.
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CHAPTER 4 
Characterisation of the Enterovirus tvoe 70 Receptor/s
Virus attachment to the cell requires interaction with a specific molecule on the 
cell surface. It follows therefore that the presence of the viral receptor is the primary 
determinant that defines a cell’s susceptibility to virus infection and therefore the tissue 
and species tropism of the virus. EV70 is unusual as an enterovirus, both in terms of its 
tropism for the human conjunctiva and reported ability to infect non-primate 
mammalian cells in culture (Yoshii et al, 1977), and in terms of its receptor usage. Both 
sialic acid and DAF have been implicated as EV70 receptors (Karnauchow et al, 1996; 
Utagawa et a l, 1982b).
Sialic acid was first implicated as a receptor for EV70 when it was reported that 
HA by EV70 was sensitive to the action of the sialic acid-cleaving enzyme 
neuraminidase (Utagawa et al, 1982b). Although sialic acid is used by a variety of 
different viruses, it is unusual as a receptor within the picornaviridae, having only been 
implicated for human EV68 and equine rhinitis virus (Stevenson et al, 2004; Uncapher 
et a l, 1991).
In 1996 DAF was implicated as the HeLa cell receptor for EV70 (Karnauchow 
et al, 1996). Although DAF is the receptor for a number of echoviruses and 
coxsackieviruses, EY70 was again unusual as the interaction with DAF was shown to 
occur at SCR domain 1, the most membrane distal of the four SCR domains in the DAF 
structure (Karnauchow et a l, 1998). In contrast, SCR domain 3 of DAF is required for 
the binding of the majority of DAF-binding enteroviruses, with only CVA21 having 
been shown to bind SCRl (Shafren et al, 1997b).
Prior to the start of this project it was also reported that EV70 bound to DAF 
even after removal of its N- and O-glycosylation sites, by site-directed mutagenesis and 
the use of chimeric proteins respectively (Alexander and Dimock, 2002). This suggests 
that the sialic acid requirement is distinct from any requirement for DAF. In addition, 
using metabolic inhibitors of O-linked and N-linked glycosylation, it was reported that 
an O-linked glycoprotein was involved in EV70 binding to HeLa cells (Alexander and 
Dimock, 2002).
The relative roles and importance of sialic acid and DAF in cellular binding and 
infection by EV70, therefore, remain unclear. In addition the nature of the sialic acid
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element of the receptor is unknown: whether sialic acid itself is sufficient for binding; 
whether the linkage to the underlying sugar is important, as for influenza virus; whether 
there is a requirement for specific downstream sugars or glycan structure; or indeed 
whether a specific glycoprotein or glycolipid is required as appears to be the case for 
polyomaviruses (Tsai et a l, 2003).
One major concern in receptor studies is the potential for adaptation of receptor 
specificity during passage in tissue culture. This is particularly the case for RNA viruses 
where error-prone RNA polymerases and the consequent existence of the virus as a 
quasispecies result in the potential for the rapid emergence of viral variants. For 
example, foot and mouth disease virus (a picornavirus) adapts to use heparin sulphate, 
in preference to integrins, on culture in CHO cells (Sa-Caiwalho et a l, 1997), and 
laboratory adapted vaccine strains of measles virus adapt to use CD46 as a receptor 
(Ono et a l, 2001). The EV70 reference strain J670/7I was isolated in Japan from 
conjunctival scrapings during the pandemic of 1970/1971. It is held by the American 
Tissue Culture Collection (ATCC), who unfortunately have no information regarding 
the early passage of the virus. Recent passage at ATCC has been in WI-38 cells, a 
primary embryonic fibroblast cell line. When using a reference strain the virus has, 
almost by definition, been extensively passaged in culture. Efforts can still be made, 
however, to standardise the passage history of the virus used during studies, and 
minimise the risks of any further adaptation. Results from such studies can then be used 
as the basis for future studies using unpassaged clinical isolates, to confirm viral 
receptor usage in vivo.
Chanter Outline
This chapter describes the derivation and passage of the EV70 J670/7Î reference 
strain used in these studies and outlines a series of experiments to investigate the 
requirements of this virus for binding to cells. This involves studies of the importance of 
sialic acid and DAF to EV70-mediated HA, and to viral binding and infection of MRC5 
cells and a variety of non-mammalian cell lines. It includes further characterisation of 
the nature of the sialic acid requirement and investigation of the site of viral binding on 
the cell surface.
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4,1 Derivation and vassale o f EV70
A fresh aliquot of EV70 J670/71 was obtained from the ATCC. As mentioned 
above this had a recent passage history in WI-38 cells, a human fibroblast cell line.
Viral growth was assessed in several human cell lines including rhabdomyosarcoma 
(RD), HeLa, human embryonic kidney, WI-38 and MRC5 (primary embryonic lung 
fibroblast). Only in WI-38 and MRC5 was a CPE observed. These are both primary 
embryonic lung fibroblast cell lines. MRC5 cells were chosen for future viral passage, 
as the viral titres obtained were marginally better than those in WI-38 cells. In MRC5 
cells EV70 grows to approximately lO^pfu per ml. MRC5 cells have the advantages of 
being human derived, and thus from the natural host of EV70, and of not having been 
transformed or immortalised. However, as a primary cell line, MRC5 cells will only 
undergo 40 to 50 population doublings before the onset of senescence. Therefore to 
ensure a constant stock of cells for these studies, cells were frozen in aliquots at 
eighteen population doublings and used from recovery until not more than 36 doublings. 
EV70 yield was not significantly different when grown in MRC5 cells of 20 and 36 
population doublings.
Although ATCC recommend that EV70 is grown at 37®C, previous studies have 
used a temperature of 33“C (Karnauchow et a!., 1996; Utagawa et al., 1982b). 
Empirically this is more in keeping with the peripheral location o f the human 
conjunctiva. To determine the optimum temperature for viral growth, one step growth 
curves were examined in MRC5 cells infected with EV70 and incubated at either 37°C 
or 33°C (figure 4.1). It can be seen that both curves are similar, although maximum 
growth at 24 hours was seen at 33°C.
To standardise the passage history of the vims used in the current studies and to 
minimise the risk of any further viral adaptation, EV70 stock from ATCC was passaged 
a standard five times in MRC5 cells at 33°C, and this vims was then used for all 
subsequent work.
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Figure 4.1 Effect o f incubation tem perature on EV70 one step growth 
curves in M RC5 cells. MRC5 cells were infected with EV70 at an m.o.i. of 3, 
and incubated at either 33°C or 37°C. Virus was harvested by freeze-thawing 
at 0, 2, 4, 6, 8, 10, 12, 24 and 48 hours and titres determined by TCID^^.
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4.2 The haemasslutination phenotvve o f EV70 is due to viral 
bindins to sialic acid and not to DAF
Viral HA can be defined as the agglutination or clumping of RBC by virus, 
forming a diffuse film in the well o f a microtitre plate. This is in contrast to the defined 
pellet seen in non-haemagglutinating controls. Viruses which have receptors expressed 
on RBC may exhibit this phenomenon. As both sialic acid and DAF are expressed at 
significant levels on RBC, both sialic acid binding viruses such as influenza virus (Ito et 
al., 1997), and DAF binding enteroviruses (Powell et al., 1998), can cause HA. HA and 
HA inhibition assays provide a straightforward and rapid method for investigating the 
interaction of viruses with their receptors and it was therefore decided to use this as an 
initial strategy to investigate the receptor specificity of EV70.
4.2.1 EV70 causes haemagglutination.
Although EV70 culture supernatant does not haemagglutinate RBC, if the virus 
is first purified by ultracentrifugation through a sucrose cushion, HA is readily observed 
(figure 4.2). This dependence on the use of purified virus has also been observed for 
CVA21 (unpublished observation, Prof. DJ Evans laboratory).
In figure 4.2 the DAF binding echovirus type 7 is used as a positive HA control 
and PBS as a negative control. The initial viral dilution used for all three viruses was 
10  ^pfu/ml, and HA by a two-fold dilution series of virus was recorded. Both EV70 
from ATCC derived stock and EV70^^^ from the infectious clone, clearly demonstrate 
HA. As purified EV70 shows HA up to an eight-fold higher dilution than echovirus type 
7 culture supernatant, the requirement for initial purification of EV70 is not accounted 
for purely by a concentration effect, and is most likely due to the removal of an 
inhibitory contaminant in the culture medium.
4.2.2 EV70 haemagglutination is inhibited by neuraminidase
To determine the contribution of sialic acid binding to the EV70 HA phenotype, 
an HA inhibition assay was carried out using the enzyme neuraminidase to remove 
sialic acid from the RBC surface (figure 4.3A). The controls in this assay were influenza 
B virus, which haemagglutinates via sialic acid binding, and CVA21, which
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Pfu/ml 10  ^rr
PBS
EV70
Echovirus 
type 7
2-fold viral dilution series 
Decreasing concentration o f virus
4.88x10^
Figure 4.2 H aem agglutination by EV70. Two-fold dilutions o f  vims, from a 
starting concentration o f  lO^pfu/ml (lowest concentration 4.88x10^), were 
mixed with RBC and HA recorded visually. EV70 and EV70^^^ were first 
purified by ultracentrifugation through a sucrose cushion, while echovim s type 
7 was used directly from clarified tissue culture supernatant. Adjacent rows are 
duplicates. EV70, EV70^^^ and echovim s type 7 all demonstrate HA.
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Figure 4.3 H aem agglutination inhibition with neuram inidase. RBC, pre­
treated with neuraminidase at the concentrations shown, were mixed with a 
constant 4HA units o f  virus and HA recorded visually. EV70, EV70^^"  ^and 
CVA21 were first purified by ultracentrifugation through a sucrose cushion, 
while influenza B virus was tested in allantoic fluid. Adjacent rows are 
duplicates A. Neuraminidase inhibits HA by EV70 and influenza B virus, but 
not by CVA21. B. Neuraminidase inhibits HA by EV70^^^.
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haemagglutinates via DAF binding. The latter was used in these assays as it is known to 
bind the same domain of DAF (SCRl) as has been reported for EV70 (Shafren et al, 
1997b). A standard amount of four HA units of each virus was added to RBC treated 
with neuraminidase at various concentrations. The neuraminidase used from 
Clostridium perfringens is reported to cleave a2-3, a2-6 and a2-8 linked sialic acid.
As expected, neuraminidase had no effect on HA by CVA21, but did inhibit 
influenza B virus HA down to a neuraminidase concentration of lOmU/ml. EV70 HA 
was also inhibited by neuraminidase, down to the lowest concentration tested of 
1.25mU/ml. This was equally the case for EV70^^^ (figure 4.3B), The inhibition of 
EV70 HA was observed at a significantly lower neuraminidase concentration than that 
required for inhibition of influenza B virus HA. This could be due to the differences in 
the affinity of the viruses for sialic acid or the number of receptor binding sites involved 
on the EV70 capsid, as compared to the influenza B virus membrane.
These results confirm the early observation of sialic acid involvement in HA by 
EV70 (Utagawa et a l, 1982b), and further demonstrate that molecularly cloned virus 
exhibits similar binding characteristics to those of the vims obtained from the ATCC 
from which it is derived.
4.2.3 EV70 haemagglutination is not inhibited by soluble DAF
Although the above studies using neuraminidase demonstrate an absolute 
requirement for sialic acid in the HA phenotype of EV70, they do not mle out a role for 
DAF in addition to sialic acid. Therefore, to determine the contribution of DAF binding 
to the EV70 HA phenotype, an HA inhibition assay was carried out using a soluble 
form of DAF expressed as a dimer, FcDAF (figure 4.4). FcDAF is a dimeric human 
DAF-Ig fusion protein comprising two DAF molecules (SCR domains 1-4) fused to the 
amino terminus of human IgGl Fc in place of the antibody Fab arms (Harris et al,
2002). CVA21 was again used as a positive control. A standard amount of four HA 
units of each vims was used and pre-incubated with a range of concentrations of 
FcDAF. As expected, CVA21 HA was inhibited by FcDAF, down to a concentration of 
10p.g/ml. In contrast no inhibition was seen for EV70, even up to concentrations of 
80qg/ml FcDAF.
These results demonstrate that DAF binding is not a significant determinant of 
the EV70 HA phenotype and that DAF does not represent a major binding site for EV70 
on RBC.
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FcDAF
80 40 20 10
EV70
CVA21
Figure 4.4 H aem agglutination inhibition with soluble FcDAF. A constant 
4HA units o f  virus, pre-incubated with FcDAF at the concentrations shown, 
was mixed with RBC and HA recorded visually. EV70 and CVA21 were first 
purified by ultracentrifugation through a sucrose cushion. Adjacent rows are 
duplicates. FcDAF inhibits HA by CVA21, but not by EV70.
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Figure 4.5 Viral binding to M RC5 cells after treatm ent with 
neuram inidase and polyclonal DAF antibody. MRC5 cells were pre-treated 
with 25mU/ml neuraminidase and/or polyclonal antibody raised against DAF 
at a dilution o f  1 in 250, and incubated with 20 OOOcpm o f  ^ 'S labelled 
CVA21, echovirus type 7 or EV70. After Ihr cells were washed and binding 
assessed using a scintillation counter. Binding is shown as a percentage o f  
binding to untreated MRC5 cells. Error bars show the range o f  results over 
duplicate assays.
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4.3 EV70 bindim and infectivitv in MRC5 cells is dependant on 
sialic acid, but not DAF
Having shown that EV70 binding to RBC is mediated primarily by sialic acid, 
rather than DAF, the roles of sialic acid and DAF were investigated in the binding to, 
and infection of, nucleated cells that the virus productively infects. The MRC5 cell line, 
used to cultivate EV70 viral stocks, was used as the host cell line for these studies.
4.3.1 Binding of EV70 to MRC5 cells is dependant on sialic acid, but not DAF
To determine the contributions of sialic acid and DAF to the binding of EV70 to 
MRC5 cells, a binding assay was carried out using radiolabelled purified 160S virus 
particles (figure 4.5). MRC5 cells were pre-treated with either 25mU/ml neuraminidase 
to remove sialic acid, or with a 1 in 250 dilution of rabbit polyclonal DAF antibody to 
block potential binding sites on DAF, or with both. Control viruses were CVA21, which 
binds SCRl of DAF, and echovims type 7, which binds predominantly to SCR3.
As can be seen from figure 4.5, the DAF antibody reduced the binding of both 
CVA21 and echovims type 7, as expected, by approximately 50%, but had no effect on 
EV70 binding. In contrast neuraminidase reduced the binding of EV70 by over 70%, 
but resulted in no reduction in binding of the other vimses tested, indeed there was an 
increase in the binding of echovims type 7 after neuraminidase treatment. Pre-treating 
cells with both DAF antibody and neuraminidase had no additional effect on the binding 
of any of the vimses. The increased binding by echovims type 7 after removal of sialic 
acid could be due to improved accessibility of the vims to DAF on the cell surface, 
either due to a steric effect or due to a change in cell surface charge (sialic acid being 
highly negatively charged).
As previously shown for RBC binding, these results demonstrate that binding of 
EV70 to MRC5 cells is mediated by sialic acid, and additionally, that DAF is not an 
important determinant of viral binding to these cells.
4.3.2 Infection of MRC5 cells by EV70 is dependant on sialic acid, but not DAF
Although DAF does not appear to be required for binding of EV70 to MRC5 
cells, it may still have an important role in the infection process; for example in vims
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entry or downstream signalling events. To determine the contributions of sialic acid and 
DAF to the infectivity of EV70 in MRC5 cells, two different assays were performed. A 
TCIDso-based assay, where virus was titrated on MRC5 cells pre-treated with 
neuraminidase or polyclonal DAF antibody (figure 4.6A), and a flow cytometry-based 
assay using pre-treated cells infected with virus and scored for the numbers of infected 
cells at 6  hours (figure 4.6B).
In the TCID50 assay neuraminidase concentrations of 5, 15 and 25mU/ml and 
rabbit polyclonal DAF antibody dilutions o f 1 in 1000, 1 in 500 and 1 in 100 were used. 
For clarity of presentation only the results for 5mU/ml neuraminidase and the 1 in 100 
antibody dilution are presented (figure 4.6 A). As can be seen the DAF antibody reduced 
echovims type 7 infection of MRC5 cells by over two logio at all time points, but had 
no effect on the titres obtained for EV70. In contrast, EV70 infection of MRC5 cells is 
blocked completely by neuraminidase up to 48 hours, whereas similar treatment of cells 
did not affect the yield of echovims type 7. The growth of EV70 seen at 96 hours is 
likely to be a consequence of regeneration of the sialated receptor in the treated MRC5 
cells. Similar results were obtained in the TCID50 assay at the other concentrations used, 
with DAF antibody dilutions up to 1 in 1000 still capable of blocking echovims type 7 
infection by several orders of magnitude, but with no effect on EV70; and higher 
concentrations of neuraminidase having no effect on echovims type 7 and having a 
greater effect on the 96 hour EV70 titres than for 5mU/ml.
The TCID50 assay results were confirmed using the flow cytometry-based assay, 
assessing the percentage of infected cells (figure 4.6B). In addition EV70^^^ was 
included to confirm that the molecularly cloned virus had the same characteristics as the 
vims from which it was derived. The polyclonal DAF antibody at a dilution of 1 in 250 
reduced the number of cells infected with echovims type 7 by over 60%, but had no 
effect on EV70 or EV70^'^^. In contrast, neuraminidase at 25mU/ml reduced the number 
of EV70 and EV70^^^ infected cells by over 80% with no effect on echovims type 7.
These results demonstrate that sialic acid is a key determinant, not only of viral 
binding, but also for the productive infection of MRC5 cells by EV70. There is no 
evidence of a role for DAF in either binding or infection by EV70 of these cells 
routinely used to cultivate the vims.
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Figure 4.6 Viral infectivity in M RC5 cells after treatm ent with  
neuram inidase and polyclonal DAF antibody. MRC5 cells, pre-treated with 
5mU/ml neuraminidase and/or polyclonal antibody raised against DAF at 1 in 
100, were infected with EV70, EV70^^^ or echovirus type 7. A TCIDj^-based 
infectivity assay. A 10-fold dilution series o f  virus was added to pre-treated 
cells. Titres were read visually after incubation for 24, 48 and 96 hrs. B Flow  
cytometry-based infectivity assay. Pre-treated MRC5 cells were infected with 
virus at an m o i. o f  3 and the number o f  infected cells assessed by flow  
cytometry 6hrs post infection. Error bars show the range o f  results over 
duplicate assays.
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4.4 The role o f sialic acid and DAF in EV70 bindins and 
infection in a variety o f cell lines
EV70 has been reported to bind and infect several non-primate mammalian cell 
lines (Yoshii et al., 1977). Both sialic acid and homologues of DAF are present on 
mammalian cells and could be contributing to binding. It was decided to investigate 
binding and infection of EV70 in a range of cell lines. The human cell lines used were 
MRC5 and RD (rhabdomyosarcoma). The non-primate mammalian cell lines used were 
CHO (Chinese hamster ovary) and RK13 (rabbit kidney), the latter having been 
reported by Yoshii et al. to support EV70 infection to titres equivalent to primate cells. 
In addition two non-mammalian cell lines were also used; XTC-2 {Xenopiis laevis. 
South African clawed toad) and C6/36 {Aedes alhopictus, mosquito larva). Sialic acid is 
known to be present on Xenopus cells. Generally sialic acids are not found in 
invertebrates, however the situation is controversial and there are exceptions such as 
Drosophila embryos (Varki, 1999).
4.4.1 EV70 binds to non-human cell lines in a sialic acid-dependant manner
The binding of ^ 'S radiolabelled purified 160S virus particles to the cell lines 
under investigation is shown in figure 4.7. Echovirus type 7 bound only to the human 
cell lines, confirming that there is insufficient homology between human DAF and any 
homologues on these cells to preserve DAF binding. Although a DAF homologue has 
not yet been identified on hamster or rabbit cells, the murine DAF homologue exhibits 
only 63% homology to human DAF (Fukuoka et ah, 1996). In contrast EV70 bound to 
all the cell lines to levels similar or greater than that seen for MRC5 cells. The 
exception was the C6/36 (mosquito) cell line; however even for these cells binding was 
detected at levels 28% of that seen in untreated MRC5 cells. In all cases, over 70 
percent reduction in binding was seen after pre-treatment of the cells with 
neuraminidase. EV70 therefore binds to non-primate cell lines, as diverse as Xenopus, 
in a sialic acid-dependant manner.
The presence or absence of sialic acid on invertebrate cells is controversial, as 
mentioned above (Varki, 1999). Although the level of EV70 binding is low on C6/36 
cells, the reduction with neuraminidase strongly suggests that on these cells binding of
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Figure 4.7 EV70 binding to a variety o f cell lines, with and without 
neuram inidase treatm ent. 10  ^ cells, untreated or treated with 25mU/ml 
neuraminidase (+ N), were incubated with 20 OOOcpm o f  labelled EV70 
or echovirus type 7. After Ihr cells were washed and binding assessed using a 
scintillation counter. Binding is shown as a percentage o f  binding to 
untreated MRC5 cells. Error bars show the range o f  results over duplicate 
assays.
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the vims was mediated by sialic acid. The low level of binding observed might be due 
to a low level of sialic acid on the surface of these cells or to differences between sialic 
acid on human and mosquito cells.
4.4.2 Expression of human DAF on non-primate cell lines does not affect EV70 
binding
The ability of EV70 to bind to DAF was further assessed using CHO (hamster) 
and XTC-2 (Xenopus) cell lines engineered to express human DAF (figure 4.8). CVA21 
was used as a control, and only bound the cell lines expressing human DAF. As seen in 
figure 4.7, EV70 efficiently bound both CHO and XTC-2 cells. Binding was not 
significantly increased when human DAF was expressed on these cells. Both the DAF 
expressing cell lines and their non-engineered parent lines showed significant and 
equivalent reductions in binding after removal of sialic acid with neuraminidase.
Indeed, in DAF expressing CHO cells binding was reduced by over 90 percent. These 
results again indicate that DAF is not involved in the binding of EV70 to cells.
In contrast to CHO cells, in this assay neuraminidase treatment of XTC-2 cells 
reduced EV70 binding by only 60%, the residual binding could be due to binding to a 
non-sialated protein, or a failure of neuraminidase to remove all forms of sialic acid on 
these cells, however, a decrease in binding of almost 90% was seen in previous binding 
assays in XTC-2 cells treated with neuraminidase (figure 4.7), suggesting that this 
obseiwation is likely to be due to interassay variability, such as differences in the quality 
of different batches of neuraminidase,
4.4.3 EV70 does not significantly infect non-primate cell lines, even when 
expressing human DAF
The infectivity of EV70 in multiple cell lines was investigated using multi-step 
growth curves over 96 hours (figure 4.9). The virus showed good growth in the three 
human cell lines used, MRC5, RD and HeLa. Of note was that despite being permissive 
for viral infection, neither RD nor HeLa cells exhibited CPE. This remained the case 
after vims was further passaged hi these cell lines five and three times respectively (data 
not shown).
There was a one logio increase in viral titres in RK13 (rabbit) cells at 24 hours, 
however this rapidly reduced, suggesting that these cells are not fully permissive for 
EV70 infection. This contrasts with the good viral yield from these cells observed by
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Figure 4.8 Viral binding to CH O  and XTC-2 cell lines expressing  
human DAF, with and w ithout neuram inidase treatm ent. 10  ^ cells, 
untreated or treated with 25mU/ml neuraminidase (+ N), were incubated 
with 20 OOOcpm o f  labelled EV70 or CVA21. After Ihr cells were 
washed and binding assessed using a scintillation counter. Binding is shown 
as a percentage o f  binding to untreated CHODAF or XTC-2DAF cells Error 
bars show the range o f  results over duplicate assays. A CHO and CHODAF 
cell lines B XTC-2 and XTC-2DAF cell lines.
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Yoshii et al, 1977 and may be due to differences in the passage history of the virus or of 
the cells themselves. Significant infection by EV70 is not seen in CHO and XTC-2 cells 
and this remained the case in the cell lines engineered to express human DAF, in 
keeping with the lack of binding to DAF described above.
Sialic acid-mediated binding to non-primate cell lines is therefore not sufficient 
for productive infection by EV70. This may be due to additional requirements for viral 
entry to the cell or incompatibility with the cellular replication machinery. These 
possibilities are further investigated in chapter five.
4,5 The EV70 recevtor on red blood cells is a GPI-anchored, 
a2-3 linked sialated slvcovrotein
Having ascertained that sialic acid is the major determinate of EV70 cellular 
binding, the nature of the sialic acid required was further investigated. As discussed in 
section 4.2, HA assays provide a convenient and rapid method for studying viral 
binding to cells and were again utilised here. Three aspects of the sialic acid 
requirement were explored: whether sialic acid itself is sufficient for binding, regardless 
of its molecular attachments; the specificity for sugar linkage; and the requirement, if 
any, for location on a specific glycolipid or glycoprotein.
4.5.1 EV70 haemagglutination is not inhibited by N-acetylneuraminic acid
To ascertain whether EV70 can bind to any sialic acid on the surface of RBC 
regardless of its molecular attachments, an HA inhibition assay was carried out using 
free sialic acid in the form N-acetylneuraminic acid (figure 4.10). The controls used 
were the DAF binding echovirus type 7, and the sialic acid binding influenza B vims. A 
standard amount of four HA units of each vims was used and pre-incubated with a 
range of concentrations of N-acetylneuraminic acid. No inhibition of HA was seen for 
any of the vimses. Although influenza vims is believed to bind sialic acid present on 
any glycolipid or glycoprotein, it does have specificity for downstream linkages, and 
free sialic acid has been found to be a poor inhibitor of influenza vims binding (Pritchett 
and Paulson, 1989). The reason for this is believed to be at least partly due to a need for 
polyvalent co-operative associations between the vims and multiple sialic acid binding 
sites. Indeed synthetic polymeric molecules with multiple sialic acid residues have
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N-acetylneuram inic acid
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Figure 4.10 H aem agglutination inhibition with N-acetylneuram inic acid 
(sialic acid). A constant 4HA units o f  virus, pre-incubated with N- 
acetylneuraminic acid at the concentrations shown, was mixed with RBC and 
HA recorded visually. EV70 was first purified by ultracentrifugation through 
a sucrose cushion, while influenza B virus and echovirus type 7 were tested 
directly from allantoic fluid and tissue culture supernatant respectively. 
Adjacent rows are duplicates. N-acetylneuraminic acid does not inhibit HA 
by any o f  the viruses. Note that at 32mM and 16mM concentrations N- 
acetylneuraminic acid alone causes HA, as shown by the lack o f  a pellet in 
wells treated solely with PBS.
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proven to be potent inhibitors of influenza virus binding (Lees et a l, 1994; Reuter et al,
1999). Pritchett and Paulson (1989) did observe inhibition of influenza virus binding to 
RBC at a concentration of lOmM N-acetylneuraminic acid. In this study the highest 
concentration giving analysable data was 8mM, with no inhibition. Concentrations of 16 
and 32mM resulted in RBC lysis, possibly due to the high negative charge on sialic 
acid.
Although it has not been possible to demonstrate inhibition of EV70 HA with 
free sialic acid, this does not conclusively prove that the vims is incapable of binding to 
sialic acid alone, but may be due to limitations of the assay method, such as cell lysis at 
high concentrations of sialic acid, and/or a requirement for sialic acid presented in 
multivalent form.
4.5.2 EV70 haemagglutination is inhibited by «2-3 specific neuraminidase
To determine whether EV70 binding is dependant upon a particular linkage of 
sialic acid to the underlying sugar, an HA inhibition assay was carried out using an a2-3 
specific form of neuraminidase derived from Streptococcus pneumoniae (figure 4.11). 
The controls in this assay were the DAF-binding echovims type 7 and influenza B virus. 
Human influenza B vims has a specificity for a2-6 linked sialic acid (Suzuki et al,
1992). A standard amount of four HA units of each vims was used and RBC were 
treated with a range of concentrations of both the non-specific and «2-3 specific forms 
of neuraminidase.
As expected neither neuraminidase had an effect on HA by echovims type 7. 
Also as expected, the «2-3 specific form of neuraminidase had no effect on HA by 
influenza B vims, while the non-specific form of the enzyme inhibited HA at 
concentrations down to lOmU/ml, comparable to those seen in figure 4.3 A. In contrast 
both the non-specific and «2-3 specific forms of neuraminidase inhibited EV70 HA and 
this was seen down to the lowest concentration used (1.25mU/ml).
All observable HA by EV70 was blocked by removal of «2-3 linked sialic acid 
from RBC, demonstrating that EV70 binds to «2-3 linked sialic acid on RBC and that 
this interaction is required for the HA phenotype of the vims.
4.5.3 EV70 haemagglutination is inhibited by PLC, PIPLC and Proteinase K.
To determine whether EV70 has a binding specificity for sialic acid on a specific 
glycolipid or glycoprotein on the RBC surface, HA inhibition assays were carried out
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Figure 4.11 H aem agglutination inhibition with a2-3 specific 
neuram inidase. RBC, pre-treated with a non-specific neuraminidase or a2-3 
specific neuraminidase at the concentrations shown, were mixed with a 
constant 4HA units o f  virus and HA recorded visually. EV70 was first 
purified by ultracentrifugation through a sucrose cushion, while influenza B 
virus and echovirus type 7 were tested directly from allantoic fluid and tissue 
culture supernatant respectively. Adjacent rows are duplicates. The non­
specific neuraminidase inhibits HA by EV70 and influenza B virus, but not 
by echovirus type 7, while the a2-3 specific neuraminidase inhibits only HA 
by EV70.
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using a range of lipases and proteases. Again echovims type 7 and influenza B virus 
were used as controls.
To determine whether the sialated receptor contained a lipid component the 
lipases PLC and PIPLC were used (figure 4.12). PLC hydrolyses the phosphate bond on 
glycerophospholipids, including the GPI anchor of GPI-anchored proteins. PIPLC 
specifically cleaves GPI anchors. The concentrations used ranged from 0.001-1 U/ml, 
however concentrations of PLC of 0.1 U/ml and over resulted in RBC lysis and so no 
data is available at these concentrations. As expected HA by influenza B virus, which 
can bind sialic acid on both lipids and proteins, was not affected by either lipase. HA by 
echovirus type 7 was also unaffected by these enzymes. Although echovirus type 7 
binds DAF, a GPI- anchored protein, it has previously been shown that the GPI anchor 
of DAF in RBC contains a fatty acid substitution which renders it resistant to cleavage 
by these enzymes (Walter et al., 1990). In contrast EV70-mediated HA was inhibited by 
both PLC and PIPLC, the latter down to low concentrations of at least 0.001 U/ml.
These results suggest that EV70 HA of RBC is due to the interaction of the virus with a 
protein attached to the cell surface via a GPI anchor.
To confirm that the virus was indeed binding to a sialated protein, an HA 
inhibition assay was carried out using the proteases proteinase K and chymotrypsin 
(figure 4.13). As expected neither protease had an effect on influenza B virus HA. 
Inhibition was seen at 6 to 8mg/ml of both proteases for echovirus type 7 and down to at 
least 2mg/ml Proteinase K for EV70. Chymotrypsin had no effect on EV70 HA. These 
results confirm that EV70 is binding to a protein on the RBC surface. Further, the 
protease cleavage profile differs from that of DAF bound by echovirus type 7.
In summary, the above results suggest that the HA of RBC seen with EV70 is 
due to binding of the virus to sialic acid on a specific molecule, or possibly group of 
molecules, on the RBC surface and that this receptor molecule is a GPI-anchored, 
sialated, a2-3 linked glycoprotein.
4.6 The EV70 recevtor on MRC5 cells is not a2~3 linked
Having shown that EV70 binding to RBC is potentially mediated by a GPI- 
anchored, sialated, a2-3 linked glycoprotein, further work was aimed to investigate 
whether this was also the case for binding to MRC5 cells. Unfortunately lipases and
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Figure 4.12 H aem agglutination inhibition with PLC and PIPLC. RBC
were pre-treated with either PLC or PIPLC at the concentrations shown, and 
the assay conducted as in figure 4.11. Both PLC and PIPLC inhibit HA by 
EV70, but not by influenza B virus or CVA21. Concentrations of PLC of 
0. lU/ml and above, resulted in RBC lysis and are not shown.
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Figure 4.13 H aem agglutination inhibition with proteinase K  and 
chym otrypsin. RBC were pre-treated with either proteinase K or 
chymotrypsin at the concentrations shown, and the assay conducted as in 
figure 4.11. Proteinase K inhibits HA by EV70 at all the concentrations tested, 
but HA by echovirus type 7 only at the higher concentrations. Chymotrypsin 
inhibits HA by echovirus type 7 at 8mg/ml, but has no effect on HA by EV70. 
HA by influenza B virus was not affected by either protease.
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proteases were found to be highly toxic for MRC5 cells and it has therefore not been 
possible to assay the effect of these enzymes on EV70 binding to these cells.
To determine whether EV70 has a binding specificity for a2-3 linked sialic acid 
on MRC5 cells, a binding assay was carried out on MRC5 cells pre-treated with either 
the non-specific or a2-3 specific forms of neuraminidase (figure 4.14), The 
concentrations used were 25mU/ml for the non-specific neuraminidase and 50 and 
25mU/ml for the a2-3 specific neuraminidase.
Echovims type 7 used as a control showed no reduction in binding with either 
neuraminidase, as expected. EV70, although showing the previously noted reduction in 
binding to MRC5 cells with the non-specific neuraminidase, did not show any reduction 
with the a2-3 specific form. It must be noted that further work requires to be done to 
establish whether the a2-3 specific neuraminidase is efficiently removing a2-3 specific 
sialic acid from the cell surface under these conditions. If confirmed, however, this 
result suggests a difference in the EV70 binding determinants on RBC and MRC5 cells. 
Several possibilities exist to explain this: it may be that in both cases the same GPI- 
anchored glycoprotein is being bound, but that the molecule is differently glycosylated 
in terms of sialic acid linkage in the two cell types; it may be that the vims is using an 
entirely different receptor on MRC5 cells from that bound on RBC; alternatively these 
results may be artefacts of the different assay formats used (HA inhibition and vims 
binding). These assays are likely to vary in sensitivity and the lack of availability of 
other linkage-specific neuraminidases means that binding to a2-6 could not be directly 
assessed.
4.7 EV70 binds to lipid raft domains on MRC5 cells
Lipid rafts are detergent-resistant microdomains on cellular membranes that 
have important functions in endocytosis and cell signalling. They are also sites rich in 
certain lipids and proteins, and in particular are known to be enriched with GPI- 
anchored proteins (Brown and London, 1998). As a GPI-anchored protein has been 
implicated in the binding of EV70 to RBC (section 4.5), the association of the vims 
with lipid rafts domains was investigated.
A membrane preparation was made from MRC5 cells pre-bound with either ^^S- 
labelled EV70 or echovims type 7, and floated on a step-wise sucrose gradient by 
ultracentrifugation. Using this method the raft fractions float to the interface of a four
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Echovirus type 7 EV70
Control
Non-specific neuram inidase  
a2-3 specific neuram inidase
Figure 4.14 Viral binding to M RC5 cells after treatm ent with a2-3  
specific neuram inidase. MRC5 cells were pre-treated with non-specific 
neuraminidase or a2-3 specific neuraminidase at the concentrations shown 
and incubated with 20 OOOcpm o f  labelled echovirus type 7 or EV70. 
After Ihr cells were washed and binding assessed using a scintillation 
counter Binding is shown as a percentage o f  binding to untreated MRC5 
cells. Error bars show the range o f  results over duplicate assays.
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percent and twenty percent sucrose layer. Equal volume fractions were collected from 
the top of the centrifuge tube and analysed for viral content by scintillation counting and 
for the protein caveolin-1 by western blot. Caveolin-1 is known to be almost exclusively 
present in lipid raft domains of the cell membrane and therefore can be used as a marker 
for raft-containing fractions (Quest et al., 2004). Figure 4.15B shows western blots for 
fractions collected from membrane flotation gradients of MRC5 cells pre-bound with 
EV70 and echovirus type 7. In both gradients caveolin-1 was present in fractions two 
and three near the top of the gradient, as expected for raft fractions. Both echovirus type 
7 and EV70 were found predominantly in the raft fractions (figure 4.15A). Echovirus 
type 7 binds DAF, a GPI-anchored, raft associated protein, and it is therefore 
unsurprising that the virus was largely located in the raft fractions. Likewise, the 
association of EV70 with raft domains is consistent with binding to a GPI-anchored 
protein, as suggested by the HA inhibition assays.
4.H DISCUSS JON
The studies described in this chapter confirm the role of sialic acid in EV70 
binding to RBC and binding to and infection of MRC5 cells. In contrast, DAF does not 
appear to be required for these processes. The studies further show that on the RBC 
surface EV70 binds to an a2-3 linked sialated GPI-anchored glycoprotein. Although the 
requirement for a2-3 linked sialic acid has not been demonstrated in viral binding to 
MRC5 cells, it has been shown that EV70 binds primarily to a protein associated with 
lipid rafts. In addition, it has been demonstrated that EV70 binds to a range of non­
human cell lines in a sialic acid-dependant manner, but that this does not result in fully 
productive infection.
4.8.1 The role of sialic acid in EV70 binding and infection
The importance of sialic acid in EV70 binding, first reported by Utagawa et al 
(1982), has been confirmed by the current studies. It has been clearly demonstrated that 
sialic acid is important for the HA of RBC, and binding and infection of MRC5 cells. 
Furthermore binding to HeLa and RD cells is also dependant on sialic acid.
Binding of EV70 to non-primate mammalian cell lines (CHO and RK13) and 
XTC-2 (Xenopus) cells has been demonstrated, although it does not cause significant 
infection of these cells. The level of binding is reduced by neuraminidase, confirming
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Figure 4.15 Raft fractionation and viral binding assay. MRC5 cells 
were incubated with 200 OOOcpm o f  *^'8 labelled EV70 or echovirus 
type 7. After Ihr cells were washed, membrane components purified and 
raft flotation carried out on a stepwise sucrose gradient as detailed in 
section 2.5.11. Fractions were collected and binding assessed using a 
scintillation counter, and the fractions containing the raft marker 
caveolin-1 determined by western blot A. EV70 and echovirus type 7 
present in each membrane fraction as a percentage o f  the total virus 
detected across each gradient. Both viruses are mainly contained in 
fraction 2, and to a lesser extent fraction 3. B. Western blots o f  EV70 
and echovirus type 7 containing gradients, probed with antibody to 
caveolin-1. Numbers above the lanes refer to fractions counted from the 
top o f  the gradient. Caveolin-1 is primarily detected in fractions 2 and 3.
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that attachment to these cells is sialic acid-dependant. It is unusual for picornaviruses to 
bind to cells that are not closely related to the viral host; human picornaviruses 
generally interact only with primate cells, perhaps reflecting the fact that most bind 
protein receptors. The broad range of cell types bound by EV70 can be explained by the 
ubiquitous nature of glycosylation and in particular sialidation. Sialic acid can be found 
on all vertebrate species and some invertebrates (e.g. echinoderms). There is debate 
regarding its presence in other invertebrates, but there are reports of its presence 
particularly in non-adult cells such as drosophila larvae; this would explain the binding 
seen on C6/36 cells (mosquito larvae cell line). The observed binding of EV70 to sialic 
acid on the non-human cell lines does not result in significant yield of virus, however 
this could be due to blockage at several points in the viral life cycle, including 
translation and replication. The use of a ubiquitous receptor such as sialic acid could 
certainly have facilitated a cross-species jump, such as that postulated for the emergence 
of EV70 as a human pathogen.
4.8.2 The role of DAF in EV70 binding and infection
These studies have demonstrated that DAF has no significant role in cellular 
binding and infection by EV70. This has been investigated using a variety of 
approaches and reagents. Firstly, soluble DAF does not prevent the HA of RBC by 
EV70. This contains all four domains of DAF, including the most membrane distal 
(SCR 1), to which EV70 has been reported to bind, and effectively inhibits HA by 
CVA21, the other SCR 1 DAF binding enterovirus. Secondly, a polyclonal antibody 
against DAF has no effect on the ability of EV70 to bind to or infect MRC5 cells. 
Although there is no formal data to show that this antibody binds to SCR 1 of DAF, 
indirect evidence comes from its ability to block binding by CVA21. Thirdly, using 
XTC-2 and CHO cell lines engineered to express human DAF, it has been shown that 
the ability of EV70 to bind or infect these cells is not affected by the presence or 
absence of human DAF on the cell surface. Indeed treatment of CHODAF cells with 
neuraminidase consistently reduces EV70 binding by greater than 90%, with no 
evidence of significant residual binding to human DAF.
The initial studies showing DAF binding were carried out in the laboratory of 
Dimock and colleagues using HeLa cells (Karnauchow et al., 1996). Binding was 
blocked by monoclonal antibodies to DAF. In addition they reported that viral binding 
to NIH3T3 cells (mouse fibroblasts) was increased 2-3 fold upon expression of human
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DAF, and the DAF expressing NIH3T3 cells were found to support EV70 growth at low 
level, while the parent cells were non-permissive. However, more recently the same 
group have published data showing that DAF is not required for the attachment to, nor 
infection of, a number of human leukocyte cell lines (Haddad et al., 2004). For example 
neither EV70 binding nor infection of U-937 cells (derived from a human histiocytic 
lymphoma) were reduced by monoclonal DAF antibodies known to block viral binding 
to HeLa cells. This was the case, despite the fact that U-937 cells were shown to express 
comparable levels of DAF to HeLa cells. The authors hypothesised that the amount or 
nature of the sialic acid receptor on these cell lines was such that the interaction of 
EV70 with DAF was circumvented. However the authors also stated that neuraminidase 
treatment of these leukocyte cell lines completely abolished viral binding, indicating 
that DAF is not only not required for EV70 binding, but, that even in the absence of 
sialic acid, EV70 is not capable of binding to DAF on these cells. The group have 
previously shown that sialidation of DAF is not necessary for binding (Alexander and 
Dimock, 2002).
Therefore, although initially, the previously published data on DAF involvement 
and the current studies appear contradictory, this is not the case. The work presented 
here taken together with the previous studies actually indicates that the primary 
component of EV70 binding and infection is sialic acid-dependant and that DAF, if 
involved, is relevant only in a limited number of cell types. Indeed HeLa cells are the 
only human cell line in which DAF binding has been demonstrated and even here 
binding is still sialic acid-dependant (Alexander and Dimock, 2002). It is also of 
importance to consider the relevance of DAF binding to EV70 infection of the human 
conjunctiva. Although DAF is known to be expressed on the human conjunctiva it is 
also present in large amounts in a soluble form in the tear film (Medof et al., 1987). If 
the virus bound DAF it might be expected that significant levels of soluble DAF might 
block binding of the virus to cell surface expressed DAF.
4.8.3 Further characterisation of the EV70 receptor
It has been shown using HA inhibition studies that the RBC receptor of EV70 is 
a sialated GPI-anchored glycoprotein. This protein shows different chemical properties 
to DAF, another GPI-anchored glycoprotein. HA by echo vims type 7, a known DAF 
binding vims, is inhibited by chymotrypsin, presumably due to proteolytic cleavage o f 
the receptor. In contrast, chymotrypsin has no effect on EV70-mediated HA, and the
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EV70 receptor is also more sensitive to Proteinase K. Additionally DAF on RBC is 
known to be poorly cleaved by PIPLC due to a fatty acid substitution in its GPI anchor 
and therefore echo virus type 7 HA is not inhibited by this enzyme, whereas EV70 HA is 
strongly inhibited by PIPLC.
These results are interesting as GPI-anchored proteins are predominantly found 
concentrated at specific cell membrane locations, lipid rafts, and have important roles in 
both cell signalling and endocytic pathways (this is discussed more fully in chapter 
five). Thus the variation in DAF requirement by EV70 may reflect conservation during 
culture adaptation of the association with lipid rafts and specific internalisation and cell 
signalling pathways, rather than of the specific receptor.
Although the HA inhibition results show the RBC receptor to be a sialated GPI- 
anchored glycoprotein, differentiated RBC are enucleate cells that the virus cannot 
infect. Therefore these results need to be corroborated in eukaryotic cells that are 
permissive for viral infection. The proteases and lipases used in the RBC assays have 
proven toxic for MRC5 cells, and so it has not yet been possible to fully compare the 
HA results to binding and infection of MRC5 cells. However, it has been shown that 
EV70 binding in MRC5 cells is localised to lipid rafts, a result consistent with binding 
to a GPI-anchored protein.
The HA inhibition assays also suggested that RBC binding was mediated via 
sialic acid with an a2-3 linkage. This used a2-3 specific neuraminidase that inhibited 
HA. However, no other linkage specific neuraminidases are available to assess whether 
a2-3 is the only sialic acid linkage involved in HA. HA assays are designed to detect 
HA inhibition by as little as four-fold and so additional binding to other forms of sialic 
acid such as a2-6 linked sialic acid cannot be ruled out. Dimock and colleagues 
(Nokhbeh et al., 2005) have recently also reported that EV70 recognises a2-3 linked 
sialic acid on human corneal epithelial cells and U-937 cells (a histiocytic lymphoma 
cell line). The group used a2-3 specific neuraminidase, but also blocked virus binding to 
cells with specific lectins known to bind either a2-3 or a2-6 linked sialic acid.
Use of an a2-3 linked sialated receptor would be consistent with other viruses 
known to primarily infect the conjunctiva e.g.H7N7 influenza virus and adenovirus 
(Ainberg et al., 2000; Olofsson et al., 2005; Skehel and Wiley, 2000), and suggests the 
interesting hypothesis that a2-3 linked sialic acid is responsible for the conjunctival 
tropism of these viruses (Olofsson et al, 2005). One function of the conjunctiva is the 
secretion of heavily glycosylated proteins known as mucins, which are also found as
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membrane bound proteins and form an important part of the tear film (Varki, 1999). 
Unfortunately very little information is available on sialic acid linkages in ocular 
mucins or elsewhere on the conjunctiva. Studies looking at lacrimal duct epithelium 
have detected both a2-3 and a2-6 linked sialic acid (Paulsen et al., 1998; Thaïe et al., 
2001). The lacrimal duct epithelium is continuous with the conjunctival epithelium, but 
differs functionally. Both a2-3 and a2-6 linked sialic acid have also been detected in 
separate studies of ocular secreted mucins (Ai'gueso et al., 1998; Aristoteli and Willcox, 
2006).
Surprisingly, given these results, the use of an a2-3 specific neuraminidase did 
not affect the binding of EV70 to MR.C5 cells, even at high concentration. To confirm 
this result it will be important to establish that the a2-3 specific enzyme is efficiently 
removing a2-3 linked sialic acid from the surface of MRC5 cells. There are a number of 
explanations for these results if they are confirmed. It is possible that the virus binds to 
an entirely different molecule on MRC5 cells than on RBC, or the same molecule with a 
different glycosylation pattern. However, it is also possible that these results could be a 
consequence of the different assay formats used on RBC (HA inhibition) and MRC5 
cells (^^S viral binding assay), and that in fact the vims is capable of recognising both 
linkage forms. The recent work from Nokhbeb et al (2005) provides evidence that there 
may be major differences in the EV70 receptor requirement between cell types. Their 
results indicate that on a human corneal cell line the receptor is an a2-3 linked O- 
glycosylated, non-GPI-anchored glycoprotein, while on U-937 cells an a2-3 linked 
glycolipid was implicated (Nokhbeh et al., 2005), while on HeLa cells the same group’s 
previous work has shown involvement of a GPI-anchored glycoprotein (DAF) 
(Karnauchow et al., 1996). It is possible that the vims has specificity for a particular 
glycosylation pattern, which might be present on different proteins or lipids in different 
cell types. As the glycosylation patterns seen in different species are much more 
conserved than protein sequence (Varki, 1999), this would tie in well with the 
observation that EV70 binds well to non-human and non-mammalian cell lines. If the 
MRC5 result is confirmed, and the vims is not primarily binding to a2-3 linked sialic 
acid in these cells, this might then suggest that although sialic add is important to viral 
binding its orientation may be unimportant or may vary in different cell types depending 
on the underlying molecule. Indeed the influenza vims HI haemagglutinin can bind to 
both a2-3 and a2-6 linked sialic acid, due to flexibility in the position of a specific 
residue (Glutamine 226) in the viral haemagglutinin (Skehel and Wiley, 2000).
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Similarly human influenza virus can effectively replicate in transgenic mice lacking 
a2-6 linked sialic acid (Glaser et al, 2007).
Further studies will be needed to unravel this complex picture. Centering future 
research on the interaction of the EV70 and the conjunctiva could circumvent the 
problems engendered by the variation of receptor usage between cell lines. There is 
currently no commercially available conjunctival epithelial cell line. Although Nokhbeh 
et al (2005) have looked at infection of a human corneal cell line; this is likely to have 
different properties to conjunctival cells, particularly in relationship to glycosylation 
patterns and mucin expression. Several groups are currently attempting to create 
conjunctival cell lines maintaining the features of conjunctival differentiation (De Saint 
Jean et a l, 2004; Diebold et a l, 2003; Gipson et a l, 2003), such a cell line would be 
extremely valuable in research on agents causing conjunctivitis, such as EV70.
4.8.4 Tissue culture adaptation of the viruses used in studies of EV70 receptors
Research on the EV70 receptor has to date been primarily carried out in the 
laboratory of Professor K Dimock, and they have reported a variable DAF requirement 
depending on tissue-type using the reference EV70 strain, J670/71 (Haddad et al, 2004). 
The work in this study, also using 1670/71, has shown no DAF involvement for EV70 
binding to RBC or MRC5 cells, and no evidence of the virus binding to human DAF on 
CHO and XTC-2 engineered to express it. It is possible that further studies using 
additional cell lines with the virus used in the current work might demonstrate a role for 
DAF, consistent with tissue-specific variation in receptor usage. This cannot be the 
entire explanation, however, as there are several areas of direct conflict between the 
previously reported studies by Dimock and colleagues (Alexander and Dimock, 2002; 
Haddad et al, 2004; Karnauchow et al, 1996) and those presented here. Firstly the virus 
used by Dimock and colleagues is cytopathic in HeLa cells, which is not the case for the 
virus used here (although this could be explained by differences in HeLa cell lineages), 
secondly the virus used here binds non-human cell lines to levels equivalent to MRC5 
cells. In particular the vims binds well to CHO cells and NIH3T3 cells (data not 
shown), while the previous reports suggested very poor binding to these cell lines 
except when engineered to express human DAF. A further difference exists between the 
current data and data from Yoshii et al (1977). This early paper provided evidence 
suggesting that EV70 1670/71 growth was comparable between HeLa cells and RK13 
(rabbit) cells, while here only very limited growth was observed in RK13 cells
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(although again this could be explained by differences in cellular lineages rather than 
the viruses). These apparent data conflicts may be explained by differences in passage 
history of the J6/70 EV70 reference strain used here and that used in the other studies. 
Yoshii et al., used virus passaged in primary cynomologous monkey kidney cells and 
that used by Dimock and colleagues was passaged in LLC-MK2 rhesus macaque kidney 
cells, a continuous cell line. No information is given in these studies on the earlier 
passage history of the viruses, nor whether the passage histoi'y of virus used was 
standardised. In the current studies the virus was grown in MRC5 primary human 
embryonic lung fibroblast cells, and used after a standard five passages in MRC5 cells. 
Therefore although all studies have used the reference strain of EV70, J670/71, there are 
differences in the more recent passage history which may well have been responsible 
for adaptation of the viral receptor usage and could explain differences in the data 
obtained. Indeed, as reported in chapter three, there are sequence differences in the 
capsid-encoding VPl sequence of the virus between that used in the current study and 
the previously published sequence for EV70 J670/71, which might be the molecular 
basis of such adaptation.
Studies along the lines of those discussed above could eventually provide an 
exact molecular profile o f what the EV70 reference strain is binding to on a particular 
cell line. However, given the possibility of confounding results due to the adaptation of 
the vims in culture, an approach using vims that has not been extensively cultured, 
would present a much more clinically relevant picture. This could be done using the 
strategy outlined in chapter three of inserting capsid sequence from a clinically isolated 
virus directly into an infectious EV70 clone.
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CHAPTER 5
Investigation of Enterovirus tvoe 70 Entry into the Cell
For productive infection to occur, the viral genome must enter the cell. 
Attachment of the virus to its cellular receptor is only the first step in this process. 
Following attachment the virus must have a mechanism to allow the virus or its genome 
to reach the site of viral replication. For picornaviruses the genome must be delivered to 
the cytoplasm, either by crossing the plasma membrane or the membranes of internal 
cellular structures. Although the term ‘viral entry’ will be used here, it is currently 
unclear for EV70 and many other viruses, whether the intact virion, or the viral nucleic 
acid alone, enters the cell.
Entry to the cytoplasm may occur directly via the formation of a pore within the 
plasma membrane, as seems to be the case for poliovirus (Hogle, 2002; Rossmann et al,
2000), or may occur via the utilisation of the host cell’s endogenous endocytic 
processes, such as the clathrin-mediated or caveolar pathways. Both of the latter two 
pathways have been implicated as the entry routes for different picornaviruses; CVB3, 
human rhinovimses type 2 and 14, parechovirus type 1 and foot and mouth disease vims 
are believed to use clathrin pathways (Berryman et a l, 2005; Chung et al, 2005; 
DeTulleo and Kirchhausen, 1998; Joki-Korpela et a l, 2001; Snyers et a l, 2003), while 
echovirus type 1 and coxsackie B vimses are believed to enter via caveolae (Coyne and 
Bergelson, 2006; Pietiainen et a l, 2004). However, both clathrin and caveolar routes of 
cell entry result in the vims being contained within a cytoplasmic vesicle (endosome 
and caveosome respectively), which the vims must exit to enable translation and 
replication to occur.
Some vimses require a pH-dependant step for entry to the cytoplasm, 
particularly in vimses entering via the clathrin route, where they pass through the acidic 
environment (pH 5.5-6) of the late endosome. Such a pH dependence has been best 
characterised for influenza vims where low pH triggers conformational changes in the 
viral haemagglutinin resulting in fusion of the viral and late endosomal membranes. 
Non-enveloped vimses have also been shown to be dependant on endosomal 
acidification, such as some rhino vimses and CVB3 (Chung et a l, 2005; Nurani et al, 
2003). In these cases exit from the endosome may involve lysis of the endosome or the 
formation of a membrane pore analogous to that of poliovims.
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Early understanding of endocytic processes was relatively simplistic, in 
comparison to the increasing complexities being revealed by current research. Multiple 
routes of cell entry exist. In addition to the well characterised clathrin and caveolar 
routes, there are many other more poorly understood pathways (Marsh and Helenius, 
2006; Pelkmans and Helenius, 2003; Sieczkarski and Whittaker, 2002a), and even 
within clathrin and caveolar pathways there is variation, for example cargo entering 
cells via the same general route, can be found in distinct cytoplasmic structures or 
locations (Marsh and Helenius, 2006), One important feature of cell entiy pathways 
which is now emerging, is the crucial involvement of multiple signal transduction 
pathways (Coyne and Bergelson, 2006; Pelkmans et al., 2005). Many viruses enter cells 
using proteins which cluster in lipid raft domains, which are now known to play key 
roles in both cellular internalisation pathways and cell signalling (Brown and London, 
1998). These domains, once believed to be primarily linked to caveolar entry, are now 
believed to have a more general role in entry pathways, including clathrin-mediated 
endocytosis (Anderson, 1998; Stoddart et al., 2002). Additionally viral entry pathways 
involve elements of the cellular cytoskeleton such as actin and tubulin, although the 
precise role of these is often unclear (Apodaca, 2001; Coyne and Bergelson, 2006; 
Lakadamyali et al, 2003; Stuart et a l, 2002).
There is not a single common route for enterovirus entry. It may be that this 
reflects the variety of different receptor and co-receptor molecules used by the different 
viruses within the genus. Binding to a particular receptor, in a particular site might 
dictate not only the route of viral entry, but also trigger specific down-stream signalling 
events. As one of only two human enteroviruses with a sialic acid component to its 
receptor, EV70 is of particular interest to study in this respect. The other enterovirus 
where sialic acid has been implicated is the less well studied EV68, now known to be a 
strain of rhino virus type 87 (Blomqvist et a l, 2002; Uncapher et a l, 1991).
To date there has been no published work regarding the route by which EV70 
gains entry to the cell following binding, nor any information relating to the importance 
of pH, signalling cascades, or the cytoskeleton during this process. EV70 has been 
classified as an enterovirus partially on the basis of acid stability (Kono et al, 1972). 
Virus from the initial EV70 epidemics and the reference strain 1670/71 were found to be 
stable at pH3 (Kono et a l, 1972). EV70 is unusual, however, in that it is only very 
rarely isolated from faeces in infected patients (Higgins, 1982); in contrast other 
enteroviruses can be easily isolated from the faeces after surviving passage through the
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acidic environment of the stomach. Interestingly, a more recetit isolate was found to be 
acid sensitive at pH3 (Oberste et a l, 2004), suggesting that the presumed acid stability 
of this serotype may not be universal.
One striking feature of EV70 is its ability to bind to multiple non-primate cell 
lines (see section4.4), even though these do not support fully productive infection. 
Although these cells may be non-permissive for viral replication, the blockage might 
occur at the stage of viral entry. If the latter, these cell lines may provide a useful 
resource for determining the precise molecular requirements for the entry of EV70.
Chapter Outline
This chapter describes a series of experiments to determine the route by which 
EV70 enters the cell. This involved the use of a range of potential inhibitory agents to 
investigate the entry pathway used by the virus and the importance of pH, cellular 
signalling and the cytoskeleton in the process. In addition the stage at which EV70 
infection in non-primate cells is blocked was investigated, using the EV70 subgenomic 
replicon and full-length infectious clone.
5.1 Clathrin-mediated endocytosis is important for EV70 
cellular entry
A number of chemicals exist which can disrupt entry pathways (Sieczkarski and 
Whittaker, 2002a). Although often not completely specific for a particular entry route, 
taken together these represent a good method for gaining an initial indication of the 
route of entry used by a particular vims (Pietiainen et al, 2004; Stuart et al, 2002). 
Results from such analyses can identify pathways for more targeted investigation, using 
dominant negative mutant proteins, which specifically inhibit steps in clathrin or 
caveolar entry pathways, or direct observation, perhaps using confocal microscopy 
approaches.
A panel o f four treatments were chosen; chlorpromazine, brefeldin A, methyl-P- 
cyclodextrin and the combination of nystatin & progesterone. Chlorpromazine is an 
inhibitor of clathrin-mediated endocytosis, it acts by causing the accumulation of 
clathrin lattices on endosomal membranes and preventing clathrin pit assembly on the
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cell surface (Wang et al., 1993). Brefeldin A has been used as an inhibitor of caveolar 
endocytosis (Dinter and Berger, 1998; Richards et a l, 2002), and is also known to cause 
disruption of the golgi (Dinter and Berger, 1998). Methyl-p-cyclodextrin and the 
combination of nystatin & progesterone are commonly used methods for disrupting 
lipid rafts. Methyl-p-cyclodextrin causes cholesterol redistribution (Hailstones et al, 
1998), while nystatin and progesterone cause the sequestration of cholesterol and 
inhibition of cholesterol synthesis respectively (Simons and Toomre, 2000). Previously 
disruption of lipid rafts has been used as a method for preventing caveolar entry, 
however it is now established that lipid rafts can also be important for clathrin-mediated 
endocytosis (Puri et a l, 2005; Signoret et a l, 2005; Stoddart et a l, 2002). EV70 has 
been shown to associate with lipid rafts on receptor binding (section 4.7), however this 
does not prove a functional raft requirement.
5.1.1 Chlorpromazine and brefeldin A reduce EV70 infectivity
The effect on EV70 entry of the pre-treatment of MRC5 cells with 
chlorpromazine, methyl-p-cyclodextrin, brefeldin A and the combination of nystatin & 
progesterone was investigated. Toxicity of these agents in MRC5 cells was first 
assessed using a range o f concentrations, based on those shown to be effective in 
previous studies (Pietiainen et al, 2004; Stuart et al, 2002). This was done by visual 
inspection of the treated cells and by assessing the number of viable cells using trypan 
blue exclusion. Both methyl-p-cy do  dextrin and nystatin showed significant toxicity in 
MRC5 cells at the concentrations used in the previous studies (lOmM and 25mM 
respectively), and so were retested at lower concentrations. In contrast, chlorpromazine 
and brefeldin A showed no toxicity at the doses used in previous studies (6pM and 8pM 
respectively), and were tested again at higher concentrations. These differences are 
likely to be due to the relative sensitivities of MRC5 cells in comparison to the cell lines 
used in other studies. The highest concentration of each agent for which no toxicity was 
observed on repeat testing, were 14pM chlorpromazine, 3mM methyl-p-cyclodextrin, 
and 13pM nystatin with 32pM progesterone, and these concentrations were used in 
subsequent assays of viral entry. Initial assays suggested a profound effect of brefeldin 
A on viral infection, even at very low concentrations, and so in this case a lower 
working concentration of 0.4pM was used. Cell culture medium was tested to ensure 
that pH was not affected by the addition of these compounds.
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Monolayers of MRC5 cells were treated in duplicate with agents at the above 
concentrations, prior to infection with EV70 or echovirus type 11 (strain 207). This 
strain of echovirus type! 1 has previously been investigated using similar methodology 
and is believed to enter via caveolae (Stuart et al., 2002). The adsorption and incubation 
steps of infection were carried out in the continued presence of the chemicals. At six 
hours post-infection cells were stained and a flow cytometry-based infectivity assay 
used to determine the proportion of infected cells. This had the advantage over viral 
titration-methods of excluding confounding effects on viral egress. An example of flow 
cytometry data from one representative assay is provided in appendices 1 and 2 
(histogram plots). The results from individual assays are detailed in appendix 3. Figure 
5.1 A shows the mean results with standard deviations, based on a minimum of three 
assays carried out on separate occasions. Results are expressed as a percentage of the 
infected cells in the untreated controls within individual assays. There was significant 
variation in some of the results between separate assays, which may have been partly 
due to the fact that MRC5 cells are a primary cell line and small differences in 
confluence, or in the number of passages undergone, might have affected the 
responsiveness of the MRC5 cells to the agents used. Attempts were made to minimise 
this effect by using cells well before senescence and at a consistent confluency. Despite 
this variation, a number of clear results could be observed.
Treatment of MRC5 cells with the clathrin pathway inhibitor chlorpromazine 
reduced EV70 infection by an average of 50% (figure 5.1 A). The use of a range of 
chlorpromazine concentrations confirmed this to be a dose related reduction (figure 
5. IB), and suggested a role for clathrin-mediated endocytosis in EV70 entry. In contrast 
chlorpromazine caused an increase in echovirus type 11 infection, consistent with 
previous observations that this virus does not use the clathrin route (Stuart et al., 2002). 
Increased activity of caveolar entry pathways may be a consequence of the blockage of 
other entiy routes, potentially explaining the increased infection seen with echovirus 
type 11. Brefeldin A is used to inhibit caveolar entry pathways, and did cause a 
reduction in infection by echovirus typel 1 of over 90% (figure 5.1 A), however a similar 
dramatic reduction was seen for EV70 infection, with a dose response assay showed the 
effect of brefeldin A on EV70 over a range of concentrations (figure 5. IB). This result 
is not consistent with the reduction seen in EV70 infection using chlorpromazine. 
However, brefeldin A is also known to cause disruption of the golgi and may be
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Figure 5.1 Viral infection in M RC5 cells treated with inhibitors o f cell 
entry. A Flow cytometry-based infectivity assay showing cumulative data 
from several experiments with standard deviations (see appendix 5). MRC5 
cells were pre-treated with 14pM chlorpromazine, 3mM methyl-p- 
cyclodextrin, 13pM nystatin with 32pM progesterone or 0.4pM brefeldin A. 
Cells were infected with virus at an m.o.i. of 3, incubated for 6 hours in the 
presence of the chemical and the proportion of infected cells assessed by flow 
cytometry. B Flow cytometry-based infectivity assay showing dose response 
of EV70 infection to increasing concentrations of chlorpromazine (at IpM, 
7pM and 14pM) and brefeldin A (at 0.1 pM, 0.4pM and 2pM).
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affecting viral replication rather than viral entry; this was assessed further in section 
5.1.2.
Echovirus type 11 infection was reduced in cells treated with both methyl-p- 
cyclodextrin and the nystatin & progesterone combination (figure 5.1 A), although for 
nystatin & progesterone the error bar reaches the level of the untreated control. In 
contrast there was no effect of nystatin & progesterone on EV70 infection, and a small 
reduction, if any, with methyl-P-cy do  dextrin. However, due to toxicity, both treatments 
were carried out using lower concentrations than those used in previous studies, and 
indeed in those studies greater effects on echovirus type 11 infection were observed. 
Therefore further work is required to assess the extent to which these concentrations are 
disrupting lipid rafts in MRC5 cells. Most methods to assess disruption of lipid rafts 
rely on the secondary effect of the disruption of caveolae and the caveolar entry 
pathway. One method which has been used, is to assess the effect of treatments on the 
entry of cholera toxin B, which is known to primarily enter via caveolae and lipid rafts 
(Pietiainen et al., 2004). Although the results of the studies presented in this section are 
inconclusive regarding the functional role of EV70 binding to lipid rafts, the previous 
results showing that EV70 does associate with lipid rafts (section 4.7) suggest that they 
may well be important.
5.1.2 Brefeldin A reduces EV70 infection by inhibition of viral replication, while 
chlorpromazine acts at the level of cell entry.
The reduction in EV70 infection seen with both chlorpromazine and brefeldin A 
could be due to effects of these agents on aspects of the viral life cycle other than entiy, 
in particular effects on viral replication or binding.
The subgenomic replicon, pLuc70, was used to assess the effect of 
chlorpromazine, methyl-p-cyclodextrin, nystatin & progesterone, and brefeldin A on 
EV70 replication. RNA was transcribed from the replicon and transfected into MRC5 
cells pre-treated at the concentrations used in the previous assays. After 6 hours 
incubation in the continued presence of the agents, luciferase activity was assayed 
(figure 5.2). Chlorpromazine, methyl-(3-cyclodextrin, and nystatin & progesterone 
treated cells exhibited luciferase levels comparable to untreated cells, demonstrating 
that these agents do not significantly effect EV70 replication. However, replication was 
reduced by two logio in brefeldin A treated cells. Therefore, although an effect of
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Figure 5.2 EV70 replication in M RC5 cells treated with potential 
inhibitors o f cell entry. MRC5 cells were pre-treated with inhibitors at the 
concentrations detailed in figure 5.1 A, and transfected with 2pg of RNA 
transcribed from pLuc70. Luciferase was assayed after 6 hours incubation in 
the continued presence of the chemicals and in the presence and absence of 
the replication inhibitor guanidine hydrochloride. Error bars show the range 
of results over duplicate assays.
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brefeldin A on EV70 entry cannot be excluded, the reduction in infection seen can be 
fully explained by an effect on viral replication.
A binding assay using radiolabelled EV70 was used to assess EV70 binding 
to cells treated with chlorpromazine (figure 5.3). Levels of binding were very similar for 
both untreated and chlorpromazine treated MRC5 cells, suggesting that this treatment 
did not affect the level of EV70 receptor expression or viral binding.
Chlorpromazine is therefore not affecting either EV70 binding or replication.
The flow cytometry-based assay used does not depend on post-replication events for the 
detection of viral infection and therefore the reduction in EV70 infection caused by 
chlorpromazine must be occurring at the level of viral entry to the cell.
5,1.3 Chlorpromazine is inhibiting clathrin-mediated endocytosis in MRC5 cells at 
the concentration used.
It was concluded in the preceding section that the reduction in EV70 infection of 
MRC5 cells treated with chlorpromazine was due to inhibition of viral entry. To 
confirm that chlorpromazine was dismpting clathrin-mediated endocytosis in MRC5 
cells as expected, a transferrin uptake assay was used, as transferrin is known to be 
endocytosed via the clathrin route. Fluorescein conjugated transferrin was added to 
untreated cells, or cells treated with chlorpromazine, methyl-p-cyclodextrin, or 
nystatin & progesterone. After fifteen minutes incubation at 37°C, non-internalised 
transferrin was removed from the cell surface using a glycine buffer at pH3, and the 
proportion of cells containing transferrin determined by flow cytometry (figure 5.4).
Less than 2% of untreated cells were positive for transferrin uptake prior to the 
3TC  incubation, showing that non-internalised transferrin had been efficiently 
removed. After 37°C incubation over 50% of untreated cells, and cells treated with 
methyl-p-cyclodextrin, or nystatin & progesterone, showed detectable transferrin 
uptake. This was reduced to 27% in MRC5 cells treated with 14pM chlorpromazine, a 
50% reduction in comparison to uptake into untreated cells. This was directly 
comparable to the 50% average reduction in the number of EV70 infected cells seen 
after chlorpromazine treatment, and demonstrated that under these conditions 
chlorpromazine is inhibiting clathrin-mediated endocytosis.
In conclusion the reduction in EV70 infection seen in chlorpromazine treated 
cells is likely to be due to inhibition of clathrin-mediated endocytosis, suggesting that 
this is the route used by the virus to gain entry to the cell.
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Figure 5.3 Binding of EV70 to M RC5 cells treated with chlorprom azine.
MRC5 ceils were pre-treated with 14pM chlorpromazine and incubated with 
20 GOOcpm o f  labelled EV70. After Ihr cells were washed and binding 
assessed using a scintillation counter. Binding is shown as a percentage o f  
binding to untreated MRC5 cells. Error bars show the range o f  results over 
duplicate assays. Chlorpromazine treatment o f  MRC5 cells does not reduce 
EV70 binding.
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Figure 5.4 Transferrin uptake in M RC5 cells treated with inhibitors of 
cell entry. MRC5 cells were pre-treated with inhibitors at the 
concentrations detailed in figure 5.1 A, and fluorescein conjugated 
transferrin added. Prior to incubation (untreated cells), or after 15 minutes 
incubation at 37°C (untreated and treated cells), cells were washed with a 
pH3 glycine buffer to remove non-internalised transferrin and analysed by 
flow cytometry, counting 5 000 events per sample. Error bars show the 
range o f  results over duplicate assays. Only chlorpromazine reduces the 
uptake o f  transferrin.
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5 . 2  vH  has a role in the EV70 life cycle
After entry via the clathrin-mediated route, viruses pass through late endosomal 
compartments where they experience an acidic pH. To determine the potential 
significance of this in EV70 entry into the cytoplasm, the effect of pH on the EV70 life 
cycle was assessed, firstly by assessing the stability of the vims to a range of pH 
conditions outside the cell, and secondly, by assessing the effect on viral infectivity of 
agents which raise the pH of late endosomes.
5.2.1 The EV70 particle is stable at late endosomal pH, but not at gastric pH
In order to assess the acid stability of EV70, sensitivity of the vims was tested to 
a range of pH from one to seven. EV70 and the echovims type 7 were incubated in 
solutions of known pH for 20 minutes at 37°C, before being assayed for infectivity in 
MRC5 cells by TCID50 (figure 5.5). Echovims type 7 is a classically acid-stable vims 
found in the faeces of infected individuals.
There were broad similarities in the pH sensitivities of these vimses, with both 
showing no, or insignificant, loss in infectivity down to a particular pH at which there 
was a dramatic reduction. However whereas echovims type 7 was stable at pH 1.7 and 
above, EV70 was only stable above pH 2.7. This difference was confirmed on repeat 
testing. Although a small difference, it is significant in terms of gastric pH. Gastric pH 
ranges from one to four and the increased sensitivity of EV70 to this pH range may 
explain its absence from human faeces in infected individuals. However, at the pH of 
late endosomes (pH 5.5-6) EV70 remained stable.
5.2.2 The effect of inhibitors of endosomal acidification on EV70 infection
Although isolated EV70 virions were found to be stable at late endosomal pH, it 
is still possible that low pH is an important factor in EV70 entry. Low pH may induce a 
conformational change in the vims which facilitates exit from the endosome, but which 
does not affect the infectivity of the EV70 virion. Alternatively, factors additional to pH 
may be required, such as attachment to the viral receptor, or the action of endosomal 
proteases. The role of late endosomal pH in EV70 infection was therefore further 
assessed.
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Figure 5.5 Effect o f pH on viral infectivity in M RC5 cells. Viral 
tissue culture supernatant was diluted 1 ; 100 in solutions at a range o f  
pH. Parallel dilution o f  supernatant from mock infected cells, and 
determination o f  the pH, gave an accurate indication o f  the pH o f  virus- 
containing solutions o f  1.3, 1.7, 2.1, 2.7, 2.9, 4.3, 5.1, 6.6, 6.8, and 7. 
Virus containing solutions were incubated at 37°C for 20 minutes, 
before the pH was adjusted to 7 with sodium bicarbonate and viral 
titres determined by TCIDjq in MRC5 cells.
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NH4CI is a weak base causing elevation of late endosomal pH (Eliassen et al, 
2000; Glomb-Reinmund and Kielian, 1998). MRC5 cells were pre-treated with a range 
of concentrations of 1S1H4C1 from 5mM to 40mM. These doses were not found to be 
toxic in MRC5 cells and did not significantly affect the pH of the culture medium. A 
TCID^o-based infectivity assay was carried out using these cells in the continued 
presence of NH4CI. EV70 titres were assessed at 24, 48 and 72 hours (figure 5.6A). In 
this assay a dose-related reduction in EV70 titre of up to 1.5-2 logio was clearly seen at 
all time points. In contrast NH4CI had no effect on echovirus type 11, a virus that is 
believed to enter via the caveolar route and therefore not to pass through late 
endosomes.
To further confirm the reduction in EV70 titres seen here, a flow cytometry- 
based infectivity assay was carried out using MRC5 cells treated with either 30mM 
NH4CI, a dose resulting in maximum reduction of EV70 titres in the TCID50 assay, or 
bafilomycin. Bafilomycin is a vacuolar ATPase inhibitor and acts to prevent 
acidification of late endosomes. Previous publications have used a wide range of 
bafilomycin concentrations, and so the highest concentrations found to be non-toxic in 
MRC5 cells, 0.3 pM, was used. MRC5 cells were pre-treated with NH4CI or 
bafilomycin, and then infected with EV70 at an m.o.i. of 3, with the agents present 
throughout a six-hour incubation. The results from individual assays are detailed in 
appendix 3, with the cumulative results from these assays presented in figure 5.6B. 
Although wide variation was seen in the results from individual assays, an overall 
reduction in EV70 infection was seen after NH4CI treatment in the flow cytometry- 
based assay, although much less marked than in the TCID^o-based assay. Bafilomycin at 
0.3pM did not have a demonstrable effect on EV70 entry in the flow cytometry-based 
assay. The difference in NH4CI results in the two assays and lack of a bafilomycin effect 
in the flow cytometry-based assay may be due to the different assay formats used, an 
additional factor may be the extent to which bafilomycin is affecting endosomal pH.
Therefore, although the NH4CI results overall suggested a role for late 
endosomal pH in EV70 infection, it will be important to assess the extent to which 
bafilomycin in particular is affecting endosomal pH in MRC5 cells. One potential way 
to do this would be the use of pH sensitive fluorescent probes which accumulate in 
acidic cellular compartments, and either fail to accumulate or alter their emission 
spectrum when endosomal pH is raised (e.g. lysosensor probes available from 
invitrogen).
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Figure 5.6 EV70 and Echovirus type 11 infection in M RC5 cells treated  
with NH 4CI and Bafilom ycin. A. TCIDjQ-based infectivity assay. Cells were 
pre-treated with a range o f  concentrations o f  NH4CI as shown, and used to 
directly determine EV70 or echovirus type 11 titres in a TCIDjq format.
Titres were determined visually at 24, 48 and 72 hours. B. Flow cytometry- 
based infectivity assay using EV70 showing cumulative data from several 
experiments with standard deviations (see appendix 5). MRC5 cells were pre­
treated with 30mM NH 4CI or 0.3pM  bafilomycin. Cells were infected with 
EV70 at an m.o.i. o f  3, incubated for 6 hours in the presence o f  the chemical 
and the proportion o f  infected cells assessed by flow  cytometry.
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5,3 Cell simallins pathways and the cytoskeleton are important 
for EV70 cell entrv
To obtain an initial indication of the importance of cell signalling and the 
cellular cytoskeleton in EV70 infection, infectivity was assessed in cells treated with a 
number of agents known to target specific signalling events or cytoskeletal elements. 
Genistein is a competitive inhibitor of tyrosine kinases, including both ahl and ^/‘c-like 
kinases, the phosphatase PP2 is a potent selective inhibitor of ivc-like kinases, and 
bisindoylmaleimide is a potent inhibitor of serine/threonine kinases, and protein kinase 
C in particular. In addition the effects of cytochalasin D and nocodazole were assessed. 
Cytochalasin D is an inhibitor of actin polymerisation whereas nocodazole causes the 
destabilisation of microtubules.
5.3.1 Inhibition of tyrosine kinases and disruption of actin reduce EV70 infectivity
Toxicity in MRC5 cells was first assessed using a range of concentrations, based 
on those shown to be effective in previous studies (Pietiainen et a l, 2004; Stuart et al, 
2002). The highest concentration of each agent for which no toxicity was observed on 
repeat testing, were 20pM genistein, 60pMPP2, 13nM bisindoylmaleimide, 2pM 
cytochalasin D and 6.6pM nocodazole, and these concentrations were used in all 
subsequent assays.
MRC5 cells were treated in duplicate with chemicals at the above concentrations 
prior to infection with EV70. In the case of cytochalasin D and nocodazole, culture 
dishes were pre-treated with poly-L-lysine to prevent cellular detachment. The virus 
adsorption and incubation steps of infection were carried out in the continued presence 
of the chemicals. At six hours post-infection cells were stained and a flow cytometry- 
based infectivity assay used to determine the number of infected cells. The results from 
individual assays are detailed in appendix 3, with the cumulative results from these 
assays presented in figure 5.7.
Genistein, PP2 and cytochalasin D caused clear reductions in the number of 
EV70 infected cells, by an average of 87%, 57% and 40% respectively, while neither 
bisindoylmaleimide, the protein kinase C inhibitor, nor the nocodazole-mediated 
disruption of microtubules, had a demonstrable effect. Use of a range of concentrations
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Figure 5.7 EV70 infection in M RC5 cells treated with kinase inhibitors 
and agents that disrupt the cytoskeleton. A Flow cytometry-based 
infectivity assay showing cumulative data from several experiments with 
standard deviations (see appendix 5). MRC5 cells were pre-treated with 
20pM genistein, 13nM bisindoylmaleimide, 60pM PP2, 6.6pM nocodazole 
and 2pM cytochalasin D. Cells were infected with virus at an m.o.i. o f  3, 
incubated for 6 hours in the presence o f  the chemical and the proportion o f  
infected cells assessed by flow cytometry. B Flow cytometry-based 
infectivity assay showing dose response o f  EV70 infection to increasing 
concentrations o f  genistein (at 5pM, lOpM and 20pM), PP2 (at 40pM, 
50pM and bOpM), and cytochalasin D (at 0.2pM, IpM and 2pM).
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confirmed the reductions by genistein and cytochalasin D to be dose-dependant (figure 
5.7B). A dose response for PP2 was less clear at the concentrations used, with little 
difference in the percentage of infected cells between 50pM and 60pM.
5.3.2 Genistein, PP2 and cytochalasin D do not affect EV70 replication
To confirm that the reductions in EV70 infection seen were not due to inhibition 
of EV70 replication, the subgenomic replicon, pLuc70, was used to assess the effect on 
EV70 replication. RNA was transcribed from the replicon and transfected into MRC5 
cells pre-treated at the concentrations used in the previous assays. After 6 hours 
incubation in the continued presence of the agents, luciferase activity was assayed 
(figure 5.8).
The level of EV70 replication observed in all treated cells was comparable to 
that seen in untreated cells, demonstrating that genistein, PP2 and cytochalasin D do not 
affect EV70 replication, but are acting to reduce EV70 infection earlier in the viral life 
cycle.
5.3.3 Genistein, PP2, cytochalasin D and nocodazole have the expected effects in 
MRC5 cells.
Further assays were conducted to confirm that the concentrations of the agents 
used in the above assays were having the expected effects in MRC5 cells. This was 
assessed by determining the levels of phosphorylated src in the kinase treated cells, and 
by immunofluorescence in cells treated with cytochalasin D and nocodazole.
Src is a tyrosine kinase that is autophosphorylated at tyrosine residue 418. The 
level of src phosphorylated at tyrosine 418 was assayed in cells treated with the kinase 
inhibitors (figure 5.9). Using an ELISA-based assay (figure 5.9A), it can be seen that 
both tyrosine kinase inhibitors reduce phosphorylation of this protein, genistein by over 
50% and PP2 by over 90%. Bisindoylmaleimide, the protein kinase C inhibitor, also 
appears to cause a small reduction in src phosphoiylation, but to a much lesser degree. 
That the observed reductions are due to changes in the levels of src phosphorylation, 
rather than changes in the amount of src protein in the cell, was confirmed by a western 
blot for src on the cell lysates used in the ELISA assay. Using a non-phosphospecific 
src antibody a duplex band was seen at the expected size of 60kDa, with broadly similar 
intensity in all samples. This antibody is reported to identify a single band; the duplex 
band seen here may be due to the presence of alternately glycosylated or modified forms
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Figure 5.8 EV70 replication in M RC5 cells treated with kinase 
inhibitors and agents that disrupt the cytoskeleton. MRC5 cells were 
pre-treated with inhibitors at the concentrations detailed in figure 5.7A, and 
transfected with 2pg o f  RNA transcribed from pLuc70. Luciferase was 
assayed after 6 hours incubation in the continued presence o f  the chemicals 
and in the presence and absence o f  the replication inhibitor guanidine 
hydrochloride Error bars show the range o f  results over duplicate assays.
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Figure 5.9 Levels o f tyrosine 418 phosphorylated src in M RC5 cells 
treated with kinase inhibitors . A Phospho-Arc quantification in MRC5 cells 
following treatment with various cell-signalling inhibitors. Inhibitor 
concentrations were as detailed in figure 5.7A. Error bars show the range o f  
results over duplicate assays B Western blot o f cell lysates used for figure 
5.9A, probed with antibody against src (not phosphospecific). Similar band 
intensities show that the differences seen in figure 5.9A are not due to 
variation in protein levels.
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of src in MRC5 cells. PP2 is a much stronger inhibitor of src kinases than genistein, 
nevertheless genistein was observed to cause the greater reduction in EV70 infection. 
This is likely to reflect the broader spectrum of tyrosine kinases which genistein inhibits 
and therefore suggests that other tyrosine kinase families, such as ahl, may be involved 
in EV70 infection.
Cytochalasin D and nocodazole treatments were confirmed to be disrupting the 
cell cy to skeleton by indirect immunofluorescence for alpha-tubulin and actin 
respectively (figure 5.10). Clear disruption of the cell sheet is seen in cytochalasin D 
treated cells stained for actin and in nocodazole treated cells stained for alpha-tubulin.
In conclusion the results in this section show that the actions of tyrosine kinases, 
and 5'/'c~like kinases in particular, are important in signalling pathways involved in 
EV70 cellular entry, and in addition that an intact actin cytoskeleton is necessary for 
efficient infection.
5,4 The block in EV70 infection in non-primate mammalian cell 
lines occurs at cell entry
EV70 has been shown to bind to hamster (CHO), rabbit (RK13) and xenopus 
(XTC-2) cells (figure 4.7), but does not result in fully productive infection in these cells 
(figure 4.9). It is not known at what step in the viral life cycle this block in infection is 
occurring. If there is a block at the level of viral entry, future studies using these cells 
have the potential to provide insights into this step in the EV70 life cycle.
The ability to introduce viral RNA from a full-length clone directly into the cell, 
makes possible the assessment of the viral life cycle in isolation from the early events of 
binding and entry. In addition a subgenomic replicon allows viral translation and 
replication to be specifically assessed. These clones are therefore useful tools in 
investigating the block to fully productive EV70 infection observed in non-primate 
cells.
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Figure 5.10 im m unofluorescence for actin and tubulin in M RC5 cells 
treated with agents that disrupt the cytoskeleton. Ceils pre-treated with 
cytochalasin D or nocodazole, were fixed, permeabilised and actin or alpha 
tubulin detected using an anti-alpha tubulin mouse monoclonal or an anti- 
actin rabbit polyclonal antibody respectively. Anti-mouse or rabbit IgG 
FITC conjugates were used as the secondary antibodies as appropriate.
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5.4.1 In non-primate mammalian cells EV70 infection is blocked at the level of cell 
entry.
To assess EV70 replication, RNA from the luciferase-encoding EV70 
subgenomic replicon, pLuc70, was transfected using lipofectamine, into three non- 
permissive cell lines; CHO (hamster), RK13 (rabbit), and XTC-2 (xenopus) and two 
permissive cell lines (MRC5 and RD). Lipofectamine was used, as electroporation did 
not result in efficient transfection in all the cell lines. As can be seen in figure 5.11, 
luciferase levels at 6hrs were comparable between the two rodent cell lines and the 
permissive cell lines, showing that EV70 replication is not blocked in these cells. 
Perhaps not unexpectedly there was no evidence of replication in XTC-2 cells which, 
being of amphibian origin, are much more divergent from human cells than those of 
other mammals.
Further evidence that CHO and RK13 cells fully support EV70 replication was 
obtained from transfection of full-length EV70 RNA transcribed from the full-length 
clone, pFLC70 (figure 5.12). EV70 titres were measured in both culture supernatant and 
in cellular lysates 6hrs post transfection. CHO and RK13 cells demonstrated EV70 titres 
comparable to MRC5 and RD cells. This shows that in addition to translating and 
replicating viral RNA, these cell lines also allow the formation of correctly assembled 
viral progeny. The observation that EV70 titres are comparable between culture 
supernatant and cell lysate shows that the virus is also capable of being released from 
these cells. This is an important observation as EV70 is not cytopathic in CHO, RK13 
or RD cells, and so suggests an active process of viral release, rather than cell lysis. In 
keeping with the lack of replication seen in the replicon assay, infectious virus was not 
recovered from XTC-2 Xenopus cells.
These results show that the two non-primate mammalian cell lines tested from 
rodents are Lilly permissive for EV70 replication, assembly and release. As it has been 
shown that the virus efficiently binds to these cells, this implies that the block to full 
infection is most likely to be occurring at the level of viral entry.
5.5 DISCUSSION
The results presented above provide preliminary evidence that EV70 enters cells 
via clathrin-mediated endocytosis, that the acid environment of late endosomes may be
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Figure 5.11 EV70 replication in a variety o f cell lines. 2 |ig o f  RNA 
transcribed from pLucTO was transfected into cells by lipofection and 
luciferase assayed at 6 hours. The assay was carried out in the presence and 
absence o f  the replication inhibitor guanidine hydrochloride. Error bars 
show the range o f  results over duplicate assays.
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Figure 5.12 EV70 titres after transfection of EV70 RNA into a variety  
of cell lines. 2[ig of RNA transcribed from pFLC70 was transfected into 
cells by lipofection and viral titres were measured by TCIDj^, after six 
hours. Error bars show the range of results over duplicate assays
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important and that src family tyrosine kinases and actin filaments are involved during 
early, pre-replication, stages in the viral life cycle. In addition the virus has also been 
shown to bind to lipid raft domains of the plasma membrane (chapter 4).
5.5.1 The dependence of EV70 on clathrin-mediated endocytosis.
The inhibitor of clathrin endocytosis, chlorpromazine, has been used here to 
demonstrate that EV70 entry into MRC5 cells is via clathrin-mediated endocytosis. 
Although non-specific effects on other entry pathways cannot be entirely excluded, 
chlorpromazine had no effect on echo virus type 1 1 , a virus believed to enter via 
caveolae. It has been shown that this is a specific inhibition of the EV70 entry process, 
as viral binding and replication are unaffected. Further, using transferrin as a marker, it 
has been shown that chlorpromazine is blocking the clathrin pathway in MRC5 cells 
under the assay conditions used.
The clathrin route was the first described and is the most widely documented 
method of viral entry to the cell (Marsh and Helenius, 2006). It is a rapid process, and 
results in viral passage through the increasingly acidic early and late endosomes, where 
penetration occurs with the virus entering the cytoplasm. Influenza virus is perhaps the 
best characterised of the clathrin using viruses (Lakadamyali et al., 2003; Skehel and 
Wiley, 2000). Other viruses using this entry route include adenovirus types 2 and 5 
(Lakadamyali et al., 2003; Meier and Greber, 2004), semliki forest virus (Marsh et al., 
1984; Meier and Greber, 2004) and a range of picornaviruses, such as foot and mouth 
disease virus, human parechovirus type l,and human rhinovirus types 2 and 14 
(Berryman et al., 2005; DeTulleo and Kirchhausen, 1998; Joki-Korpela et a l, 2001; 
Snyers et al., 2003). However, not all picornaviruses use this route, as both coxsackie B 
viruses and echovirus type 1 are believed to use the caveolar method of entry (Coyne 
and Bergelson, 2006; Pietiainen et al., 2004).
The use of an established endocytic pathway allows viruses to rapidly traverse 
the highly structured submembranous region of the cell. While precise information on 
the EV70 life cycle is limited, there are a number of features of the clathrin pathway 
that may be significant in facilitating viral entry. One feature is the exposure of the virus 
to acidic conditions in late endosomes, which could then be exploited by the virus to 
allow entiy from the vesicle into the cytoplasm. The reduction in infection seen by 
raising endosomal pH with NH4CI suggests that this may be important for EV70. 
Clathrin-mediated entry may also allow specific delivery of the virus to its site of
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transcription and translation, as it becorning apparent that the clathrin pathway allows 
internalised cargo to be delivered to functionally and geographically distinct endosomes 
within the cell (Marsh and Helenius, 2006). Entry route is undoubtedly influenced by 
the receptor/s used by the virus; this may not only associate the virus with a specific 
internalisation site on the cell membrane, such as lipid raffs, but viral binding can 
initiate signalling events via the receptor to facilitate entry as discussed below.
An important point is that viruses may use more than one route of entry to the 
cell, either simultaneously or when the preferred pathway is blocked. For example, 
influenza virus, though well characterised as using the clathrin route, can also enter the 
cell by a non-clathrin, non-caveolar route (Rust et a l, 2004; Sieczkarski and Whittaker, 
2002b). It is also possible that the entry pathway may vary depending on the cell type.
Further work will be needed to confirm the chlorpromazine-based results and 
use of the clathrin-mediated endocytic pathway for EV70 entry. One more specific way 
of determining whether a virus enters via the clathrin or caveolar routes is the use of 
dominant negative proteins. These have been successfully used to investigate the route 
of entry of a number of viruses (Sieczkarski and Whittaker, 2002b). Various dominant 
negative mutants have been created; in particular mutants of the Eps 15 protein, which 
is associated with clathrin coated pits (Benmerah et al, 1999), and a dominant negative 
form of caveolin (Pelkmans et al, 2001). Attempts were made during this project to 
confirm the EV70 entry route by expressing these mutant proteins in MRC5 cells, 
however, it was found that the transfection process used in the assay greatly reduced the 
ability of MRC5 cells to be infected by EV70 (data not shown). Further possibilities are 
to use these proteins to investigate EV70 in a different cell line or the use of confocal 
fluorescent microscopy to examine co-localisation of the virus and cellular components 
involved in entry processes, as has been done for a number of viruses (Pietiainen et a l, 
2004; Rust et al, 2004).
5.5.2 Viral Penetration and requirement for a low pH environment
EV70 has been classified as an enterovirus partially on the basis of acid stability 
at pH3 (Kono et al, 1972), although the expected reclassification of enteroviruses and 
rhino viruses indicates that acid stability may not necessarily be a distinguishing feature 
of this genus. It is unusual, however, in that it can only very rarely be isolated from 
faeces in infected patients (Higgins, 1982), in contrast other enteroviruses can be easily
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isolated from the faeces after surviving passage through the acidic environment of the 
stomach.
In this chapter EV70 has been shown to be acid-labile below pH 2.7. This is an 
important observation in relation to viral pathogenesis, in that vims will not be expected 
to survive the gastric environment, and explains the failure to isolate vims from the 
faeces of infected patients. A more recent isolate strain ofEV70 has been found to be 
acid labile at pH 3 (Oberste et al., 2004), suggesting that relatively few changes may be 
required to render the EV70 capsid sensitive to a wider range of pH. In contrast, the 
vims is clearly stable at the pH of late endosomes, suggesting that the vims should be 
stable in these compartments. However this does not mle out a possible role for 
endosomal pH in viral penetration. Additional factors, present in endosomes, may be 
important in regulating the viral response to low pH, such as continued attachment to 
the viral receptor or exposure to endosomal proteases. Preliminary work, showing a 
dose-dependant reduction in EV70 infection in MRC5 cells treated with NH4CI, 
suggests that pH may well be important in EV70 entry. This result clearly requires 
further confirmation, especially as bafilomycin had no apparent effect on viral entry in 
MRC5 cells (although this may have been due to toxicity preventing effective treatment 
concentrations from being used).
Many vimses entering via the clathrin route have been shown to require a low 
pH step during infection, most obviously influenza vims where acid pH causes a 
conformational change in the viral haemagglutinin resulting in membrane fusion 
(Skehel and Wiley, 2000), but also for non-enveloped viruses, such as adenovimses. 
Adenovimses exit via endosomal lysis following a conformational change in the penton 
base of the capsid induced by low pH (Medina-Kauwe, 2003) and low pH steps have 
also been implicated for foot and mouth disease vims, CVB3 and rhino vim ses 
(Berryman et al., 2005; Chung et al., 2005; Nurani et al., 2003), although here the 
significance remains uncertain. Some vimses, such as reovimses and coronavimses, 
require the additional action of endosomal proteases (Ebert et al., 2002; Simmons et al,
2005).
If EV70 infection is confirmed to be reliant on low endosomal pH, there are a 
variety of ways in which this could be acting. Low pH may trigger conformational 
change within the EV70 capsid, potentially in combination with viral receptor 
attachment or endosomal proteases. Such capsid changes might trigger the uncoating of 
the vims, potentially forming a pore within the endosomal membrane through which the
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vims can penetrate, analogous to the membrane pore formed by poliovims (Hogle,
2002; Rossmann et al., 2000), or endosomal lysis might result, analogous to the 
adenovimses (Medina-Kauwe, 2003).
5.5.3 L ipid rafts and cellular signalling in EV70 entry
EV70 has been shown to associate with lipid rafts upon binding to MRC5 cells 
via sialic acid. As yet the evidence is insufficient to determine whether this interaction 
is absolutely necessary for EV70 infection. However, as lipid rafts are dynamic regions 
of the cell surface with multiple functions in endocytic and signalling pathways (Brown 
and London, 1998), it is likely that this association has a strong functional basis.
Although traditionally associated with caveolar entry pathways (Quest et al, 
2004), rafts have been implicated as a site of endocytosis via other pathways; clathrin- 
mediated endocytosis (Puri et a l, 2005; Signoret et al, 2005; Stoddart et al, 2002) and 
non-clathrin, non-caveolin routes (Zeng et al, 2003). This perhaps reflects the 
importance of cell signalling in all cell entry processes, as rafts function as cell 
signalling platforms within the cell membrane (Simons and Toomre, 2000). External 
stimuli, such as viral binding, can result in dramatic changes in the protein composition 
of lipid rafts, with the recmitment of further proteins. Particular proteins are 
preferentially associated with rafts; these include GPI-anchored proteins, j/r-family 
kinases and certain transmembrane proteins and G proteins. Simons and Toomre (2000), 
suggest that rafts act as ‘concentrating platforms for individual receptors, activated by 
ligand binding’. Rafts can thus recmit proteins to an environment where they are 
exposed to the actions of a variety of kinases and phosphatases and act as the starting 
point for signal transduction pathways. The potential importance of this in viral 
infection is highlighted by the finding that binding of coxsackie B vimses to DAF 
present in lipid rafts, results in concentration and cross-linking of DAF, with the 
clustering of proteins including activated src kinases and abl (Coyne and Bergelson, 
2006).
The sensitivity o f EV70 infection to the inhibitors genistein and PP2 has 
demonstrated the dependence of early stages in the EV70 life cycle on the activity of 
tyrosine kinases, and of ^ rc-family kinases in particular. No effect was observed in cells 
treated with the protein kinase C inhibitor, bisindoylmaleimide, however it is important 
to note that inhibition of protein kinase C activity has not yet been confirmed under the 
assay condition used. Tyrosine kinases play key roles in signal transduction pathways,
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and src family kinases, in particular, are known to associate with lipid rafts (Simons and 
Toomre, 2000).
The importance of signal transduction in viral entry, including clathrin 
pathways, is now well established (Brodsky et a l, 2001; Greber, 2002). The entry of 
vesicular stomatitis virus via the clathrin route has been shown to be associated with 
alterations in the activities of over 90 distinct kinases (Pelkmans et al, 2005). Over 95% 
of the clathrin pits with which influenza virus associates are formed de novo after viral 
binding (Rust et al, 2004), presumably through virus-induced signalling events. Viruses 
may directly activate signalling pathways by binding to a receptor with integral 
signalling functions, as is the case for the low-density lipoprotein receptor of minor 
group rhino viruses (Hofer et a l, 1994). Alternatively viral binding may cause 
interactions between the receptor and other molecules involved in signalling pathways. 
This is the method by which proteins with a GPI anchor initiate signalling; as they lack 
a cytoplasmic domain, they exert their effects via interactions with the external or 
transmembrane domains of other signalling proteins. This may be the situation for 
EV70 if the receptor is indeed GPI-anchored, as suggested by HA studies (chapter 4). 
Signalling may not only facilitate viral entry by direct stimulation of entry pathways, 
but also by recruiting necessary co-receptors to the lipid raft (Simons and Toomre, 
2000), or by triggering translocation of the virus to the site of a second receptor. The 
later has been shown for coxsackie B vimses (Coyne and Bergelson, 2006), where 
binding to DAF triggers abl kinase activity, resulting in movement of the vims to the 
epithelial tight junction, where it can bind to CAR, an otherwise inaccessible receptor.
5.5.4 The role of the cytoskeleton in EV70 entry
Cytochalasin D reduces EV70 infectivity in MRC5 cells, but has no effect on 
replication. As this agent blocks actin polymerisation, this suggests a role for the actin 
cytoskeleton in EV70 entry. In contrast, the dismption of microtubules using 
nocodazole had no effect on EV70 infection.
Both microtubules and actin form part of the cellular cytoskeleton and have 
important roles in endocytic processes (Apodaca, 2001). Microtubules are involved in 
the localisation of organelles within the cell and transport between organelles. They are 
one of the primary mechanisms by which vimses have been found to traverse the 
cytoplasm (Greber and Way, 2006). The precise role of microtubules in endocytic 
pathways however, is not clear, as depolymerisation with nocodazole has variable
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effects depending on the cell type and end-point being assessed (Apodaca, 2001). That 
EV70 endocytosis itself does not require intact microtubules in MRC5 cells might 
therefore not be an unexpected finding, however the lack of effect of nocodazole on 
EV70 infection further suggests that EV70 uses a non-microtubule-based route, after 
release from the endosome, to reach its site of replication.
Actin is abundant in the submembranous region forming the cortical 
cytoskeleton of the cell. It has been strongly linked to endocytic processes, although the 
need for actin varies depending on cell type (Fujimoto et al., 2000), growth conditions 
and specific membrane subdomains (Apodaca, 2001). For example, actin appears to be 
required for the uptake of influenza virus and vesicular stomatitis virus from the apical, 
but not basolateral membranes of polarised epithelial cells (Gottlieb et al., 1993). The 
precise role of actin in endocytosis is unknown, it may be acting as a scaffold for 
assembly of the endocytic machinery or to regulate the entry of receptors into vesicles 
(Apodaca, 2001). The requirement for an intact actin cytoskeleton in EV70 infection 
might therefore be associated with its requirement for endocytosis of the virus into 
MRC5 cells. Another explanation is that actin is required for movement of the virus, 
either via translocation to a separate region of the cell membrane prior to entry, or 
within the cytoplasm following exit from the endosome. Coyne and Bergelson (2006), 
showed that localised actin rearrangements, induced by tyrosine kinases were 
responsible for the translocation of DAF bound coxsackievirus to the tight junction for 
interaction with CAR. In the cytoplasm, tyrosine kinase-mediated signalling induced by 
SV40 and vaccinia viruses, results in the formation of comet-like actin tails, believed to 
propel the vimses through the cytoplasm (Frischknecht et al, 1999; Pelkmans et al,
2002). If actin tails are involved in EV70 movement within the cytoplasm, this might 
explain the lack of effect of the dismption of microtubules on EV70 infection.
5.5.5 Species restriction in EV70 infection
It has been shown that the block in EV70 infection in CHO (hamster) and RK13 
(rabbit) cells occurs after viral binding but before replication. This suggests that the 
block is occurring during viral entry and penetration of the cytoplasm. In contrast EV70 
was not found to be capable of replicating in XTC-2 cells (Xenopus).
The finding that EV70 RNA is not replicated after transfection into cells of 
Xenopus origin is perhaps not surprising given the evolutionary distance between 
humans and amphibians. Similarly, poliovims RNA is not replicated after injection into
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Xenopus oocytes. Interestingly, however, the addition of only two factors from HeLa 
cell extracts allows efficient translation and replication to occur (Gamarnik and Andino,
2006), and this may therefore also be a useful model for future investigations into the 
cellular requirements for EV70 replication
The block to EV70 entry in CHO and RK13 cells has a number of potential 
explanations. One possibility is that the entry pathway in these cells is not compatible 
with that required by EV70. Although clathrin-mediated endocytosis is observed in all 
mammalian cells, there are likely to be differences in either the components of the 
pathway or the signalling pathways associated with it. However, poliovims can 
productively infect mouse L cells engineered to express the poliovims receptor 
(Mendelsohn et al., 1989; Wood and Hull, 1999) and CVA21 can infect L cells 
expressing its receptor ICAM-1 (Shafren et al., 1997a), suggesting that at least some 
potential routes of enteroviral entry are sufficiently conserved. Another possible reason 
for the block in infection observed with EV70 is lack of an effective receptor or 
receptors. Although these cells express a sialated receptor to which EV70 can bind, the 
nature of the underlying molecule may differ between non-permissive and permissive 
cells, such that entry does not follow binding. Alternatively there may be a lack of an 
essential co-receptor. Many vimses have been shown to require more than one receptor. 
Coxsackie B vimses are recmited to the cell via the ubiquitously expressed DAF, but 
require interaction with CAR for uncoating and release of viral RNA (Coyne and 
Bergelson, 2006), and it is hypothesized that rotavimses require as many as three 
separate receptor interactions (Arias et al., 2002). Thus the sialated receptor may be 
sufficient to recmit the vims to the cell, but another receptor/s may be needed for EV70 
entry.
CHO or RK13 cells are therefore potentially valuable tools in future EV70 
research. By transfecting in cDNA libraries, clones could be found which result in the 
fully productive infection of these cells by EV70. These might then identify the 
functional receptor and/or co-receptors required for EV70 entry and infection of cells.
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CHAPTER 6 
Final Discussion and Future Work 
6.1 Future directions in EV70 recevtor and entry studies
6.1.1 Current understanding and future research goals.
Although improving, the current understanding of how enteroviruses gain entry 
to the cell for replication remains limited. Only for poliovims are the steps required 
relatively clear and, even for this well understood vims, there is some debate and 
uncertainty. The evidence suggests differences in the routes and mechanisms used for 
different members of the genus. Therefore, as the best characterised group D 
enterovims, and one of only two human enterovimses with a requirement for cell 
surface sialic acid, further understanding of EV70 entry may help give a fuller 
appreciation of the overall picture of how enteroviral genomes gain entry to the cellular 
cytoplasm.
The work presented in this thesis has demonstrated the essential role of sialic 
acid as a receptor in the binding and infection of MRC5 cells by EV70. Additionally 
sialic acid has been shown to be the primary determinant of vims-mediated HA and 
binding to non-human cell lines. The central role of sialic acid is corroborated by other 
studies using cell lines productively infected by EV70 (Alexander and Dimock, 2002; 
Haddad et al, 2004; Nokhbeh et al, 2005). On RBC the vims has been shown to bind a 
GPI-anchored glycoprotein with a2-3 linked sialic acid. However this was not the case 
in MRC5 cells, where binding was unaffected by the removal of a2-3 linked sialic acid, 
and other work has suggested the involvement of a variety of different categories of 
sialated molecules on different cell types (Nokhbeh et al, 2005). Potential reasons for 
the apparent variation in the identity of the sialated receptor have been discussed in 
chapter 4, such as specificity for a specific glycosylation pattern (rather than a specific 
glycoprotein or lipid) or adaptation of the vims to growth in different cell lines.
The sialic acid-mediated binding of EV70 to rodent cell lines is not sufficient to 
permit entry of the vims into the cell. As discussed in chapter 5 this could be due to the 
absence of a specific coreceptor on these cells, or to the vims binding to a sialated 
molecule which cannot support internalisation or uncoating.
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A number of features of EV70 entry into MRC5 cells have been determined.
The current study suggests that internalisation occurs via the clathrin-mediated 
endocytic pathway and that this occurs in association with lipid raft domains in the cell 
membrane, although a functional role for lipid rafts in EV70 entry has not yet been 
demonstrated. Additionally there has been shown to be involvement of cellular 
signalling pathways {src tyrosine kinases in particular) and the actin cytoskeleton. 
Furthermore, the acidic pH in late endosomes is likely to be important for EV70 
penetration, although further work is required to confirm this, and determine its specific 
role.
The aims of future research will be to identify the GPI-anchored protein or 
proteins to which the virus is binding on RBC, and to determine the nature and identity 
of the receptor on MRC5 cells if this is different. It will be important to determine 
whether the virus interacts with a specific individual glycosylated molecule, or to a 
variety of related molecules, and if the latter, to establish the common carbohydrate 
stmctures and protein or lipid components required for viral binding. In addition further 
investigation is required to ascertain whether these interactions are sufficient to enable 
subsequent viral entiy into the cell, or whether a further coreceptor may be necessary.
In addition to the identification and characterisation of the EV70 
receptor/coreceptors, elucidation of the interaction between the receptor and viral capsid 
is important. In particular whether the interaction of the virus and receptor occurs within 
the viral canyon, as with poliovims, human rhinovims type 14 and CVB3 (He et al., 
2000; Olson et al., 1993; Xiao et al., 2001), or elsewhere on the capsid as for DAF 
binding vimses (He et al., 2002; Pettigrew et al, 2005). The direct consequences of the 
binding of EV70 to its receptor/s also need to be established; particularly whether, and 
in what circumstances, the receptor interaction results in viral uncoating and the nature, 
and importance for productive infection, of any down-stream signalling events that 
might be directly triggered by viral binding.
The preliminary findings relating to the entry pathway of EV70 need to be 
confirmed, with the aim of future studies being to establish an integrated picture of the 
precise molecular and cellular steps involved in delivery of the viral genome to the 
cytoplasm.
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6.1.2 Future research strategies and approaches
There are a number of approaches that can be used to identify viral receptor 
candidates. These include methods directly assessing viral binding, such as virus 
overlay protein blot assays (VOPBA) and recent glycan microarray technology, as well 
as screening using panels of antibodies and cDNA libraries.
VOPBA would be a particularly useful technique in the case of EV70, both to 
further investigate the nature of viral binding, and to specifically identify potential 
candidate receptors. The assay involves binding of labelled virus to membrane proteins 
extracted from the cells of interest and separated on a native gel. VOPBA has been used 
to identify several viral receptors including a 55kDa protein which is the receptor for 
adenovirus type 37, a cause of keratoconjunctivitis (Wu et al., 2001). The assay could 
potentially provide information on whether EV70 is binding to a single GPI-anchored 
protein on RBC, or a variety of proteins, by observation of binding to single or multiple 
protein bands respectively. Overlay assays using RBC could be compared with those 
using MRC5 cells or even non-primate cell lines. Analysis of binding patterns in cells 
treated with neuraminidase would give further information, in particular on whether an 
additional non-sialated coreceptor exists. There are however, several drawbacks to such 
analyses; if the virus binds to a significantly large numbers of different sialated proteins 
it may not be possible to differentiate specific binding from background, and in 
addition, binding to glycolipids would not be identified. However, should discreet bands 
be seen, mass spectrometry could then be used to identify potential receptors.
The non-permissive cell lines, CHO and RK13, could be particularly useful in 
the screening of cDNA libraries, looking for clones capable of rendering these cell lines 
fully permissive for viral infection. This approach would identify sialated or non- 
sialated proteins that are specifically required for EV70 entry, rather than just binding. 
Cells rendered permissive for EV70 infection could be detected using a p-galactosidase- 
linked antibody and the cDNA clone present identified by sequencing. Again, however, 
this approach is limited by its failure to allow identification of glycolipid receptors, and 
also as the defect in entry may not be receptor-related. Another potential problem is that 
the glycosylation of human proteins may not be conserved when expressed in non­
human cell lines.
An alternative approach, that has the advantage of being able to identify both 
glycoprotein and glycolipid receptors, is the use of pools of monoclonal antibodies 
raised against membrane components. These can be screened for the ability to block
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viral infection. Subsequently the specificity o f blocking antibodies can be established. 
ICAM-1 was initially identified as a receptor by identifying a 95 kDa protein recognised 
by an antibody capable of blocking rhinovirus infection (Greve et a l, 1989).
Although the above approaches may identify candidate receptors for EV70, they 
will not directly provide information on the requirement for specific glycosylation 
patterns or glycan sequences, nor will they yield useful results if the binding specificity 
is purely for a specific glycan moiety. If a receptor protein is identified its glycosylation 
can be determined, but this is not a straightforward task and requires first that the 
glycoprotein or glycolipid be purified and then the glycan groups detached and analysed 
using a combination of techniques including chromatography and mass spectrometry 
(Varki, 1999). As many proteins contain multiple glycan groups, and the exact structure 
of these can vary between individual molecules at the same site, interpretation is often 
complex. One particularly attractive technique for directly identifying the glycan 
structures to which a vims can bind, is the use of recently developed glycan micro arrays 
(Blixt et al, 2004). These include over 200 glycan sequences, representing the major 
glycan stmctures found on glycoproteins and glycolipids, to which vims binding can be 
assessed. This would allow direct assessment of the glycan stmctures to which EV70 
can bind; however, useful results would only be obtained if the vims is capable of 
binding to these in the absence of an underlying protein or lipid.
The availability of a full-length infectious clone now makes possible reverse 
genetic approaches to examine the effect of mutations at sites of interest within the 
EV70 genome. However, studies to identify the site of receptor binding on the EV70 
capsid are limited at present, as the exact receptor is not known, and also due the lack of 
information on the precise stmcture of the EV70 virion that would enable accurate 
identification of the position of residues on the capsid surface. Residues potentially 
involved in binding in the canyon or at the axes of symmetry could be determined by 
comparison to known enterovims structures; however there is likely to be too much 
sequence variation to make this a reliable strategy. One potentially informative 
approach would be to investigate the significance of the differences in capsid sequence 
between the vims used in these studies, and the published EV70 sequence; in particular 
the relevance to viral binding of the cluster of four base changes within a short 45 base 
region of VPl. Once a receptor is identified, it may be possible to examine crystal 
stmctures of the vims-receptor complex.
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Viral uncoating of EV70 has not yet been studied, however this is an important 
step in release of the viral genome into the cytoplasm. Uncoating assays involve looking 
for evidence of a change in the viral sedimentation coefficient from the native 160S 
particle to the 135S or ‘A’ particle (Curry et a l, 1996). Although there is still some 
doubt regarding whether the 135S particle is a true intermediate in the process, it has 
been used as a convenient method for monitoring uncoating. Questions that could be 
addressed include whether EV70 uncoats upon binding to the surface of MRC5 cells, or 
whether there are further requirements, such as exposure to low pH, as is the case with 
some rhino viruses (Nurani et al, 2003). Uncoating could also be assessed on non­
primate cell lines, giving information on the functionality of the receptor on these cells.
The use of dominant-negative proteins to investigate the effect on viral entry of 
inhibiting specific endocytic pathways has been discussed (section 5.5.1). However, 
another potential approach, which could also allow wider aspects of the entry pathway 
to be assessed, is the use of fluorescent microscopy. This would require either the 
availability o f an antibody raised against EV70 that binds the 160S particle, or the 
production of fluorescently labelled vims. Indeed, previous studies have shown that 
enterovims capsids can be successfully labelled without affecting receptor interactions 
(Kremser et al, 2004a; Pietiainen et al, 2004). Confocal microscopy could then be used 
at various time points following binding to examine the co-localisation of virus with 
potential receptors, markers of intracellular stmctures or elements of the cellular 
cytoskeleton. In addition the associations of vims capsids and viral RNA could be 
differentiated by taking advantage of the dynamic nature of the capsid, which allows 
viral RNA to be labelled inside intact particles (Kremser et a l, 2004b). Studies can be 
enhanced by following the movement of individual vims particles and the use of real­
time fluorescent microscopy, as has been done for influenza vims (Lakadamyali et a l,
2003). However, such studies may be more challenging where there is a high particle to 
infectious unit ratio as is the case for enterovimses.
6.1.3 Source of virus for future studies
Vims can be derived either from cultured vims or from infectious clones. The 
use of vims recovered from infectious clones enables a ready supply of vims, which can 
be recovered unchanged over time, and which can easily be used by different 
laboratories to allow collaboration and ready comparison of research results. However, 
such vims will be uniform, and not representative of the variety of sequences present
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within the viral quasispecies. The quasispecies may well be of clinical relevance, for 
example in terms of pathogenesis (Domingo et al, 2006). One possibility is that the rare 
occurrences of acute flaccid paralysis due to EV70 are due to a minor component of the 
quasispecies that allows the virus to access the central nervous system. If this were the 
case, studies using cloned virus might not be relevant to this aspect of the viral 
pathogenesis.
The potential problems of the use of highly passaged virus and reference strains 
have been discussed, and indeed observations during this study have suggested that 
there may be adaptation of EV70 to growth in different cell lines; for example changes 
from the published sequence and variation in findings between different laboratories. 
One way to circumvent this problem would be the use of clinical isolates; in particular 
to engineer sequences from these into the infectious EV70 clone, avoiding the need for 
further culture. It might also be possible to compare vims isolated from the conjunctiva 
and the central nervous system of patients with paralysis and compare binding 
characteristics and potential differences in tropism. One problem that has been 
encountered in this study is the difficulty of obtaining clinical isolates. The last outbreak 
of EV70 reported in the literature was in 1996 in Delhi, India (Maitreyi et a l, 1999). 
Despite contact with a number of laboratories across Asia, it was not possible to obtain 
any samples from EV70 epidemics. It is likely that a more extensive search would 
locate some such samples, additionally closer contacts with diagnostic laboratories 
within South East Asia would allow early collaboration should a further outbreak be 
detected.
6.1.4 Cell lines and models for use in future studies
The studies here have primarily centred on EV70 infection of MRC5 cells.
There were a number of advantages to use of this cell line; the vims grows 
cytopathically in it and to good titre, it is derived from the natural host of the vims 
(human), and it is a primary cell line that is not transformed and transformation is 
known to have wide-ranging effect on the expression of cell surface molecules and their 
glycosylation (Varki, 1999). Additionally recent passage of the vims at ATCC has been 
in WI-38 cells, another embryonic lung fibroblast cell line. However there were a 
number of disadvantages to the use of MRC5 cells, including a number uncovered 
during this study. As a primary cell line, it is possible that increasing passage results in 
changes within the cells. Cells were used over a span of 18 population doublings well
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before senescence, and this was shown not to affect viral yield, however other more 
subtle effects could not be excluded. Certain approaches were not possible using MRC5 
cells, due to problems of sensitivity to treatment with proteases and lipases and reduced 
EV70 infection in cells that had undergone transfection. Although human, these cells 
are fibroblasts, rather than epithelial like the cells of the conjunctiva. Epithelial cells are 
characterised by polarity, having distinct apical and basal membranes, and this may 
affect receptor expression patterns or endocytic pathways.
To overcome this last point, it would be desirable to use a conjunctival cell line. 
As yet no good conjunctival cell lines are readily available. One cell line derived from 
human conjunctiva (Chang), has been shown to be less differentiated and differ in 
several key characteristics from primary conjunctival cells (De Saint Jean et al., 2004). 
Other candidate immortalised conjunctival cell lines, which show at least the same 
pattern of mucin expression to native conjunctiva are potential future candidates 
(Diebold et al., 2003; Gipson et al., 2003). The use of neuronally derived cell lines 
would also be useful, particularly where neuronal tropism and pathogenesis is being 
investigated.
Of course cell lines do not accurately represent the in vivo situation, and one 
hope for the future would be the availability of an animal model of EV70 infection. 
Intraspinal injection of the virus caused paralysis in chimpanzees, however EV70 (at 
least in this study) does not appear to efficiently infect rodent cell lines. It may be 
possible by serial passage of virus in murine cell lines to derive a virus that can 
efficiently infect them, which might then also permit infection of the host species, but 
with the risk of alteration in the viral receptor usage. Another solution would be the 
generation of transgenic animals, perhaps expressing a candidate human receptor 
protein. For example poliovims research has been greatly helped by the availability of a 
transgenic mouse model that expresses PVR (Ren et al., 1990). However, the expression 
of a receptor molecule may not always result in the expected pathology; for example 
CVA21 causes paralysis in mice transgenic for ICAM-1, as opposed to the respiratory 
symptoms associated with human infection. Further cell culture based research will be 
important in elucidating the requirements for the generation of an animal model for 
EV70. Such a model would be particularly important for future studies investigating 
EV70 tropism and pathogenesis.
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6,2 Central themes in viral attachment and entry
6.2.1 Receptor usage and delivery of the viral genome into the cell
A successful virus must be capable of transferring its genome between cells and 
between organisms. To do this it must be capable of associating with a cell that can 
support its life-cycle, and be able to deliver its genetic material, and any viral proteins 
required for replication and translation, to the interior of that cell.
The choice of receptor is obviously an important factor in this process. As will 
be discussed in the next section, the receptor largely dictates which cell types and 
species a virus can infect. The cell type infected must be able to efficiently support the 
viral life-cycle, not only intracellularly, but also in terms of the organism as a whole and 
the mechanism of transmission of the virus. EB V, for example, is believed to have dual 
tropism for its primary site of replication and latency, the B cell, and for the epithelial 
cells of the oral mucosa which permit efficient transmission between individuals in 
saliva (Faulkner et al., 2000). Viruses that cause acute illnesses, with relatively short 
periods of viral excretion, must be able to efficiently infect tissues to which they have 
ready access and exit. Infection of the respiratory tract, which is seen for a very wide 
range of viruses including influenza viruses, rhinoviruses and adenoviruses, is not only 
facilitated by inhalation, but is also an easy site for exit and transmission between 
individuals by sneezing and coughing (often a consequence of viral infection). Viruses 
can enter the digestive tract easily by ingestion, and exit easily in the faeces where 
transmission may be further facilitated by diarrhoea; the ease by which such enteric 
infections can be transmitted by faecal oral contact and fomites is attested to by the 
frequency and extent of rotavirus outbreaks in children, and intractable hospital 
outbreaks of norovims (Bishop, 1996; Chadwick et al., 2000). The conjunctiva also 
represents an easily accessible target for EV70, particularly it situations of poor 
hygiene, where rubbing of eyes (which will be increased due to the irritation of 
inflammation), result in contamination of hands and the environment. In the case of 
viruses which cause chronic or latent infection poor accessibility of tissues may be 
overcome by the length of time for which virus can be excreted. For example HCV 
infects the liver, which is accessed primarily via the blood stream, either iatrogenically 
or via needle-sharing. However, in the 80% of infected individuals where chronic HCV
1 6 6
Chapter 6 Final discussion and future work
infection is established, the continued presence of the virus in the blood stream for the 
life-time of the patient ensures opportunities for transmission (Shepard et al., 2005).
The receptor is not only important in associating the virus with the correct target 
cell, but also in facilitating entry and the viral life-cycle within the cell. In chapter 5, the 
importance of cellular binding in terms of entry was discussed, with important factors 
being the location of the receptor on the cell surface and the triggering of endocytic 
pathways. However, there may also be wider effects. Signal transduction effects may 
not only assist internalisation, but may also render the cell receptive for later stages of 
the viral life-cycle; for example by up regulating the expression of proteins required for 
viral translation and replication. One of the major challenges a virus has to overcome is 
the host immune system. Many viruses, such as adenoviruses and herpes viruses, 
encode a number of proteins with cytokine and immune functions. Viruses with smaller 
genomes, such as picornaviruses, may achieve similar results by using as receptors 
proteins with immune functions. For example, it has been suggested that binding to 
members of the RCA family of proteins by Epstein-Barr virus, measles virus and many 
enteroviruses, may be selected for, in some way allowing the viruses to avoid 
complement related cell damage (Lindahl et al., 2000). However, DAF may be favoured 
as a receptor for other reasons: for example via its association with cell signalling 
pathways, such as those involved in the lipopolysaccharide receptor complex, of which 
DAF is a part (Heine et al., 2003). In addition DAF has been observed to be removed 
from the cell surface both by endocytic mechanisms, potentially favouring viral entry, 
and also by shedding from the cell surface, which might be a mechanism for promoting 
eventual viral release from the cell.
Conceptually viral internalisation (as opposed to actual crossing of cellular 
membranes) is not a difficult challenge for a virus, as many cell surface molecules are 
naturally endocytosed following ligand binding. Indeed viruses seem capable of using a 
variety of routes either between families, within families (such as the Picormvfridae) 
and even for individual viruses, as influenza virus can use both clathrin-mediated and 
clathrin-independent methods of endocytosis (Marsh and Helenius, 2006; Sieczkarski 
and Whittaker, 2002b). It may be postulated that a specific route of entry is required to 
ensure delivery of the virus to the correct site of viral replication in the cell. This is 
potentially important for some viruses, however for others it seems an unlikely 
constraint on the virus; for example RNA derived from cloned enteroviruses is 
efficiently replicated, even when delivered non-specifically to the cytoplasm by
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electroporation. Perhaps the important challenge for the virus is the requirement to 
deliver its genome, and any necessary proteins, to the internal cellular environment.
This requires that the viral nucleic acid cross cell membranes, either the plasma 
membrane or the membrane of intracellular vesicles, and also that the virus is released 
from the viral particle itself (uncoating), and these processes are often tightly linked.
Virus particles can be described as existing in a metastable state (Marsh and 
Helenius, 2006; Steven et al., 2005). They require a structure that is sufficiently stable 
in the extracellular environment to allow efficient transfer from one infected cell to the 
next and from one infected organism to the next. However, this structure must also be 
capable of being readily destabilised to allow uncoating, and release of the viral nucleic 
acid into the cell. Perhaps the primary requirement of a specific route of endocytosis, 
and partly for a specific receptor, is in fact to ensure exposure of the virus to a set of 
factors that trigger this process. Poliovims, for example, requires only contact with the 
viral receptor on the cell membrane to trigger uncoating, with the formation of a 
membrane pore allowing penetration, while other picornavimses also require receptor 
interaction, but with the additional factor of low pH in late endosomes (Nurani et al., 
2003), and this may also be the case for EV70. Many enveloped vimses, such as 
influenza vims, also require low pH to induce conformational changes in viral proteins 
that trigger membrane fusion and nucleic acid release (Marsh and Helenius, 2006;
Skehel and Wiley, 2000). Other vimses may require specific cellular proteases or 
reducing environments as triggers of uncoating and penetration (Ebert et al., 2002; 
Greber et al., 1996; Li et al., 1998; Simmons et al., 2005).
6.2.2 Tropism and pathogenesis
It is well established that the viral receptor is the primary determinant of species 
tropism. The engineering of transgenic mice to express specific viral receptors, has been 
used to create animal models for a number of viral infections, including poliovims, 
measles and the SARS coronavims (Patterson et a l, 2001; Ren et a l, 1990; Tseng et al, 
2007). In the case of influenza vimses the receptor specificity largely dictates the host 
species, with a2-3 linked sialic acid specific for avian strains and a2-6 for human 
strains. In avian vimses a change in specificity, from a2-3 to a2-6 linked sialic acid, is 
associated with an increase in the ability of the virus to infect and be transmitted among 
humans. Changes in receptor specificity may therefore be an important mechanism by
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which animal viruses might emerge as new human pathogens, and may well have been a 
contributory factor in the emergence of EV70.
It is clear that receptor usage is also of primary importance in viral tissue 
tropism; if the receptor is not expressed on a particular tissue the virus will not infect it. 
Some viral receptors are indeed expressed on a very limited range of cell types; for 
example CD4, the HIV receptor is found primarily on T-lymphocytes, and the RBC 
P antigen is the receptor for human parvovhiis B19, which specifically infects RBC 
progenitors (Heegaard and Brown, 2002). However, many viral receptors are expressed 
on a much wider range of tissues then are infected in vivo. In transgenic mice, PVR, the 
poliovims receptor, is expressed in a wide range of tissues, including the kidneys and 
lung, which is similar to PVR expression in humans (Ren and Racaniello, 1992); despite 
this, in both humans and mice, poliovims replication is largely restricted to the intestine 
and neuronal tissues. Human influenza vims predominantly infects the respiratory tract, 
despite the presence of a2-6 linked sialic acid on a wide range of tissues, and although 
avian H7N7 influenza vims (with a specificity for a2-3 linked sialic acid) can infect the 
conjunctiva, other avian influenza vimses with the same specificity do not. Therefore 
other factors must exist that influence tissue tropism in vivo. Perhaps one of the most 
obvious is that the vims must have physical access to a particular tissue to infect it.
Thus major group rhino vim ses may not infect the gut epithelium, not because these 
cells lack ICAM-1, but because viral infectivity is destroyed by gastric acid before the 
vims reaches the intestine. Poliovims may not infect the kidney as they do not have 
ready access to this organ, and this possibility is to some extent corroborated by the fact 
that renal cell cultures derived from PVR transgenic mice do support poliovims 
infection (Ren and Racaniello, 1992). Other detemiinants of tissue tropism might relate 
to viral requirements for specific entry routes, activation of cell signalling pathways or 
the presence of essential coreceptors. In addition to these early events in the viral life­
cycle, there may be a requirement for tissue-specific cellular factors in viral replication, 
transcription and translation.
Pathogenesis is usually a result of the primary tissue tropism of a vims; for 
example HIV infects T-lymphocytes and causes immunodeficiency, HCV infects 
hepatocytes and causes hepatitis, human parvovims B19 infects RBC precursors and 
causes anaemia and EV70 infects the conjunctival epithelium and causes conjunctivitis. 
However, where a particular infection causes less common pathology, the picture is less 
clear. EV70 causes acute flaccid paralysis rarely, in one in ten thousand cases, and this
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is also a rare result of infection with a number of other non-polio enteroviruses. This 
may be due to the inability of these viruses to replicate in neuronal tissue unless there 
exists within the quasispecies a virus with altered tropism, or to a chance event that 
allows the virus to cross the blood brain barrier and access the central nervous system. 
Alternatively central nervous system infection or symptoms may be determined by host 
factors, such as the ability to mount an effective immune response against the virus.
6 3  EV70 as a human vatho2en
EV70 infection has been characterised by a dramatic emergence in the human 
population. Assuming estimates of the date of a common, presumably animal-based, 
EV70 ancestor are correct (Takeda et al., 1994), within four years of its emergence, 
EV70 had spread to several countries and infected over 20 million people. This viral 
success story was presumably due to its emergence as a highly infectious virus that was 
easily spread between individuals, particularly in areas of crowding or poor hygiene. 
However, now forty years on, EV70 outbreaks are observed in much smaller clusters 
and have been separated by up to ten years. There is also a suggestion of changes in the 
clinical presentation of the infection.
Following the initial Southeast Asian pandemic of 1970/1971 numerous smaller 
outbreaks were reported in Africa, India and Japan until the early 1980s (Higgins,
1982). During a ten-year period, from the mid-1980s, EV70 infection was rarely 
detected (Saitoh-Inagawa et al., 1999); however, in the mid-1990s several epidemics 
(affecting thousands, rather than millions) occurred in India and Japan (Maitreyi et al., 
1999; Uchio et al., 1999). The last outbreak of EV70 infection reported in the literature 
was in Delhi in 1996. These later outbreaks were less well reported than the initial 
pandemic, however a number of interesting observations were made. Firstly the virus 
proved more difficult to culture than previously, and secondly, outbreaks were smaller 
and symptoms milder, with fewer haemorrhagic features and potentially fewer 
neurological side effects (although with the smaller numbers affected this cannot clearly 
be determined), there also seemed to be an increase in the proportion of infections 
occurring in children (Bern et al, 1992; Maitreyi et al, 1999; Uchio et a l, 1999).
The decrease in the incidence and size of EV70 outbreaks may have been due to 
high levels of immunity in the population following the 1970/1971 pandemic, and this 
may not have supported further outbreaks in these regions. However, infection has'been
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observed in areas and individuals previously infected, suggesting that immunity is not 
complete (Bern et al., 1992), and additionally with the biith of a new largely susceptible 
generation the frequency o f infection would have been expected to increase after an 
interval, and this is not the pattern seen. Perhaps a more likely explanation, given the 
potential changes in symptoms, epidemiology and viral characteristics, is that the virus 
is adapting to its new human host. Given the initial success of the virus this is most 
likely to have been due to immune pressures, with the severity of the initial symptoms 
suggesting a vigorous immune response in the conjunctiva. Further adaptation may have 
reduced the immune stimulus, allowing prolonged viral shedding and a less long-lasting 
immunity. An alternative explanation, which cannot be discounted, is that there has 
been more than one introduction of the virus into the human population following 
changes in the virus within its natural host that rendered it more transmissible to 
humans.
EV70 remains a potentially significant human pathogen, however, and despite 
its recent reduction in incidence and potentially severity, it is still capable of causing 
large epidemics with the potential for severe neurological consequences in the 
individual. Due to its capacity for rapid spread it can incapacitate large proportions of 
the working population in a small geographical area within a short period of time, with 
resultant economic chaos, and in a world where paralysis due to poliovirus is becoming 
increasingly rare due to the effectiveness of the eradication campaign (Kew et al,
2005), other viral causes o f acute flaccid paralysis are gaining in significance. A further 
risk is, that as an RNA virus capable of considerable adaptation, and also as a relatively 
new human pathogen still adapting to the human host, a strain may emerge in the future 
with increased neurotropism or the potential to cause long-lasting ocular damage. It is 
also relevant that EV70 was being considered as one of only three viruses in Iraq’s 
Bioweapons program (Stone, 2002).
The changes and adaptability of the virus present unique problems in the 
diagnosis and management of EV70 infection. With fewer cases and milder symptoms 
the clinical diagnosis may be less obvious, with symptoms being overlooked or 
misdiagnosed as adenoviral conjunctivitis. Traditionally enteroviral infections have 
been diagnosed by tissue culture that may fail to isolate more recent fastidious strains, 
indeed even the reference strain does not result in observable CPE in many standard cell 
lines. Where CPE is observed, enterovirus identification requires further typing by 
neutralisation, which is now more difficult due to the withdrawal of the World Health
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Organisation’s serotype-specific antibody neutralisation pools. Currently many 
diagnostic laboratories have switched to PCR as a method for identifying viral 
infections, including enteroviruses. The identification of EV70 would then require that 
the primers used for generic enterovirus PCRs and typing by sequencing (usually YPl 
specific) are capable of amplifying EV70. Given that there are currently only three 
known group D enteroviruses, the data set for designing such primers is very small.
Even where specific EV70 primers are used, changes in viral sequence may prevent 
detection of more recent isolates.
There are currently no effective antivirals in use against picornaviruses. The 
most promising compounds are the so-called WESl compounds (originally developed at 
Sterling Winthrop in the USA), which act by occupying the base of the viral canyon and 
stabilising the capsid, thus preventing uncoating. Pleconaril is one such compound that 
showed promise in early trials in enterovirus infections and was used clinically on a 
compassionate basis from the late 1990s (Webster, 2005). Pleconaril was shown to have 
a broad activity against rhinoviruses and enteroviruses, although was never formally 
tested against EV70. However in 2003, following failure to obtain a licence for the 
treatment of the common cold in the USA, pleconaril production was discontinued. 
Another treatment which might prove useful against EV70 infection is polyvalent sialic 
acid compounds, which have been shown to be effective against influenza virus 
(Matrosovich and Klenk, 2003).
EV70 is a highly adaptable virus, which remains a threat to the human 
population. Further research into early steps in the viral life-cycle, and in particular the 
interaction of the viral capsid with its receptor and the cell, is essential to our 
understanding of viral pathogenesis and of the action of potential antiviral compounds. 
Of particular importance is that these studies are not limited to use of the reference 
strain, but that clinically relevant viral strains or cloned viral sequences are used to test 
the efficacy of potential treatments and to compliment future research.
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Appendix 1 Example of histogram plots from one flow cytometry-based entry assay using EV70. MRC5 cells were treated with 
the agents indicated, at the concentrations detailed in section 5.1.1 and figure 1.5A, and infected with EV70 at an m.o.i. o f  3. After 6 
hours incubation in the continued presence o f  the inhibitors, cells were washed, fixed, permeabilised and EV70 detected using the 
primary antibody, anti-enterovirus 70 mouse monoclonal 854, and an anti-mouse IgG FITC conjugate as the secondary. Cells were 
analysed by flow cytometry. A plot o f forward versus side scatter for the untreated cells was used to gate the population o f intact 
cells. 10 000 gated events were counted per sample, and the number o f  counts plotted against FLl-H (FITC staining).
■ ■ ■  Control, uninfected cells. -------  Control, EV70 infected untreated cells. ------  EV70 infected treated cells.
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Appendix 2 Example of histogram plots from one flow cytometry-based entry assay using Echovirus type 11. MRC5 cells were treated 
with the agents indicated, at the concentrations detailed in section 5.1.1 and figure 1.5A, and infected with echovirus type 11 at an m.o.i. o f  
3. After 6 hours incubation in the continued presence o f the inhibitors, cells were washed, fixed, permeabilised and echovirus type 11 
detected using the primary antibody, anti-enterovirus mouse monoclonal 5-D8/1, and an anti-mouse IgG FITC conjugate as the secondary. 
Cells were analysed by flow cytometry. A plot o f forward versus side scatter for the untreated cells was used to gate the population o f intact 
cells. 10 000 gated events were counted per sample, and the number o f  counts plotted against FLl-H (FITC staining), 
r r z ]  Control, uninfected cells. Control, echovirus type 11 infected untreated cells -------  echovirus type 11 infected treated cells.
Proportion of infected cells, as a percentage of the untreated, infected controls for each assay.
CO z
Ml!
EV70 A B C D E F G H 1 J K Mean SD
Chlorpromazine 65 39 92 29 35 36 49 24.37
MethylBcyclodextrin 68 83 102 100 68 93 71 84 14.95
Nystatin / Progesterone 110 122 117 112 91 121 112 11.41
Brefeldin A 7 4 7 5 10 4 6 2.32
Gemstein 28 3 9 13 13.05
PP2 40 39 49 43 5.51
Bisindoylmaleimide 157 93 157 136 36.95
NH4C1 48 85 95 76 33.86
BaiSlomycin 109 104 95 103 7.09
Nocodazole 148 100 112 120 24.98
Cytochalasin D 55 74 55 61 10.97
Echo 11 H 1 J K Mean SD
Chlorpromazine 150 134 111 132 19.6
MethylBcyclodextrin 35 6 64 35 29
Nystatin / Progesterone 60 102 32 74 35.23
Brefeldin A 9 9 13 10 2.31
Appendix 3 Results from flow cytometry-based entry assays used to construct figures 5.1 A and 5.7A. Columns A to 
K represent assays done on separate occasions. Monolayers of MRC5 cells were pre-treated with chemicals at the 
concentrations detailed in the relevant sections, and infected with either EV70 or echovirus type 11 at an m.o.i. of 3. Cells 
were then incubated for 6 hours in the presence of the chemical and the proportion of infected cells assessed by flow 
cytometry, counting 10 000 events per sample. The proportion of infected cells is given as a percentage of the untreated 
infected controls in each assay. The results presented in columns A to K represent the mean results from duplicate assays 
done in parallel, while the final two columns give the mean results, with standard deviation, for assays done on separate 
occasions. Inter-assay variation was noted to be far greater than intra-assay variation (data not shown).
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